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The need for new antimicrobials with novel mechanisms of action is becoming 
one of the most urgent requirements in modern medicine. Antimicrobial peptides 
(AMPs) are naturally occurring compounds which possess a rapid killing 
mechanism and low resistance potential. Consequently, they are being viewed 
as potential alternatives to traditional antibiotics. One of the major factors limiting 
further development of AMPs is off target toxicity. Enhancements to antimicrobial 
peptides which can maximise antimicrobial activity whilst reducing mammalian 
cytotoxicity would make these peptides more attractive as future 
pharmaceuticals. 
 
Smp24 and Smp43 are AMPs derived from the venom of the scorpion Scorpio 
maurus palmatus. This study sought to better understand the relationship 
between structure, function and bacterial selectivity of these peptides by 
performing single amino acid substitutions. The structure-function relationship of 
the two AMPs has been investigated by performing N-terminal, mid-chain and C-
terminal amino acid substitutions and determining the effect this has on the 
antimicrobial and cytotoxic activity of the peptides. The structural implications of 
the amino acid substitutions have been investigated via homology modelling and 
circular dichroism spectroscopy. 
 
Functional improvements have been made to modified peptides when compared 
with native Smp24 and native Smp43, which have produced peptides with 







Table of Contents 
Dedication – i 
Quote- ii 
Abstract- iii 
Table of contents- iv 
List of figures- xi 
List of tables- xiv 
1 Introduction ............................................................................................................ 1 
1.1 Antibiotics and the emergence of resistant pathogens .......................................... 2 
1.2 Antibiotic resistance mechanisms .......................................................................... 7 
1.3 Modern antimicrobial drug discovery .................................................................... 9 
1.4 Antimicrobial peptides ........................................................................................ 10 
1.5 Antimicrobial peptide conformation .................................................................... 12 
1.5.1 α-helical peptides ............................................................................................................... 13 
1.5.2 β-sheet containing peptides ............................................................................................... 14 
1.5.3 Peptides with α and β elements ......................................................................................... 14 
1.5.4 Linear peptides rich in particular amino acids ................................................................... 14 
1.6 Structural characteristics of AMPs ....................................................................... 15 
1.6.1 Structure ............................................................................................................................ 16 
1.6.2 Charge ................................................................................................................................ 16 
1.6.3 Amphipathicity ................................................................................................................... 17 
1.6.4 Hydrophobicity ................................................................................................................... 17 
1.6.5 Polar angle .......................................................................................................................... 17 
1.7 Mechanism of action ........................................................................................... 18 
1.7.1 Barrel-stave model ............................................................................................................. 21 
1.7.2 Toroidal pore model ........................................................................................................... 21 
1.7.3 Carpet model ...................................................................................................................... 22 
1.7.4 Other mechanisms of pore formation ............................................................................... 23 
1.7.5 Mechanism of action and cell membrane composition ..................................................... 25 
1.7.6 Other mechanisms of action .............................................................................................. 26 
1.8 Natural resistance towards AMPs ........................................................................ 28 
1.9 Antimicrobial peptides in therapeutic usage and the design of new peptides ...... 31 
1.9.1 AMPs in clinical usage ........................................................................................................ 31 
v 
 
1.9.2 Designing new peptide analogues ..................................................................................... 35 
1.10 Strategies for AMP production ............................................................................ 37 
1.11 Venoms ............................................................................................................... 37 
1.11.1 Scorpion venom ............................................................................................................. 39 
1.11.2 Scorpio maurus palmatus .............................................................................................. 41 
1.11.3 Smp24 ............................................................................................................................ 41 
1.11.4 Smp43 ............................................................................................................................ 44 
1.12 Scope of the present study .................................................................................. 46 
2 General Methods .................................................................................................. 47 
2.1 Materials ............................................................................................................. 48 
2.2 Peptide synthesis ................................................................................................ 48 
2.3 Minimum inhibition concentration (MIC) assay ................................................... 48 
2.4 Minimum bactericidal concentration (MBC) assay ............................................... 49 
2.5 Minimum biofilm eradication concentration (MBEC) assay .................................. 49 
2.6 Haemolysis assay ................................................................................................. 50 
2.7 Cytotoxicity assays .............................................................................................. 50 
2.7.1 Eukaryotic cell culture line maintenance ........................................................................... 50 
2.7.2 Cytotoxicity assays ............................................................................................................. 51 
2.7.3 LD50 calculations ................................................................................................................. 52 
2.7.4 T-test on data ..................................................................................................................... 52 
2.7.5 Therapeutic index ............................................................................................................... 52 
2.8 Circular dichroism ................................................................................................ 52 
2.8.1 Methodology ...................................................................................................................... 52 
2.8.2 Data analysis ...................................................................................................................... 53 
2.9 Modelling ............................................................................................................ 53 
2.9.1 Helical wheel projections ................................................................................................... 53 
2.9.2 Ab-initio modelling ............................................................................................................. 54 
2.9.3 3D-modelling ...................................................................................................................... 54 
2.9.4 Hydrophobic moment ........................................................................................................ 54 
2.10 Gene synthesis .................................................................................................... 54 
2.10.1 Transformation of plasmids ........................................................................................... 55 
2.10.2 Polymerase chain reaction (PCR) to confirm transformation ........................................ 55 
2.10.3 Agarose gel electrophoresis .......................................................................................... 56 
vi 
 
2.11 Production of Smp24 with the STII leader sequence ............................................ 56 
2.12 Purification of the STII/Smp24 peptide ................................................................ 57 
2.12.1 Cation exchange I .......................................................................................................... 57 
2.12.2 Cation exchange II ......................................................................................................... 57 
2.13 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) ........... 58 
2.14 Tris-tricine PAGE .................................................................................................. 59 
2.14.1 TRIS-tricine gel composition (12%) ................................................................................ 59 
2.14.2 Pre-cast gels .................................................................................................................. 60 
2.14.3 Pre-cast gradient gel ...................................................................................................... 61 
2.15 MALDI ................................................................................................................. 61 
2.16 Immunological detection of Smp24 by anti-Smp24 antibodies ............................. 61 
2.16.1 Raising antibodies in rabbits .......................................................................................... 61 
2.16.2 Dot blot .......................................................................................................................... 61 
2.17 Galleria mellonella pathogenicity assay ............................................................... 62 
2.17.1 Preparation of larvae ..................................................................................................... 62 
2.17.2 Pathogenicity assay ....................................................................................................... 62 
2.17.3 Log rank reduction test. ................................................................................................ 63 
2.18 Affinity tagged protein over production ............................................................... 63 
2.18.1 Protein overproduction ................................................................................................. 63 
2.18.2 Identification of fusion protein by dot blot ................................................................... 64 
2.19 Affinity-tagged protein purification ..................................................................... 64 
2.19.1 Further optimisation ..................................................................................................... 65 
2.20 Site-directed mutagenesis ................................................................................... 65 
3 Elucidating the relationship between structure and. Antimicrobial activity og AMPs 
from venom ............................................................................................................. 67 
3.1 Introduction ........................................................................................................ 68 
3.2 Study aims ........................................................................................................... 69 
3.3 Experimental design ............................................................................................ 70 
3.4 Results ................................................................................................................. 74 
3.4.1 Peptide sequences ............................................................................................................. 75 
3.4.2 Minimum inhibitory concentrations and Minimum bactericidal concentrations .............. 77 
3.4.2.1 Smp24 antimicrobial activity .................................................................................... 77 
3.4.2.2 Smp24 microbial inhibition ....................................................................................... 80 
vii 
 
3.4.2.3 Smp24 bactericidal activity ....................................................................................... 81 
3.4.2.4 Comparison between MIC and MBC ......................................................................... 82 
3.4.3 Smp43 antimicrobial activity .............................................................................................. 84 
3.4.3.1 Smp43 microbial inhibition ....................................................................................... 85 
3.4.3.2 Smp43 bactericidal activity ....................................................................................... 86 
3.4.3.3 MIC: MBC ratios for Smp43 ...................................................................................... 87 
3.5 Anti-biofilm activity ............................................................................................. 89 
3.5.1 Biofilm vs planktonic MICs ................................................................................................. 90 
3.5.2 Comparison of anti-biofilm activity of Smp24 and Smp43 with commercially available 
lipopeptide antibiotics ...................................................................................................................... 91 
3.6 Structural investigations: Circular Dichroism ........................................................ 91 
3.6.1 CD spectroscopy of Smp24 ................................................................................................. 91 
3.6.2 TFE titration of Smp24 ....................................................................................................... 93 
3.6.3 CD spectroscopy of Smp43 ................................................................................................. 95 
3.7 Discussion ........................................................................................................... 96 
3.7.1 Structural differences between modified peptides ........................................................... 97 
3.7.2 Comparison of AMPs to commercially available lipopeptide antibiotics ........................... 98 
3.7.3 AMPs and anti-biofilm activity ........................................................................................... 99 
3.8 Conclusions ....................................................................................................... 101 
4 Investigating the relationship between structure, cytotoxicity and haemolysis of 
AMPs from venom ................................................................................................. 103 
4.1 Introduction ...................................................................................................... 104 
4.2 Study aims ......................................................................................................... 104 
4.3 Experimental design .......................................................................................... 105 
4.4 Results ............................................................................................................... 107 
4.4.1 Haemolysis ....................................................................................................................... 107 
4.4.1.1 Haemolytic activity of modified Smp24 peptides ................................................... 107 
4.4.1.2 Haemolytic activity of modified Smp43 peptides ................................................... 108 
4.4.2 Cytotoxicity against liver and kidney cells ........................................................................ 109 
4.4.2.1 Cytotoxic activity of modified Smp24 peptides ...................................................... 110 
4.4.2.2 Cytotoxic activity of modified Smp43 peptides ...................................................... 111 
4.4.3 Cytotoxicity of AMPs against skin cell lines ...................................................................... 113 
4.4.3.1 Cytotoxicity of modified Smp24 peptides against human skin cells ....................... 113 
4.4.3.2 Cytotoxicity of modified Smp43 peptides against immortalised keratinocytes ..... 114 
4.4.3.3 Human Urothelial Epithelial Cells (HUEPC) ............................................................. 116 
viii 
 
4.5 Discussion ......................................................................................................... 117 
4.5.1 Haemolysis of Smp24 ....................................................................................................... 117 
4.5.2 Haemolysis of Smp43 ....................................................................................................... 118 
4.5.3 Haemolysis as a measure of cytotoxicity ......................................................................... 119 
4.5.4 Eukaryotic cytotoxicity ..................................................................................................... 120 
4.5.4.1 Membrane composition ......................................................................................... 121 
4.5.4.2 Cytotoxicity of Smp24 ............................................................................................. 122 
4.5.4.3 Cytotoxicity of Smp43 ............................................................................................. 123 
4.5.5 Therapeutic applications .................................................................................................. 124 
4.6 Conclusions ....................................................................................................... 125 
5 Modelling the relationship between structure and function ................................ 127 
5.1 Structural investigations relating to antimicrobial activity ................................. 128 
5.2 Study aims ......................................................................................................... 128 
5.3 Experimental design .......................................................................................... 129 
5.4 Structural investigations relating to antimicrobial activity ................................. 129 
5.4.1 Structural investigations of Smp24 K7F ........................................................................... 129 
5.4.2 Structural investigations of Smp24 S3K ........................................................................... 131 
5.4.3 Structural investigations for Smp43 W3A/W5A/W14A ................................................... 132 
5.4.4 Relating structure to function: Smp24 S3K and Smp24 K7F ............................................. 134 
5.4.5 Polar angles and hydrophobic moments .......................................................................... 136 
5.4.6 Relating structure and function: Smp43 S24K, Smp43 S43K and Smp43 W14A .............. 140 
5.4.7 Smp43 S43K ...................................................................................................................... 143 
5.4.8 Smp43 W14A .................................................................................................................... 143 
5.4.9 The role of charge and hydrophobicity on Smp43 function ............................................. 143 
5.5 Structural investigations relating to eukaryotic toxicity ..................................... 149 
5.5.1 Haemolysis of Smp24-derived modifications ................................................................... 149 
5.5.2 Haemolysis of Smp43-derived modifications ................................................................... 151 
5.5.2.1 Cytotoxicity of Smp24-derived modifications ......................................................... 152 
5.5.3 Cytotoxicity of Smp43 ...................................................................................................... 153 
5.6 Therapeutic indices ........................................................................................... 155 
5.6.1 Therapeutic indices of modified Smp24 peptides ............................................................ 155 
5.6.2 Therapeutic indices of modified Smp43 peptides ............................................................ 156 
5.6.3 Therapeutic indices of peptides against urothelial cells .................................................. 158 
5.6.3.1 Therapeutic indices of lipopeptide antibiotics ....................................................... 159 
5.7 Conclusions ....................................................................................................... 161 
ix 
 
6 Optimisation of recombinant production of venom-derived peptides in E.coli BL21
 .............................................................................................................................. 163 
6.1 Introduction ...................................................................................................... 164 
6.2 Study aims ......................................................................................................... 165 
6.3 Experimental design .......................................................................................... 165 
6.3.1 Recombinant expression of antimicrobial peptides in E. coli ........................................... 165 
6.3.2 Experimental design for the overproduction of Smp24 protein ...................................... 168 
6.3.3 Vector design for the expression of Smp24 ..................................................................... 170 
6.3.4 Transformation & Confirmation of transformation ......................................................... 172 
6.3.5 Recombinant production of Smp24 protein .................................................................... 172 
6.3.6 Validation of protein overproduction .............................................................................. 173 
6.3.7 Protein purification .......................................................................................................... 174 
6.3.8 Validating the presence of Smp24 ................................................................................... 176 
6.3.8.1 SDS-PAGE ................................................................................................................ 176 
6.3.8.2 TRIS-tricine PAGE .................................................................................................... 177 
6.3.8.3 Matrix assisted laser desorption/ionisation time of flight mass spectrometry 
(MALDI-TOF MS) ........................................................................................................................ 177 
6.3.8.4 Detection of Smp24 in the presence of salt ........................................................... 179 
6.3.9 Additional protein purification ......................................................................................... 181 
6.3.10 Immunological detection of Smp24 ............................................................................ 182 
6.3.11 Alternative approach for protein detection ................................................................ 184 
6.4 Limitations of the signal peptide expression system .......................................... 186 
6.5 Plasmid construct design with affinity tag ......................................................... 189 
6.5.1 Transformation ................................................................................................................ 194 
6.5.2 Affinity tagged protein over production .......................................................................... 194 
6.5.3 Affinity tagged protein purification .................................................................................. 195 
6.5.4 Additional optimisation .................................................................................................... 196 
6.5.5 Mutagenesis of Smp peptides .......................................................................................... 197 
6.6 Discussion ......................................................................................................... 202 
7 General Discussion .............................................................................................. 208 
7.1 Improving the understanding of structure and function ..................................... 209 
7.2 AMPs and membrane interactions ..................................................................... 211 
7.3 Elucidating the mechanism of action ................................................................. 213 
7.4 Development of novel antimicrobials ................................................................ 214 
x 
 
7.5 Recombinant peptide production ...................................................................... 215 
7.6 Improving the stability of AMPs ......................................................................... 216 









List of Figures 
 
Figure 1.1: Structural classes of AMPs ............................................................ 13 
Figure 1.2: factors influencing structure of AMPs. ............................................ 15 
Figure 1.3: Interactions between amphipathic AMPs and prokaryotic and 
eukaryotic membranes. ..................................................................................... 20 
Figure 1.4: Visual representation of pore formation ......................................... 23 
Figure 1.5: Mechanisms of cell death by AMPs ............................................... 27 
Figure 1.6: Mechanisms of antimicrobial peptide resistance ............................ 29 
Figure 3.1: Helical wheel projections ................................................................ 71 
Figure 3.2: Mutation strategy for scorpion AMPs ............................................. 73 
Figure 3.3: Helical propensity of Smp24, S3K and K7F in aqueous (0% TFE) and 
membrane mimetic (60% TFE) conditions. ....................................................... 92 
Figure 3.4: CD spectra for the titration of TFE (0-60%) for Smp24, Smp24 S3K 
and Smp24 K7F ................................................................................................ 94 
Figure 3.5: the helical propensity of Smp43 in water (0% TFE) and in membrane 
mimetic conditions (60% TFE). ......................................................................... 95 
Figure 4.1: Mutation strategy for scorpion AMPs ........................................... 106 
Figure 5.1: Structural analysis of Smp24 and modifications .......................... 130 
Figure 5.2: Structural analysis of N-terminal charge modification of Smp24 .. 131 
Figure 5.3: Structural analysis of tryptophan substitutions in Smp43 ............. 133 
Figure 5.4: Spatial distribution of Smp24, S3K  and K7F ............................... 135 
Figure 5.5: Atomic representations of Smp24 and derived modifications ...... 137 
Figure 5.6: Spatial diagrams for Smp43, Smp43 S24K, Smp43 S43K and Smp43 
W14A. ............................................................................................................. 141 
Figure 5.7: Polar facet representation in Smp43 and derived modifications .. 142 
Figure 5.8: Spatial distribution of Smp43 and Smp43 W3A/W5A/W14A ........ 145 
Figure 5.9: Sequence homology between Smp43 and Pandinin 1. ............... 147 
Figure 5.10: Structural  modifications of Smp24 ............................................ 150 
Figure 5.11: Structural modifications to Smp43. ............................................ 152 
Figure 5.12: Helical wheel projections of Smp24, Smp24 S3F, Smp24 K7F and 
Smp24 D23F ................................................................................................... 153 
xii 
 
Figure 5.13: Helical wheel projections of Smp43, Smp43 S24K, Smp43 S43K 
and Smp43 W3A ............................................................................................. 154 
Figure 5.14: The calculated TI’s of modified Smp24 peptides against HepG2, 
HEK-293, HaCaT and sheep erythrocytes.. .................................................... 155 
Figure 5.15: The calculated TI’s of modified Smp43 peptides against HepG2,, 
HEK-293, HaCaT and sheep erythrocytes. Statistical significance was 
determined by performing a T-test on the data ............................................... 157 
Figure 5.16: Calculated TIs for Smp24 and Smp43 against human uroepithelial 
cells (HUEPC). ................................................................................................ 158 
Figure 5.17: Calculated TI’s of daptomycin and PMB against liver, kidney, skin 
and red blood cells. ......................................................................................... 159 
Figure 5.18: Observable differences in TI for Smp24 and Smp43 against all cell 
lines used in this study. ................................................................................... 160 
Figure 6.2: Vector design for the expression of neurotoxins in E. coli.. ......... 167 
Figure 6.1: Strategy for the production of recombinant Smp24 in a prokaryotic 
expression system. ......................................................................................... 169 
Figure 6.3: pET22b(+) vector map and the corresponding codon usage 
sequences for STII and Smp24 for insertion of the gene between the HindIII and 
NdeI restriction sites. ....................................................................................... 171 
Figure 6.4: Visualisation of the PCR product from the extraction of 
pET22b/STII/Smp24 from E. coli BL21 λDE3 ................................................. 172 
Figure 6.5: SDS-PAGE gel of the overproduction of Smp24 in E. coli ........... 173 
Figure 6.6: Purification of Smp24 ................................................................... 175 
Figure 6.7: MALDI-MS spectral identification of Smp24 ................................. 178 
Figure 6.8: MALDI MS analysis of Smp24 ..................................................... 180 
Figure 6.9: AKTA A280 trace for additional purification of Smp24 ................... 181 
Figure 6.10: Optimisation of antibody detection using dot blot for the detection of 
Smp24 ............................................................................................................. 183 
Figure 6.11: Immunological detection of expressed proteins in E. coli. ......... 184 
Figure 6.12: Galleria mellonella pathogenicity results .................................... 188 
Figure 6.14: The design of pET22b/STII/FLAG/Smp24. ................................ 191 
Figure 6.15: Creation of the vector pET22b/Smp24/FLAG ............................ 193 
Figure 6.16: Agarose gel electrophoresis for the transformation of FLAG-tagged 
vectors in to E. coli BL21 λDE3 ....................................................................... 195 
Figure 6.18: Dot blot analysis of Smp24-FLAG purification ........................... 196 
xiii 
 
Figure 6.19: Dot blot analysis of Smp24-FLAG purification. .......................... 197 
Figure 6.20: Agarose gel electrophoresis depicting the mutagenesis of Smp24.





List of Tables 
 
Table 1.1: Common components of eukaryotic and prokaryotic membranes and 
the charge states observed. .............................................................................. 26 
Table 1.2: Membrane and intracellular targets of AMPs ................................... 28 
Table 2.1: SDS-PAGE reagent composition ..................................................... 58 
Table 2.2: Final SDS-PAGE running conditions ............................................... 59 
Table 2.3: Gel and buffer composition for the analysis of protein fractions by 
TRIS-tricine PAGE. ........................................................................................... 60 
Table 2.4: PCR cycling conditions for site-directed mutagenesis ..................... 66 
Table 3.1: Sequence and parameter data for Smp24 and derived modifications.
 .......................................................................................................................... 75 
Table 3.2: Sequence and parameter data for Smp43 and derived modifications.
 .......................................................................................................................... 76 
Table 3.3: Antimicrobial activity of Smp24 and modified peptides as determined 
by broth microdilution assay and bactericidal assay. ........................................ 79 
Table 3.4: MIC: MBC ratios for Smp24 and derived modifications ................... 83 
Table 3.5: Antimicrobial activity of Smp43 and modified peptides as determined 
by broth microdilution assay. ............................................................................. 84 
Table 3.6: MIC: MBC ratios for Smp43 and derived modifications ................... 88 
Table 3.7: Anti-biofilm activity of Smp24 and Smp43 as defined by MBIC and 
MBEC values .................................................................................................... 89 
Table 4.1: Sequence and parameter data for Smp24 and derived modifications.
 ........................................................................................................................ 107 
Table 4.2: Sequence and parameter data for Smp43 and derived modifications.
 ........................................................................................................................ 107 
Table 4.3: Haemolytic activity presented as HC50 values for Smp24 and derived 
modifications used within this study. ............................................................... 107 
Table 4.4: Haemolytic activities of Smp43 and the modified peptides displayed 
as HC50 values. ............................................................................................... 108 
Table 4.5: Cytotoxic activities of Smp24-derived peptides against liver and kidney 
cell lines. ......................................................................................................... 110 
Table 4.6: Cytotoxic activities of Smp43 and derived modifications against liver 
and kidney cell lines. ....................................................................................... 112 
xv 
 
Table 4.7: LD50 concentrations for modified Smp24 peptides against an 
immortalised human keratinocyte cell line (HaCaT). ....................................... 113 
Table 4.8: Cytotoxicity profiles of Smp43 and derived modifications displayed as 
LD50 values against the HaCaT cell line. ......................................................... 115 
Table 4.9: Membrane potential differences between primary and secondary cell 
lines ................................................................................................................. 116 
Table 4.10: Cytotoxicity assessment of native Smp24 and Smp43 against 
HUEPC cells ................................................................................................... 116 
Table 6.1: The amino acid sequence for the signal peptide (STII) and neurotoxin 
II sequence (NTII) is shown in black. .............................................................. 168 
Table 6.2: Primer design for the site-directed mutagenesis of 
pET22b/STII/Smp24. Primers were redesigned for the creation of the S3K mutant 
as previous attempts to modify the gene were unsuccessful. ......................... 199 
Table 6.3: Confirmed sequences of mutated Smp24 peptides, as produced by 
site-directed mutagenesis. .............................................................................. 201 
Table 7.1: Comparison of prokaryotic and eukaryotic activity of Smp24, Smp43 





3D Three dimensional 
3FTxs Three-fingered toxins 
A Alanine 
AAMP Anionic antimicrobial peptide 
ABC ATP binding cassette 
AFM Atomic force microscopy 
AIM Autoinduction media 
AMP Antimicrobial peptide 
AMR Antimicrobial resistance 
APS Ammonium persulphate 
ASP Antibiotic stewardship programme 
ATP Adenosine triphosphate 
bp Base pair 
BSA Bovine serum albumin 
BSAC British Society for Antimicrobial Chemotherapy 
CaCl2 Calcium chloride 
CARB-X Combatting antibiotic resistant bacteria biopharmaceutical accelerator 
CAUTIs Catheter-associated urinary tract infections 
CD Circular dichroism 
CH3COONa Sodium acetate 
CHCA α-cyano-4-hydroxycinnamic-acid  
CHO Chinese hamster ovary 
CL Cardiolipin 
cm Centimetre 
CRE Carbapenem-resistant Enterobacteriaceae 
cUTI Complicated urinary tract infection 
CV Column volume 
D Aspartic acid 
D-AAs D-amino acids 
Da Dalton 
DBPs Disulphide bridged peptides 
dH2O.  Distilled water 
DLA Diffusion limited aggregation 
DMEM Dulbecco's modified Eagle's medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Dinucleotide phosphate 
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine  
E  Glutamic Acid 
ELISA Enzyme linked immunosorbent assay 
EPS Extracellular polymeric substances 
xvii 
 
ESBL Extended-spectrum β-lactamase 
ESKAPE 
Enterococcus faecium, Staphylococcus aureus, Klebsiella 
 pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa  
and Enterobacter species 
EUCAST European Committee on Antimicrobial Susceptibility Testing 
F Phenylalanine 
FAO The Food and Agricultural Organisation of the United Nations 
FCS Foetal calf serum 
FDA Food and Drug Administration 
GNB Gram negative bacilli 
GRAS Generally recognised as safe 
GRAVY Grand average of hydropathy 
GVG Glycine-valine-glycine 
H Histidine 
HaCat Human keratinocyte cell line 
HC50 Lethal haemolysis 50% lysis 
HCl Hydrochloric acid 
HEK-293 Human embryonic kidney cell line 
HepG2 Hepatic cell line 
HGT Horizontal gene transfer 
HM Hydrophobic moment 
HUEPC Human urothelial epithelial cells 
I Isoleucine 
IPTG Isopropyl-1-thio-β-D-galactopyranoside  
IUD Intrauterine device 
K Lysine 
kb Kilobase 
KCl Potassium chloride 
kDa Kilodalton 
KH2PO4 Potassium phosphate 
KSI Ketosteroid isomerase 
L Litre 
LB Luria Burtani 
LD50 Lethal dose 50% death 
LDH Lactate dehydrogenase 
LPS Lipopolysaccharide 
LRRT Log-rank reduction test 
M Molar 
m/z Mass to charge ration 
MALDI-MS  Matrix assisted laser desorption/ionisation mass spectrometry  
MALDI-
TOF  Matrix assisted laser desorption/ionisation time of flight 
MATE Multi-drug and toxic compound extrusion 
MBC  Minimum bactericidal concentration 
MBEC Minimum biofilm eradication concentration 
xviii 
 
MBIC Minimum biofilm inhibition concentration 
MD Molecular dynamics 
MDR Multi-drug resistant 
MF Major facilitator 
mg Milligram 
µg Microgram 
MgCL2 Magnesium chloride 
MGE Mobile genetic elements 
MgSO4 Magnesium sulphate 
MH Muller Hinton 
MIC Minimum inhibition concentration 
ml Millilitre 
mM Millimolar 
MRE Mobile resistance elements 
MRSA Methicillin-resistant Staphylococcus aureus 
mV Millivolts 
Na2HPO4 Sodium phosphate dibasic 
nAchRs Nicotinic acetylcholine receptors  
NaCl Sodium chloride 
NADH Nicotinamide adenine dinucleotide 
nc Not calculable 
ND Not determined 
NDBPs Non-disulphide bridged peptides 
NDM New Delhi metallo- beta lactamase 
ng Nanogram 
NH4Cl Ammonium chloride 
NHS National Health Service 
NI Non-injected 
NICE National Institute of Clinical Excellence 
nm Nanometre 
NMR  Nuclear magnetic resonance 
NT Not tested 
NTII Neurotoxin II 
OD Optical density 
OIE Organisation for Animal Health 
PBP Penicillin binding protein 
PBS Phosphate buffered saline 
PC Phosphatidylcholine 
PCR Polymerase chain reaction 
PE Phosphatidylethanolamine 
PG Phosphatidylglycerol 
PI Isoelectric point 





PMB Polymyxin B 
PMQR Plasmid-mediated quinolone resistance 
PS Phosphatidylserine 
Q Glutamine 
QCM-D Quartz crystal microbalance dissipation 
R Arginine 
RNA Ribonucleic acid 
RND Resistance-modulation division 
ROS  Reactive oxygen species 
RP-HPLC Reversed-phase high performance liquid chromatography 
rpm Rotations per minute 
RPP Ribosomal protection protein 
S Serine 
SDM Site-directed mutagenesis 
SDS Sodium-dodecyl sulphate 
SDS-PAGE Sodium dodecyl-sulphate polyacrylamide gel electrophoresis  
SM Sphingomyelin 
SMR Small multi-drug resistance 
spp Species 
SPPS Solid-phase peptide synthesis 
SRP Signal-recognising protein 
STII Signal peptide II 
subsp Subspecies 
TB Mycobacterium tuberculosis 
TBS Tris buffered saline 
TBST Tris buffered saline with Tween-20 
TEMED Tetramethyl ethylenediamine 
TFA Trifluoroacetic acid 
TFE 2,2,2-trifluoroethanol  
TI Therapeutic index 
TL Temporin L 
U Units 
UBI Ubiquicidin 
µl  Microlitre 
µM  Micrometre 
UPEC Uropathogenic E. coli 
UTI Urinary tract infection 
UV Ultraviolet 
V0 Potential difference 
VRE Vancomycin-resistant Enterococci 
W Tryptophan 
WHO World Health Organisation 
Y Tyrosine 









1.1 Antibiotics and the emergence of resistant pathogens 
 
Antibiotics have been the primary treatment option for bacterial infection since 
their introduction in the 1940s and have saved millions of lives worldwide 
(Sánchez and Demain 2017). The discovery of penicillin and sulphonamides in 
the 1920's started the antibiotic era and spurred the 'Golden Age' of antimicrobial 
drug development which continued in to the 1960s and saw the discovery of 
almost all of the drug classes used today (Santos-Beneit et al. 2017). For many 
years antibiotics were used freely, the evolution of resistance had been foreseen 
but was underestimated because it would be dependent upon the rate of 
beneficial mutation, which was likely to be low. The unexpected capacity of 
bacterial populations to rapidly evolve such widespread resistance to antibiotics 
has severely impacted the advances in antibacterial chemotherapeutics over the 
past 50 years (Bell and Gouyon 2003). Antibiotics have been too frequently 
prescribed to treat non-bacterial conditions and prescribed at times when the 
drugs were unnecessary as a result of patient demand (Alumran et al. 2013). This 
has been exacerbated by the unregulated usage of antibiotics in some countries, 
such as Greece, in which antibiotics can be bought from markets and pharmacies 
without a prescription or even in the absence of a trained pharmacist or other 
medical professional (Karakonstantis and Kalemaki 2019). Additionally, the 
usage of antibiotics has spread to non-medical areas and has historically been 
largely unregulated (Laxminarayan et al. 2013, Yidong et al. 2017). Initially the 
use of antibiotics in animals was for the treatment and prevention of diseases 
including mastitis (Bacanlı and Başaran 2019). In the 1940's an enhanced growth 
rate was observed in livestock issued antibiotics, as such, the use of antibiotics 
as growth promoters quickly became common practice in livestock farming 
(Graham et al. 2007). The lack of understanding of the unique features of 
antibiotics and the subsequent risk of resistance spread has significantly 
contributed to the present epidemic (Laxminarayan et al. 2013). 
 
In recent years, the world has come to face two important and linked problems; 
1) the emergence and spread of resistance in pathogenic bacteria and 2) the lack 
of development of novel chemotherapeutics. The development of antimicrobial 
resistance not only generates an increasing economic burden in the healthcare 
setting, but also has a significant impact on patient morbidity and mortality 
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(Santos-Beneit et al. 2017). The World Health Organisation (WHO) has claimed 
antibiotic resistance is one of the greatest threats to human health, with the 
prospect of untreatable bacterial infections being on the horizon (MacFadden et 
al. 2015, Viens and Littmann 2015). Clinical practice was once revolutionised by 
the introduction of antibiotics, which enabled invasive surgery to be performed 
with substantially decreased risk and previously dangerous infections could be 
treated with minimal side effects. Sadly, it seems this era has passed and we are 
now entering in to what has been termed the 'resistance era' (Santos-Beneit et 
al. 2017).  
 
Virtually all significant bacterial infections have become resistant to the first 
antibiotic treatment of choice, with hospital acquired infections becoming of 
increasing concern (Lohner and Hilpert 2016). Recent studies have also 
suggested that antimicrobial resistant pathogens can be more virulent than their 
antibiotic-susceptible counterparts, which also contributes to patient morbidity 
and mortality (Wang-Kan et al. 2017). In recent years, multidrug-resistant Gram 
positive organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) 
are less concerning due to the introduction of daptomycin, linezolid and 
tigecycline to combat such infections (Chopra et al. 2008). Ceftaroline is a “new” 
cephalosporin (approved in 2010) which has activity against many Gram positive 
organisms including MRSA, penicillin-resistant Streptococcus pneumoniae and 
Streptococcus pyogenes (Kaushik et al. 2011, Armengol-Porta et al. 2016). 
Ceftobiprole is another cephalosporin with activity against a wide range of Gram 
positive and Gram negative bacteria, including MRSA, as well as penicillin- and 
ceftriaxone-resistant Streptococcus pneumoniae, Enterobacteriaceae and 
Pseudomonas aeruginosa. Ceftobiprole has been authorised for the treatment of 
clinical and community-acquired pneumonia (Vaneperen and Segreti 2016). The 
National institute for Clinical Excellence (NICE) has approved the usage of 
ceftobiprole in the UK for the treatment of hospital and community acquired 
pneumonia (excluding ventilator-associated pneumonia) (NICE, 2019) Although 
these drugs are welcome agents to treat bacterial infection, it does highlight that 
drug discovery is comparatively easier for compounds effective against Gram 
positive bacteria as opposed to Gram negative bacteria (Chopra et al., 2008).  
Infections caused by Gram negative bacteria are difficult to treat due to many 
pathogens being intrinsically resistant to many antibiotics, which predates their 
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usage in the medical and agricultural setting (Blair et al. 2014). Gram negative 
bacterial infections are of increasing concern, owing to continual resistance 
acquisition (Brown, 2015). β-lactamase producing bacteria have been able to 
withstand β-lactam antibiotics, which led to the introduction of imipenem, the first 
carbapenem antibiotic, in 1985 (Papp-Wallace et al. 2011). The widespread 
usage of carbapenems resulted in the inevitable development of bacterial 
resistance, with the first isolated carbapenem-resistant Enterobacteriaceae 
(CRE) reported in the 1990s (Lutgring, 2019). The resistance rate of several 
Gram negative species toward carbapenems in some developing countries has 
been reported at up to 50% (Brown, 2015). Consequently, the threat of multidrug-
resistant (MDR) Gram negative organisms, including CREs, is having a 
significant impact in the healthcare setting (Viens and Littmann 2015).  
 
The rapid increase in Gram negative resistant bacteria is of great concern when 
met by a lack of compounds available to treat such infections. Most antibiotics in 
clinical usage today originate from discoveries made in the mid-twentieth century, 
and critical gaps remain in our understanding of antibiotics and their targets 
(Sinha and Kesselheim 2016). The issues with the need for new antibiotics in an 
era of continually emerging resistance coupled with a gap in our understanding 
of drug-target interaction and the resultant resistance development of bacteria 
has been exacerbated by the fact that numerous large, for-profit pharmaceutical 
companies have abandoned active antibiotic development groups due to 
concerns about returns on investment. The combination of these factors has led 
to the drug development pipeline being referred to as weak or broken and could 
lead to a threat of untreatable infection in the future (Chopra et al. 2008, Sinha 
and Kesselheim 2016). However, there is cause for optimism with new business 
models fostering the development of new vaccines to pre-empt potential future 
treatment issues (Ahmad and Khan 2019). In August 2019, the safety and 
immunogenicity of a chlamydia vaccine has been assessed at clinical trial level 
(Abraham et al. 2019). As the first vaccine for genital chlamydia to enter human 
clinical trials, it highlights the potential of utilising different strategies to prevent 





Infection management has become more challenging due to a lack of novel 
compounds on the market. To combat CRE infection, ceftazidime/avibactam was 
introduced in 2015 but reports of resistance soon followed (Livermore et al. 2018). 
In 2017, Vabomere (meropenem and vaborbactam) was granted US Food and 
Drug Administration (FDA) approval for the treatment of patients >18 years of age 
with complicated urinary tract infections (cUTIs). In vitro reports show a low 
propensity for resistance selection of meropenem-vaborbactam resistance and 
infrequent cross-resistance between ceftazidime/avibactam (Hackel et al. 2018, 
Peri et al. 2019) which is very promising for the longevity of Vabomere in clinical 
practice but the history of antibiotic resistance development would suggest 
Vabomere resistance will eventually emerge. 
 
In addition to the problems associated with treating Gram negative bacteria, drug-
resistant Mycobacteria also pose a major clinical challenge. Tuberculosis (TB) 
constitutes a global health burden with an estimated 1.5 million deaths annually 
attributed to TB. The emergence of drug-resistant TB threatened the global 
control of the disease, with multi-drug, extensive-drug and total-drug resistant TB 
being of heightened concern (Momin et al. 2017). In August 2019, the FDA has 
approved the usage of Pretomanid tablets in combination with bedaquiline and 
linezolid for the treatment of adults with extensively-drug resistant TB or non-
responsive multidrug-resistant pulmonary TB, which accounts for an estimated 
490, 000 newly diagnosed cases annually across the world (FDA, 2019 (a)). 
 
The development of antimicrobial drugs less susceptible to bacterial resistance 
is one of the greatest difficulties faced by pharmaceutical companies and new 
approaches to drug design are required to combat the antimicrobial resistance 
issues (Jenssen et al. 2006). Additionally stricter regulation for the usage of 
antimicrobials is required to prevent the same limited lifespan of drugs being 
faced in the future (Walia et al. 2019). 
 
Since the mid 1970's, the diversity and scale of the antimicrobial resistance 
burden has grown; initially the development of resistance was met by the 
introduction of new antimicrobials to bypass that resistance but since the 1990's 
there has been an antibiotic drug discovery void (Tang et al. 2014). Antimicrobial 
drug development has a substantial disincentive for pharmaceutical companies, 
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largely due to the limited financial return on the large investment required for 
antimicrobial drug development (Talbot et al. 2006). The development of new 
antibiotics is also more expensive, as a result of increased regulatory 
requirements, while newer screening methods for potential compounds have not 
been as successful as was first hoped (MacGowan and Macnaughton 2017). 
Resultantly, major pharmaceutical companies have stopped or severely 
restricted their investments for antimicrobial discovery and development, which 
has now left drug discovery efforts to small companies and universities (Sánchez 
and Demain 2017). 
 
Successful control and prevention of MDR bacteria can be achieved through 
commitment to antibiotic stewardship programmes (ASPs) (Abbas and Stevens 
2018). The United Kingdom and United States have entered a transatlantic 
partnership to try and combat the antimicrobial resistance issue, with the 
Wellcome Trust committing £125 million over 5 years. The Combatting Antibiotic 
Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) initiative aims to fill 
the 'antibiotic void' to support early research into alternative antibiotics, with 
combined funding of $450 million (Wellcome Trust, 2017). Furthermore, Antibiotic 
Action is a UK-based initiative which was launched in 2011 and funded by the 
British Society for Antimicrobial Chemotherapy (BSAC) to raise global awareness 
of antibiotic resistance. Antibiotic Action seeks to inform and educate the general 
public in addition to clinical professionals on the importance of selective usage of 
antibiotics when required whilst promoting the importance of infection prevention 
and control (BSAC, 2019). 
 
In addition to CARB-X and Antibiotic Action, One Health has been launched. One 
Health is the collaborative effort of multiple health science professions to attain 
optimal health for people, domestic animals, wildlife, plants, and the environment 
(McEwen and Collignon 2018). The World Health Organisation (WHO), the Food 
and Agriculture Organization of the United Nations (FAO) and the World 
Organisation for Animal Health (OIE) speak with one voice to take collective 
action to reduce the emergence and spread of AMR (WHO, 2018). As many of 
the antibiotic classes used in humans are also used in animals, the strategies of 
One Health include making improvements in antimicrobial use and regulation. 
This covers antimicrobial policy, surveillance, stewardship, infection control, 
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sanitation, animal husbandry and the search for alternatives to antimicrobials 
(McEwen and Collignon 2018). 
 
The National Health Service (NHS) has launched a new scheme to test the 
world’s first “subscription” style payment model to incentivise pharmaceutical 
companies to develop new antimicrobial drugs (Department of Health and Social 
Care, 2019). Currently, drug companies are paid by the volume of antibiotics sold 
and low returns on investment in development creates a disincentive for 
investment due to a lack of financial return (Ventola 2015). The trial will be led by 
NICE and NHS England and NHS Improvement which will test a model in which 
the NHS pays for drugs upfront based upon their usefulness. This will make the 
financial investment required to develop a new drug (estimated £1 billion) more 
attractive as they will still be paid for the drug even though it may be stored for 
last resort usage (Department of Health and Social Care, 2019).  
 
All of these programmes listed above are working to promote awareness about 
antibiotic resistance, with emphasis on infection control, resistance surveillance  
and antibiotic stewardship. These factors are critical to maintain the efficacy of 
existing antibiotics against emerging resistant pathogens. However, the 
development of novel agents is a key component of the overall strategy to 
manage the antibiotic resistance issue. Programmes, such as the NHS pre-
payment trial aiming to promote antimicrobial discovery programmes by removing 
the financial “risk”, is an important step towards returning to a full pipeline of 
antimicrobials but will only address global market failure if other countries follow 
the UK’s lead.  
 
1.2 Antibiotic resistance mechanisms 
 
Antibiotic resistance is a natural result of Darwinian selection. Bacteria have 
developed resistance to all antibiotics in clinical usage; with resistance to the last-
resort antibiotic colistin being one of the latest examples (Santos-Beneit et al. 
2017).  Understanding the mechanisms by which bacteria become resistant to 
antibiotics contributes to the search for therapeutics which combat these 
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mechanisms. Mechanisms of antibiotic resistance include efflux, antibiotic 
inactivation, biofilm formation and target modification (Khameneh et al. 2016).   
 
Antibiotic resistant bacteria can be divided in to two subsets 1) intrinsic/innate 
resistance and 2) acquired resistance. The former is dependent upon an 
individual bacterium's biological properties (Khameneh et al. 2016). For example, 
aerobic bacteria are intrinsically resistant to metronidazole as they are unable to 
reduce the drug anaerobically to its active form (Bendesky et al. 2002). Of the 
latter subset, bacteria can develop antimicrobial resistance via de novo mutations 
or by horizontal gene transfer of mobile genetic elements. Genetic mutations are 
usually random single-gene polymorphisms which occur at a rate of 10-9 to 10-10 
per gene (Tang et al. 2014). These mutations are the result of errors in 
chromosomal replication or incorrect repair of damaged DNA (Khameneh et al. 
2016). 
 
Mobile genetic elements carrying resistances (mobile resistance elements or 
MRE) play a key role in the spread of antimicrobial resistance (AMR) as they 
spread through the bacterial population through horizontal gene transfer (HGT) 
(Durão et al. 2018). MRE typically confer antibiotic resistance by enzymatic 
inactivation (Wright 2005), efflux (Poole 2005), synthesis of enzymes to native 
targets (Wellington et al. 2013) or target protection (Nguyen et al. 2014).  
 
Antibacterial resistance is a major problem in the clinical setting, with treatment 
options becoming increasingly diminished for bacterial infections. Another clinical 
challenge is the control and eradication of biofilm-forming bacteria, which can 
adhere to indwelling medical devices (Stewart and Costerton 2001) and surfaces, 
including sinks, within the hospital environment (Walker and Moore 2015). 
 
Biofilms are surface-attached microbial communities able to attach to biotic or 
abiotic surfaces (Parrino et al. 2019). Bacterial cells within a biofilm are 
embedded in a matrix consisting of a self- synthesised layer of extracellular 
polymeric substances (EPS). EPS form the architecture of biofilms and are 
composed of polysaccharides, proteins, lipids and mucus which functions as a 
matrix holding the biofilm together (Kim and Lee 2016). Bacterial cells within the 
biofilm matrix are inherently drug resistant. Bacterial cells dwelling within the 
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biofilm can require up to 1000x the antimicrobial concentration required to kill 
their planktonic single-cell counterparts (Brandenburg et al. 2019). As such, 
biofilm treatment is of heightened clinical concern. Biofilms are often recalcitrant 
to both the immune response and antimicrobial treatment, making biofilm-
associated infections difficult to treat (Henly et al. 2019).  
 
Common biofilm-associated infections include catheter-associated urinary tract 
infections (CAUTIs) and biofilm formation on in-dwelling devices which in extreme 
circumstances can lead to biofilm-associated sepsis (Kennedy et al. 2010, 
Isabelle et al. 2018, Henly et al. 2019). Other clinically important biofilms present 
in chronic wounds, such as diabetic foot ulcers (Alvarado-Gomez et al. 2018), 
and biofilm contamination of burns patients by Pseudomonas aeruginosa 
(Brandenburg et al. 2019).  
 
Due to the antibiotic resistance issues discussed above, there is an urgent need 
for new antibiotics with novel modes of action to combat the ever-growing 
antimicrobial resistance challenge.  
 
1.3 Modern antimicrobial drug discovery 
 
The rise in bacterial resistance is met by a decline in antibiotic drug development. 
Numerous pharmaceutical companies have abandoned the antimicrobial 
research and development field which has only fuelled the growing public crisis 
(Owens and Ambrose, 2007). The regulatory and economic barriers have caused 
15 out of 18 of the larger pharmaceutical companies to completely pull out of the 
antibiotic field (Bartlett et al., 2013). The number of antibacterial drugs approved 
by the FDA has declined by 75% between 1983 and 2007 according to FDA 
statistics, with only a handful of pharmaceutical companies retaining active 
antimicrobial discovery programmes (Boucher et al., 2009). Despite this, 
antimicrobial drugs are still reaching the market. Three antibacterial drugs were 
approved by the FDA in 2018, which include plazomicin for the treatment of 
urinary tract infections (UTIs) (Shaeer et al. 2019), eravacycline for the treatment 
of complicated intraabdominal infections (Solomkin et al. 2018) and 
omadacycline for the treatment of community acquired pneumonia (Opal et al. 
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2019). Equally, three antibacterial drugs were approved in 2017, which included 
ozenoaxcin for the treatment of impetigo (Canton et al. 2018), Vabomere for the 
treatment of complicated UTIs (Hackel et al. 2018) and delafloxacin for the 
treatment of acute skin and soft tissue infections (Corey et al. 2019) although 
reports have already emerged of delafloxacin-resistant S. aureus isolates (Iregui 
et al. 2019). Despite reported resistance issues, the approval of new drugs offers 
some optimism for antimicrobial therapy, as two drugs were approved by the FDA 
in 2016 (Bezlotoxumab for Clostridium difficile infection (Bartlett 2017) and 
Obiltoxaximab for the treatment of inhalation anthrax (Greig 2016)) and one drug 
approved in 2015 (ceftazidime-avibactam) (Mosley et al. 2016). Three 
antibacterial drugs have already been approved by the FDA in 2019 (Pretomanid, 
Recarbrio and Lefamulin) (Momin et al., 2017; Rodvold, 2019, FDA 2019 (b)), 
which suggests, despite regulatory hurdles, new antibacterial drugs are reaching 
the market and this could be starting to increase.  
 
The limited introduction of new antibiotics reaching the market, coupled with 
declining expertise within the field of antibiotic production demonstrates a 
demand for new drug discovery and development strategies (Tomaras and 
Dunman, 2015). The development of new antimicrobial drugs is crucial if we are 
to avoid a future where simple infections become life threatening once more 
(Butler et al. 2016). There have been efforts to search for alternative antimicrobial 
drugs over the past two decades (Irazazabal et al., 2016). 
 
One group of molecules proposed to fill the antibiotic void is antimicrobial 
peptides (AMPs), which inhibit and kill bacteria by non-specific mechanisms 
(Sánchez and Demain 2017). AMPs have been extensively studied for over 40 
years. The interest in the design and development of AMPs as potential 
therapeutic agents has resurged in recent years due to a rapid increase in drug-
resistant infections (Lee et al. 2019). 
 
1.4 Antimicrobial peptides 
 
Antimicrobial peptides (AMPs) are evolutionarily conserved, vital components of 
innate immunity and considered a crucial aspect of the innate immune system for 
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almost all living organisms (Datta et al. 2015, Chen et al. 2019). The production 
of AMPs has been reported in numerous groups of organisms, including bacteria, 
fungi, plants and animals (Haugen et al. 2008). In microorganisms, AMPs are 
produced as a result of biological evolution to gain access to nutrients (Zhu et al. 
2017a). For other organisms, AMPs are an ancient form of defence against 
invading pathogens and infection. AMPs act as the first line of innate defence 
against bacterial, fungal and viral invasion due to their location in tissues and 
organs commonly exposed to airborne pathogens (Datta et al. 2015, Zhu et al. 
2017b). In addition to the antimicrobial activities of cationic peptides, they also 
demonstrate antitumor activity and growing evidence suggests cationic peptides 
have a role in the modulation of the immune responses, especially in 
inflammation and infection (Dai et al. 2008, Lee et al. 2019). It has also been 
suggested that the presence of AMPs in venoms can act as a weapon against 
both predators and prey (Falcao et al. 2014). Due to their selectivity for 
prokaryotic membranes, and their unique membrane-permeating mechanism of 
action for which microbes have little natural resistance, the spotlight has moved 
towards AMPs as potential novel antimicrobials (Zasloff 2002, Zhu et al. 2017a) 
 
Despite the diversity of antimicrobial peptides and the living entities they are 
derived from, most AMP's share common physicochemical properties (Zhu et al. 
2017b). They demonstrate a multitude of functions, but their main activity is 
bactericidal which is often achieved by the selective disruption of prokaryotic 
membranes (Bobone et al. 2012). AMPs are typically small in size, ranging from 
12 to 60 amino acids in length, amphipathic, contain a net positive charge of +2 
to +9 and approximately 50% hydrophobicity (Jenssen et al. 2006, Datta et al. 
2015, Memariani et al. 2016). There has been growing interest in the discovery 
and investigation of AMPs due to increasing levels of antibiotic resistance in 
pathogenic bacteria and the aforementioned lack of therapeutic options 
(Barksdale et al. 2016).  
 
AMPs exhibit a unique membrane-targeting mechanism of action, which 
compared with the single-target mechanism of action of current antibiotics, 
creates an interesting drug development prospect (Zhang et al. 2017). The 
hydrophobicity demonstrated by these peptides results in many AMP's forming 
α-helices, particularly upon interaction with phospholipid bilayers, which in turn 
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activates the pore forming mechanism of action (Schmidtchen et al. 2014). AMPs 
have many attractive properties such as broad-spectrum activity, a rapid killing 
mechanism, limited side effects, synergistic activity when used in combination 
therapy with antibiotics and a limited capacity to invoke resistance (Memariani et 
al. 2016). In addition to broad-spectrum antimicrobial activity, AMPs also have 
been shown to possess strong anti-fungal, anti-viral, anti-protozoan activity as 
well as exhibiting killing mechanisms towards cancer cells (Yu et al. 2015, 
Bittencourt et al. 2016).  
 
1.5 Antimicrobial peptide conformation 
 
AMPs can be classified in to four different structural groups: linear α-helical, β-
sheet containing peptides (often stabilised by disulphide bonds) peptides 
composed of both α and β elements or linear extended structures devoid of α or 
β elements but commonly rich in one particular amino acid (Koehbach and Craik 
2019). Of these, the most extensively studied are the α-helical peptides, which 
lack a tertiary structure and remain in extended, un-structured conformations until 
contact with the cell membrane (Dennison et al. 2005). Examples of structural 







Figure 1.1: Structural classes of AMPs. (A) Magainin-2, an α-helical peptide, (B) rattusin, 
a β-sheet containing AMP, (C) heliomycin, an insect defensin containing α-helical and β-
sheet regions and (D) bovine indolicidin, a linear AMP.  
 
1.5.1 α-helical peptides 
 
The α-helical peptides can be further separated into mono-helical or di-helical 
structures, with di-helical AMPs generally being less cytotoxic. Examples of this 
include the magainins isolated from the skin of the African tree frog Xenopus 
laevis. Magainin 2 adopts a di-helical structure and is less cytotoxic than other 
well categorised mono-helical AMPs, such as melittin (Zasloff 1987). The 
Pandinins isolated from the venom of the scorpion Pandinus imperator also 
demonstrate this phenomenon. Pandinin 1 is a di-helical peptide which confers a 
low-level of haemolysis whilst Pandinin-2 is a smaller, mono-helical peptide which 








1.5.2 β-sheet containing peptides 
 
Many of the β-sheet containing peptides are stabilised by one or more disulphide 
bonds. The β-sheet containing peptides can be further subcategorised in to α-
defensin peptides and β-hairpin peptides based upon their cysteine content and 
structural characteristics (Koehbach and Craik 2019). Protegrin-1 is an example 
of a β-hairpin peptide. Derived from porcine blood, protegrin-1 is an 18-amino 
acid peptide with a charge of +7 and is stabilised by two disulphide bonds 
(Kokryakov et al. 1993). Defensins are small, cationic cysteine rich peptides 
which are endogenously produced by virtually all species as a first line of bacterial 
defence. They can be sub-categorised in to three separate groups (Zhu and Gao 
2013). The α-defensins are a subgroup composed of three antiparallel β-strands 
which are linked by a disulphide bond in a trans arrangement. The α-defensins 
contain a salt bridge, which is important for proteolytic stability and folding, but is 
not related to antimicrobial activity (Koehbach and Craik 2019).  
 
1.5.3 Peptides with α and β elements 
 
Other classes of defensins often have structures containing both α and β-
elements. Defensins have been found in numerous mammals, including humans, 
as well as invertebrates and plants. The defensins can be further subcategorised 
based on the arrangement of their  disulphide bonds (Koehbach and Craik 2019). 
One group of defensins is the cis-defensins, where the third disulphide bond 
connects the N-terminal loop with the second β-sheet to form cysteine-stabilised 
αβ-defensins (Koehbach 2017). This motif is also commonly found in scorpion 
venom-derived neurotoxins, such as toxins affecting potassium channels (α-
KTxs) (Zhu et al., 2014), which could contribute to the antimicrobial activity 
demonstrated by some neurotoxins. 
 
1.5.4 Linear peptides rich in particular amino acids 
 
Some peptides do not adopt a particular 3D structure either in solution or upon 
contact with membranes and are referred to as extended linear structures. These 
peptides are devoid of α-helices and β-sheets and are often rich in one particular 
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amino acid, such as glycine, proline, tryptophan or histidine (Koehbach and Craik 
2019). An example of a linear AMP is bovine indolicidin.  Bovine indolicidin is a 
tryptophan-rich 13-mer isolated from bovine neutrophils and carries a charge of 
+3. It demonstrates potent antimicrobial activity against S. aureus and E. coli, 
with almost complete sterilisation of cultures observed at 10 µg/ml (Selsted et al. 
1992). 
 
1.6 Structural characteristics of AMPs 
 
The ability to selectively target prokaryotic cell membranes over host membranes 
is an essential factor for AMPs. As such, the biochemical composition of AMPs 
plays an important role in function (Yeaman and Yount 2003). The factors critical 





Figure 1.2: Factors influencing structure of AMPs. 
 
The composition of AMPs and the amino acid sequence does not only influence 
the biochemical factors (charge, amphipathicity, hydrophobicity) but also 
influences the 3D-structure (conformation and polar angle). Therefore, it is 
postulated that changes to the primary structure can profoundly affect the 
structure-function relationship of the antimicrobial peptide in solution and 
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therefore activation at the bacterial membrane. Changes in the relative ratios of 
charge/hydrophobicity/amphipathicity may have a major effect on structure and 
function. The investigation of this relationship will enable antimicrobial peptides 
to be optimised for maximum antimicrobial effect and minimum host cytotoxicity 




AMPs are a unique and diverse group of molecules, which can be divided in to 
groups based on amino acid composition and structure, as previously discussed 
(Section 1.5) (Travkova et al. 2017). Many AMPs are believed to be unstructured 
or adopt extended conformations prior to interaction with target cell membranes 




A positive charge is generally required for antimicrobial activity and there is a 
strong correlation between peptide cationicity and antimicrobial activity (Travkova 
et al. 2017). The net cationic charge of AMPs is typically due to the presence of 
lysine and arginine residues and it facilitates membrane interaction with 
prokaryotic cells due to their weakly negative surface charge. These amino acids 
usually form highly defined cationic domains within the peptide structure (Hicks 
et al. 2013, Lakshmaiah Narayana and Chen 2015). Increasing the charge of 
AMPs has been demonstrated to increase the antimicrobial activity in numerous 
studies (Bessalle et al. 1992, Huang et al. 2015). In parallel, it has also been 
shown that the elimination of peptide cationic charge drastically reduces 
antimicrobial activity (Schmidtchen et al. 2014). 
 
Whilst the majority of AMPs are cationic, anionic AMPs have been described. 
Dermicidin is a 47-amino acid AMP derived from human sweat glands, which 
carries an overall anionic charge (Schittek et al. 2001). The mechanism of action 
of anionic AMPs (AAMPs) is not fully understood, but some AAMPs use metal 
ions to form cationic salt bridges with anionic components of bacterial cell 





Amphipathicity is an essential characteristic for microbial membrane binding and 
can be adopted by numerous peptide conformations. Amphipathicity can be 
measured quantitatively via the hydrophobic moment, which is calculated as the 
vectoral sum of individual amino acid hydrophobicities, normalised to that of an 
ideal helix. An increased hydrophobic moment results in increased membrane 
permeabilising and haemolytic activities against target membranes. This may 
have an active role in host cell cytotoxicity. If the action of AMPs is considered as 
a combination of electrostatic and hydrophobic activity, for neutral membranes 
where electrostatic interactions are minimised, hydrophobic moments may have 
a key role (Travkova et al. 2017). 
 
The amphipathic properties enable AMPs to permeabilise lipid membranes to 
form pores which ultimately cause cell lysis (Nakatsuji and Gallo 2012, Taute et 
al. 2015).  There is growing evidence that membrane damage is only one aspect 
of the mechanism of action of AMPs and other targets may include inhibition of 
DNA, protein, cell wall and cell membrane synthesis or the stimulation of autolysis 




Peptide hydrophobicity is defined as the percentage of hydrophobic amino acids 
within a peptide, which for most AMPs is approximately 50%. Hydrophobicity is 
essential for interactions between AMPs and membranes (Travkova et al. 2017). 
However, an increase in hydrophobicity is associated with a lack of antimicrobial 
specificity and increased haemolysis and mammalian cell toxicity (Dathe et al. 
1997, Tossi et al. 2000a). Therefore, many AMPs are moderately hydrophobic, 
to enable optimisation of antimicrobial activity against host toxicity. 
 
1.6.5 Polar angle 
 
Polar angle is a measure of the relative proportion of polar and non-polar angles 
of the peptide. A polar angle of near 180° is achieved when the hydrophilic and 
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hydrophobic fractions are approximately equal (Perrin et al. 2016), additionally 
polar angle can give some indication of the mechanism of action of AMPs 
(Uematsu and Matsuzaki 2000). 
 
1.7 Mechanism of action 
 
AMPs are effective against a wide range of bacterial pathogens, including MDR 
bacteria such as Acinetobacter baumanii, methicillin-resistant Staphylococcus 
aureus (MRSA) and MDR- Mycobacterium tuberculosis. The mechanisms of 
actions of AMPs vary depending on structure and classification and the specific 
mechanisms of actions of AMPs are yet to be fully understood. To avoid the same 
potential resistance issues which have occurred with antibiotics, understanding 
the mechanisms of actions of AMPs prior to introduction in the clinical setting may 
offer a therapeutic advantage and enable the molecules to be enhanced to further 
limit the potential for bacterial resistance to develop (Ong and Wiradharma 2014, 
Taute et al. 2015, Barksdale et al. 2016).  AMPs have been shown to interact with 
bacterial membranes and in most instances cause membrane disruption, which 
has widely been thought of as the mechanism of action but other binding targets, 
such as DNA, peptidoglycan, lipopolysaccharide (LPS), and enzyme interference 
have also been noted (Juba et al., 2015; Barksdale et al., 2016; Memariani, et 
al., 2016; Peschel and Sahl, 2006). Additionally, some AMPs have demonstrated 
multi-targeting mechanisms of action, being active at a membrane and 
intracellular level (Memariani et al. 2016). Antibiotics generally function via 
targeting a single site or process and resultantly a simple mutation of modification 
in that target can result in the bacteria developing resistance to the antibiotic 
(D’Costa et al. 2011). As AMPs are multi-target inhibitors, the ability of bacteria 
to develop resistance to AMPs is also reduced. The modification of a single target 
would not induce total resistance to AMPs, but may cause changes to the overall 
efficacy (Memariani et al. 2016). 
 
Most bacterial outer membranes are electronegative due to the presence of high 
levels of anionic phospholipids, such as phosphatidylglycerol, 
phosphatidylethanolamine, LPS and cardiolipin. In contrast, mammalian 
membranes are electroneutral due to the presence of zwitterionic phospholipids, 
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such as phosphatidylcholine (Li et al. 2016).  It has been well established that 
initial electrostatic interactions between the positively charged peptides and the 
negatively charged bacterial membrane are a crucial step in the mechanism of 
action of the peptides (Huang 2000) and that this activity is dependent upon the 
structure, length and complexity of the polysaccharides found in the outer layer 
of the cell membrane (Samy et al. 2016).  
 
The degree of amphipathicity exhibited by the peptides has also been 
demonstrated to be essential for membrane disruption and subsequent 
antimicrobial activity (Irazazabal et al. 2016), as shown in figure 1.3. According 
to the accepted model for membrane disruption, the cationic and hydrophobic 
surfaces of AMPs assemble by electrostatic interaction with the negatively 
charged lipid head groups in bacterial membranes. This leads to hydrophobic 
interactions upon contact with the membrane, where the peptides accumulate 
(Yeaman and Yount 2003). After reaching a threshold concentration, the peptides 
undergo conformational changes and insert in to the hydrophobic interior of the 
lipid bilayer, which causes pore formation and disruption to the membrane (Juba 
et al. 2015). The formation of pores can lead to the translocation of peptides to 
the inner leaflet of the bilayer, where they accumulate and continue to cause 







Figure 1.3: Interactions between amphipathic AMPs and prokaryotic and eukaryotic 
membranes. AMP organises into an amphipathic structure with discrete pockets of 
charge (yellow) and hydrophobicity (green) to aid insertion into the prokaryotic 
membrane. Prokaryotic membranes contain a high proportion of acidic phospholipid 
head groups, which assemble to create a membrane with an anionic charge. 
Electrostatic interactions between the anionic membrane and cationic peptide occur and 
the hydrophobic regions of the peptide insert into the membrane, which leads to pore 
formation. The eukaryotic membrane contains zwitterionic phospholipid head groups, 
which assemble to form a membrane with an overall neutral charge. The AMP is unable 
to form initial electrostatic interactions with the eukaryotic membrane and thus it cannot 
bind. Figure adapted from Zasloff, 2002. 
 
The overall mechanism of action is more complicated than simple cation-anion 
interactions and is typically multi-site involving hydrophobic and hydrophilic 
domains of both the peptides and the membranes.  The membrane disruptive 
mechanism of the peptides is influenced by the formation of pores. Biophysical 
studies have provided three general models for mechanisms of membrane 
disruption and pore formation (Lohner and Hilpert 2016). The formation of pores 
enables ions to travel through the pores, destroying the membrane potential 
which leads to a decline in ATP synthesis and cell metabolism which ultimately 
gives rise to cell death. In all proposed mechanisms of pore formation, following 
the initial electrostatic interactions, a threshold concentration must be reached 
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before membrane disruption can occur (Huang 2000, Shai 2002). The proposed 
models for mechanisms of pore formation are the barrel-stave, toroidal pore and 
carpet models.  
 
1.7.1 Barrel-stave model 
 
In the barrel-stave model, peptide oligomerisation induces the formation of a 
central lumen. AMPs reach the membrane, where they bind as a monomer and 
then adopt an α-helical conformation (Hancock 1999). The hydrophobic regions 
of the peptide align with the lipid core region of the bilayer and the hydrophilic 
regions of the peptides face inwards to create a central pore. This model creates 
a highly ordered cylindrical pore surrounded by peptides in the transmembrane 
orientation (figure 1.4) (Shai 2002, Brogden 2005). Alamethicin is a linear 20-
amino acid long antimicrobial peptide derived from the fungus Trichoderma viride 
(Li and Salditt 2006).  It’s mechanism of action has been well characterised by 
the formation of barrel-stave pores (Perrin et al. 2016). 
 
1.7.2 Toroidal pore model 
 
In the toroidal pore model, the pore lumen is lined with both AMP and 
phospholipid head groups (Ong and Wiradharma 2014). The hydrophilic face of 
AMPs inserts into the membrane surface, inducing bending of the bilayer which 
causes the upper and lower leaflet to meet. This creates an ordered structure, 
with interactions between both lipid head groups and AMPs lining the pore, with 
the pore generally being smallest in the middle and larger at both ends. This 
creates a highly ordered pore (figure 1.4) (Brogden 2005, Mihajlovic and Lazaridis 
2010). An example of a toroidal-pore forming peptide is melittin, which is derived 
from bee venom (Gauldie et al. 1976). Studies have shown that melittin adopts 
its α-helical structure at the membrane and then assembles in to oligomers to 
form toroidal pores. Additionally melittin has been shown to bind to LPS, 
polysachharides, chitin (from yeast) and peptidogylcan from Gram positive 
bacteria, which may explain the broad spectrum of activity shown by melittin as it 





Other studies have suggested that in addition to the anticipated highly ordered 
toroidal pore structutres, irregular toroidal pores can also form. Molecular 
dynamics (MD) simulations with magainin revealed significantly irregular toroidal 
pore formation, with 1-2 monomers located in the central pore lumen and further 
peptides lining the rim (Mihajlovic and Lazaridis 2010). Sengupta et al., (2008) 
reported similar findings for melittin against 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DDPC) membranes.  
 
1.7.3 Carpet model 
 
In the carpet model, peptides accumulate on the surface of the bilayer until they 
reach a threshold concentration. Once this threshold is met, the peptides form 
transient pores, allowing more peptides to access the inner leaflet of the 
membrane. This leads to the peptides creating a 'carpet' on each layer of the 
membrane, with peptides spanning the transmembrane surface. This leads to 
membrane curvature, micelle formation and ultimately membane disintegration 
(figure 1.4) (Shai 2002, Brogden 2005). The cecropins were originally isolated 
from the haemolymph of the giant silk moth, Hyalophora cecropia. These AMPs 
possess antibacterial and anticancer activity in vitro (Moore et al. 1996). Cecropin 
is a prototype of α-helical linear AMPs which operates by a carpet mechanism 








Figure 1.4: Visual representation of pore formation. Hydrophilic regions are shown in red 
and hydrophobic regions are shown in blue. Barrel-stave pore model (A), peptides 
aggregate at the membrane and insert perpendicularly into the cell membrane to create 
a highly ordered pore. The hydrophobic regions of the peptide align with the lipid core 
whilst the hydrophilic regions line the interior of the pore. The carpet model (B), peptides 
associate parallel to the membrane to form an extensive 'carpet.'  At critical 
concentrations, the peptides form holes in the membrane, which allows further peptides 
to access the membrane. Following disruption of the bilayer curvature, the membrane 
disintegrates and forms micelles. The toroidal pore mechanism (C), peptide helices insert 
into the membrane which causes the lipid monolayers to bend continuously through the 
pore which creates a pore composed of phospholipid head groups and inserted peptides. 
Diagram adapted from Brogden, (2005). 
 
1.7.4 Other mechanisms of pore formation 
 
Recent models have blurred the lines between the three commonly proposed 
mechanisms of pore formation. Whilst the toroidal pore, barrel-stave and carpet 
models remain the most commonly proposed mechanisms of pore formation, a 
number of other mechanisms have been proposed including the interfacial, leaky 
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slit, aggregate, electroporation, sinking raft, lipid segregation and diffusion limited 
aggregation models.  
 
The interfacial activity model is described as 'the ability of a molecule to bind to a 
membrane, partition in to the membrane-water interface and alter the packing 
and organisation of the lipids (Wimley 2010). This mechanism is dependent upon 
the balance of hydrophobic and electrostatic interactions between peptides, 
water and lipids; this model also suggests that the activity of such peptides may 
be more dependent on amino acid composition and physico-chemical properties 
as opposed to specific amino acid sequences (Wimley 2010).  
 
The leaky slit model suggests the lipid-bound peptides form a linear, amphipathic 
arrangement with the hydrophobic side of the peptide aggregate facing the lipid 
bilayer. Toxicity would be caused by the other surface of the linear aggregate 
being hydrophilic, as this facet cannot seal by hydrophobic interactions with the 
opposing contacting bilayer. Resultantly, lipids in the hydrophilic surface are 
forced to adopt a highly positive curvature. The resulting leaky slit would be highly 
permeable to solutes and difficult for the cell to repair (Zhao et al. 2006).  
 
In the aggregate model, peptides insert into the bilayer and cluster into large 
unstructured aggregates which span the membrane. The aggregates are 
proposed to be adhered to water molecules, which creates channels enabling the 
leakage of ions and other molecules out of the cell (Xiao et al. 2015). These 
membrane pores do not always cause membrane depolarisation and as such, 
are thought to arise to enable the entry of AMPs to act on intracellular targets 
(Wu et al. 1999). 
 
The molecular electroporation method describes how a highly charged peptide in 
close proximity to the membrane creates an electric field to trigger pore formation. 
To enable pore formation, it has been suggested the AMP must bind to the lipid 
membrane and cause at least a 0.2 V electrostatic potential across the membrane 
(Miteva et al. 1999).  
 
In the sinking raft model, a mass imbalance caused by the peptide binding to the 
outer leaflet is responsible for membrane perturbation. The mass imbalance 
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leads to membrane curvature and perturbation which allows small peptide 
aggregates to sink deeply into the bilayer and cross it, which gives rise to the 
“sinking raft” terminology. 
 
The lipid segregation model is underpinned by peptide-lipid biding, which causes 
defects in the membrane and results in the intracellular contents leaking out of 
the cell (Teixeira et al. 2010). Epand et al., (2009) suggested the lipid segregation 
model could explain the differences in observable minimum inhibitory 
concentration (MIC) values between bacterial species for the same peptide, 
suggesting the contribution of the phospholipids affected the antimicrobial 
activity. Epand et al (2008) postulated the antimicrobial activity of some peptides 
was restricted to the affinity for phospholipids. They demonstrated the peptide 
KR-12 was effective only against bacteria composed of anionic and zwitterionic 
bacteria whilst the peptide GF-17 demonstrated activity against peptides 
composed solely of anionic phospholipids or membranes composed of both 
anionic and zwitterionic phospholipids.  
 
A two-dimensional diffusion limited aggregation (DLA) model has been described 
whereby particles moving with Brownian motion coalesce upon contact with an 
aggregate. The branched structure in DLA arises as particles are captured by the 
extremities of the aggregate before diffusing to the centre. The DLA model 
assumes that a particle immediately attaches to a cluster, however in many 
kinetic processes in biology binding occurs with a certain probability due to 
required binding orientation and the need to overcome an energy barrier (Heath 
et al. 2018). 
 
1.7.5 Mechanism of action and cell membrane composition 
 
The mechanism of action of AMPs has been linked with membrane composition 
which varies between prokaryotic and eukaryotic species (Teixeira et al. 2010).  
The phospholipid content of lipid membranes differs between bacterial species, 
with E. coli membranes being composed predominantly of 
phosphatidylethanolamine (PE) and S. aureus membranes being largely 
composed of phosphatidylglycerol (PG) and cardiolipin (CL) (Hayami et al. 1979, 
Sohlenkamp and Geiger 2016). The phospholipid content of eukaryotic cells 
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varies between cell type and location (Schurer et al. 1993, Müller et al. 1996). 
Examples of common components of bacterial and mammalian cell membranes 
are listed in table 1.1. 
 
Table 1.1: Common components of eukaryotic and prokaryotic membranes and the 













Negative Induces negative charge into 




Neutral Second most abundant 
phospholipid in eukaryotic cells 
Phosphatidylserine (PS) 
 












Neutral Induces presence of lipid rafts 
Cholesterol 
 
Negative Modulates the lipid bilayer 
 
 
1.7.6 Other mechanisms of action 
  
Most studies investigating the mechanisms of action of AMPs focus on the cell 
membrane but limited research has been conducted to investigate mechanisms 
beyond cell membrane lysis (Bobone et al. 2012). AMPs have been discovered 
which target intracellular processes. Pleurocidin was isolated from the mucus of 
the winter flounder (Pleuronectes americanus) and inhibits macromolecular 
synthesis (Ageitos et al. 2017). Indolicidin binds to DNA to inhibit DNA synthesis, 
buforin II can bind both DNA and RNA to inhibit DNA and RNA synthesis (Shah 
et al. 2016). AMPs have been identified which can inhibit DNA synthesis, RNA 
synthesis, LPS synthesis, peptidoglycan synthesis, cell division whilst other 
AMPs have shown activation of cytolytic enzymes (Le et al. 2017). Examples of 






Figure 1.5: Mechanisms of cell death by AMPs. (A) Disruption of cell membrane integrity. 
(B) Inhibition of nucleic acid synthesis. (C) Inhibition of enzymes essential for the cross 
linking of cell wall proteins. (D) Inhibition of ribosome function and protein synthesis. (E 
& F) Blocking of chaperone proteins to inhibit protein folding. (G) Disruption of 
mitochondrial membrane integrity and efflux of ATP and NADH. (H) Inhibition of cellular 
respiration and induction of reactive oxygen species (ROS) formation. Figured adapted 
from Peters et al., 2010. 
 
Some AMPs have demonstrated multi-target mechanisms of action, such as 
activity at the membrane level and via the targeting of intracellular components 
(Harrison, Abdel-Rahman, et al. 2016, Malanovic and Lohner 2016). Examples 
of peptides with membrane targeting and non-membrane targeting mechanisms 









Table 1.2: Membrane and intracellular targets of AMPs 
 
Mechanism of action Peptide 
Toroidal pore Magainin 2, melittin, protegrin-1 
Carpet Cecropin, melittin, dermaseptin  
Barrel-stave Alamethicin 
Inhibition of protein synthesis Indolicidin, pleurocidin 
Flocculation of intracellular components AAMPs 
 
 
1.8 Natural resistance towards AMPs 
 
A low resistance potential makes AMPs an attractive foundation for the 
production of new antimicrobial drugs (Dong et al 2015). Bacteria have 
presumably been exposed to AMPs for millions of years, yet widespread 
resistance to these peptides has not been identified (Fjell et al. 2011). AMPs act 
on multiple cellular targets, as opposed to a particular dominant target or group 
of homologous targets for conventional antibiotics. As AMPs do not interact with 
a specific receptor, the ability of targets to develop resistant phenotypes is 
markedly low (Marr et al. 2006, Panteleev et al. 2015, Ageitos et al. 2017). 
 
It has been suggested that bacteria would have to redesign their cell membranes, 
diminishing the net negative charge in order for resistance to develop (Marr et al. 
2006, Panteleev et al. 2015). Although initially thought to be unlikely, the 
modification of bacterial membranes to prevent AMP binding has been observed. 
This form of passive resistance has been demonstrated in Morganella, Proteus 
and Serratia species which are naturally resistant to AMPs. These bacteria have 
an increased proportion of positively charged lipid A subunits, which diminishes 
the overall negative charge of the membrane and thus prevents AMP binding 
(Andersson et al. 2016). Whilst membrane changes have been observed, it is not 
expected that microorganisms will be able to rapidly change the lipid composition 
in response to AMPs targeting the cytoplasmic membrane. (Chen et al. 2005) 
This mechanism of resistance only results in a modification to the minimal 
inhibitory concentration, as bacteria capable of these membrane charge 
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modifications are inhibited by many AMPs at high concentrations. The reason for 
this is three-fold: 1) bacteria are incapable of completely neutralising the overall 
anionic charge of their membranes, 2) the binding of AMPs is not solely 
dependent on the physico-chemical properties of the target membrane, 3) 
composition and secondary structure of the AMPs is also crucial for binding to 
the membrane (Peschel and Sahl 2006, Ageitos et al. 2017). Additionally, the 
emergence of AMPs with a naturally high cationic charge (such as hBD3 with a 
charge of +10) has been attributed as a counter-evolutionary response to 
overcome the charge resistance mechanism displayed by certain bacteria 
(Peschel and Sahl 2006). 
 


















Figure 1.6: Mechanisms of antimicrobial peptide resistance.  (A) Bacteria can secrete 
proteases which can degrade the AMP before binding occurs. (B) The membrane 
composition can be adjusted to reduce the anionic charge, which decreases the binding 
affinity the AMP has for the prokaryotic membrane.  (C) Bacteria may secrete proteins 





Inducible resistance to AMPs  has been discovered in both Gram negative and 
Gram positive bacteria, such as the production of peptidases capable of digesting 
the AMPs before binding can occur (Peschel and Sahl 2006). An example of this 
is the resistance developed by S. aureus to dermicidin by the induction of a 
specific protease enzyme (Ageitos et al. 2017).  
 
Even though some bacterial species have demonstrated resistance to AMPs, the 
molecules are still present despite bacterial evolution. From a therapeutic 
perspective, peptides capable of resisting degradation would be attractive if oral 
delivery was desired. Modifications to peptides can contribute to making AMPs 
resistant to proteolytic degradation, thus making them even more attractive 
therapeutics. The inclusion of disulphide bonds, proline residues and the 
amidation of the C-terminus can contribute to arming AMPs with a defence 
strategy against proteolysis (Peschel and Sahl 2006). It has also been shown that 
AMPs containing D-amino acids reduce the development of microbial resistance 
by proteolysis whilst simultaneously having an increased biologic effect (Ageitos 
et al. 2017). The incorporation of β-amino acids in to the structure of AMPs has 
also demonstrated peptide enhancement by improving the selectivity (Lee et al. 
2017).  
 
The knowledge of resistance issues prior to the introduction of AMP-based drugs 
can inform the design of molecules with a reduced capacity to invoke bacterial 
resistance and hopefully this will mean these drugs have a more enhanced 
therapeutic shelf-life compared with conventional antibiotics (Ageitos et al. 2017). 
The ability to generate resistance for some AMPs in clinical trials by repeatedly 
exposing bacteria to AMPs at sub-inhibitory concentrations has proven 
unsuccessful, which further demonstrates the promise of these peptides to 






1.9 Antimicrobial peptides in therapeutic usage and the design of 
new peptides 
 
Previous attempts to induct AMPs into therapeutic use have been complicated, 
with the antimicrobial peptide Pexiganan being a primary example. Pexiganan (a 
22-amino acid membrane disrupter analogue of the Xenopus peptide, magainin) 
is a broad-spectrum antimicrobial peptide which was developed for the topical 
use for the treatment of infection in diabetic foot ulcers, which unfortunately 
received a non-approval letter from the FDA in 1999 (Fox 2013). The non-
approval status was issued after phase II trials demonstrated that pexiganan was 
no more effective at treating diabetic foot ulcers than existing antibiotics (Gottler 
and Ramamoorthy 2009). The usage of “noninferiority” trials for approving new 
antibiotics has been extensively questioned. When attempting to discover new 
treatments for untreatable infections, for which there is no “good” treatment 
option, it seems illogical that there cannot be an alternative treatment option equal 
to the gold standard of the current treatment when a “silver” or “bronze” treatment 
may have a significant impact on patient morbidity (DiNubile 2016). 
 
1.9.1 AMPs in clinical usage 
 
Currently, a handful of antimicrobial peptides are being used clinically, with 
polymyxin E and B being the most commonly used. Polymyxin E, also known as 
colistin, has been used over the past 50 years to control infection. Previously, the 
drug had been used sparingly due to nephrotoxicity and neurotoxicity 
complications when administered intravenously. However, a steady rise in Gram 
negative antimicrobial resistance has resulted in colistin being re-introduced as 
the last-resort drug to treat infection. This subsequent overuse of the peptide 
antibiotic has led to the emergence of colistin resistance (Andersson et al. 2016, 
Rhouma et al. 2016). A novel colistin resistance mechanism termed MCR-1 has 
been identified on a mobilised plasmid isolated from E. coli, Klebsiella 
pneumomiae and Pseudomonas spp. in China. Studies have also found the 
presence of this gene in human Enterobacteriaceae, suggesting the resistance 
is being transmitted horizontally from animals to humans (Quesada et al. 2016, 
Rhouma et al. 2016). Gram negative bacteria employ several mechanisms to 
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protect against attack from colistin. The modification of the membrane to increase 
the overall charge by LPS modification which reduces the membrane activity of 
colistin has been noted. The overexpression of efflux pumps and the 
overproduction of capsule polysaccharide have been demonstrated as 
mechanisms of bacterial defence against colistin but no mechanisms of 
enzymatic degradation have been reported (Aghapour et al. 2019).   
 
Despite the knowledge of colistin resistance mechanisms, the presence of colistin 
resistance has rarely been reported in consecutive clinical isolates (Longo et al. 
2019) and the overall prevalence of colistin resistance is low. The prevalence of 
colistin resistance was investigated from agricultural areas known for the usage 
of colistin in the meat industry. Of 647 Salmonella isolates from European broiler 
meat, a resistance rate of 5.5% was observed. The percentage of colistin 
resistance was deemed lower in isolates obtained from the intestines of 
agricultural animals, with a colistin resistance rate of 1% determined for E. coli 
isolates from European pigs (Kempf et al. 2016).  33,765 clinical isolates of 
Enterobacteriaceae were analysed between 2010 and 2014, 4% of Gram 
negative bacilli were determined as colistin resistant with MICs ranging from 2-
32 mg/L (Rossi et al. 2017) highlighting the low prevalence of colistin resistance 
in the clinical setting. In Europe, the incidence of colistin resistance in Salmonella 
spp and E. coli spp is generally low, with sporadic incidences of high resistance 
levels (Apostolakos and Piccirillo 2018).  
 
However, encouragingly, resistance issues are not present for all AMP-based 
antibiotics in the clinical setting. Tyrothricin was the first AMP introduced following 
clinical trials in the 1930s and despite widespread usage over 60 years, there has 
been no bacterial resistance to tyrothricin observed. Tyrothricin contains a 
mixture of linear and cyclic D-amino acids, which have armed the peptide with a 
defence strategy against bacteria (Ageitos et al. 2017).  
 
Nisin is one of the most studied bacteriocins and was the first antimicrobial 
peptide awarded a general recognised as safe (GRAS) status for food 
applications by the FDA (Martins et al. 2010). Bacteriocins are bacterially 
produced, ribosomally synthesised AMPs which are small, heat-stable peptides 
active against other bacteria (Cotter et al. 2005). It is estimated that 30-99% of 
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bacteria and Archaea produce at least one bacteriocin, which can be narrow 
spectrum or broad spectrum. The bacteriocin producing organism is immune to 
its own bacteriocins (Cotter et al. 2005). Nisin is produced by Lactococcus lactis 
sub-species lactis and widely used as a food additive to prevent food spoilage by 
bacteria (Jagus et al. 2016). Whilst generally not active against Gram negative 
bacteria, it does have antimicrobial activity against Gram positive bacteria such 
as Clostridium botulinum and Listeria monocytogenes (Martins et al. 2010). The 
mechanism of action of nisin is exerted by the formation of pores in the bacterial 
cell membrane and inhibiting peptidoglycan synthesis by targeting lipid-II, the 
membrane-bound peptidoglycan precursor (Champak Chatterjee et al. 2005, 
Ageitos et al. 2017). Some Gram positive bacteria which are repeatedly exposed 
to increased nisin concentrations have demonstrated nisin resistance. Numerous 
mechanisms of resistance have been identified and differ between strains (Zhou 
et al. 2014).  However, modifications to the structure of nisin have produced a 
peptide with enhanced antimicrobial activity (including activity against Gram 
negative isolates), though the mechanism of action is still not fully understood 
(Field et al. 2012). Further investigations into structural modification of nisin will 
provide more information on the structure, function and properties of the peptide 
which could result in the development of a variant less susceptible to resistance. 
 
Bacitracin is an AMP produced by Bacillus subtilis, which was discovered in 1943. 
It is a polypeptide antibiotic, which is composed of a heptapeptide cyclic structure 
and a thiozalone ring stabilised by an amide link between the side chains of Lys-
6 and C-terminus of Arg-12. These features of the bacitracin structure have been 
shown to protect it from proteolytic degradation (Nie et al. 2016). Its mechanism 
of action is dependent upon the presence of metal ions (Zn2+, Mn2+, Ni2+ and 
Cu2+) and involves the inhibition of peptidoglycan synthesis (Ageitos et al. 2017). 
Enterococcal and Staphylococcal species isolated from animals have been 
shown to possess bacitracin resistance, but evidence suggests the prevalence of 
this resistance has not increased over time, despite widespread usage of 
bacitracin as a growth promoter in livestock (Aronson 2016). As widespread 
resistance has not been seen, this is encouraging for development of more AMPs 




Daptomycin is a novel lipopeptide antibiotic, which was approved in 2003 in the 
United States and in 2006 in Europe, for the therapeutic treatment of skin and 
skin-structure infections caused by S. aureus (MRSA and methicillin-sensitive S. 
aureus), Streptococcus agalactiae, Streptococcus dysgalactiae subsp equisimilis 
and vancomycin-resistant Enterococci (VRE) (Taylor and Palmer 2016). 
Daptomycin displays rapid in vitro bactericidal activity against many clinically 
relevant Gram positive pathogens (Ma et al. 2017). The mechanism of action 
remains to be fully understood, but it has been well established that the 
mechanism involves disruption of the cytoplasmic membrane, is dependent on 
the presence of calcium and is limited to Gram positive bacteria. Although only 
being released relatively recently, daptomycin has been widely used in the clinical 
setting and it remains the only member of the cyclic lipid class of antibiotics 
approved for clinical use. Clinical resistance to daptomycin is rare, which may be 
in part related to the inclusion of several D-amino acids in its structure (Taylor 
and Palmer 2016). Unlike synthetic drug production, daptomycin has been 
produced recombinantly in bacterial culture. The initial strategy of production was 
insufficient and unsustainable due to toxicity from the expressed daptomycin 
towards the bacterial culture. To combat this, the recombinant production of 
daptomycin has been optimised to obtain a greater yield via the utilisation of 
strategies such as medium optimisation, fermentative strategy, genetic 
engineering modification, and metabolic flux analysis (Ng et al. 2014). The 
successful recombinant production of Daptomycin demonstrates a cheap and 
efficient strategy for the production of peptide drugs in a bacterial system, which 
could be utilised in the future for the production of AMPs.  
 
Peptide 'antibiotics' are being used clinically, but there are factors which have 
limited their application to date, such as nephrotoxicity, but the increase in 
antimicrobial resistance has seen an increase in their therapeutic usage (Choi et 
al. 2016, Nie et al. 2016). Peptide based drugs have a wide range of applications 
and it is anticipated that the approval of peptide based drugs by the FDA will grow 
significantly. Presently, there are 140 peptide based drugs in clinical trials and 
over 500 therapeutic peptides undergoing preclinical development. These drugs 
are mostly targeted towards metabolic diseases and oncology, however, the 
growing antibiotic resistance crisis has demanded new strategies for the 
discovery of novel antimicrobial therapeutics (Fosgerau and Hoffmann 2015). 
35 
 
Previously, regulatory authorities were less prepared to accept adverse-side 
effects with antimicrobials compared with other drug classes and they have 
historically been required to demonstrate superiority over existing therapeutic 
agents. This has led to the rejection of many candidate drugs, including AMPs. 
After previously being rejected, pexiganan once again entered clinical trials, as 
Locilex, with the developers (Dipexium Pharmaceuticals) liaising with the FDA to 
develop pexiganan as a topical drug to treat drug-resistant bacterial infections 
associated with diabetic foot ulcers (Fox 2013). As of January 2019, no recent 
reports of development for phase IV have been reported for pexiganan for the 
treatment of skin and soft tissue infections in the USA. This highlights that despite 
the rapid clinical need for new antimicrobial drugs, the regulatory hurdles facing 
antimicrobials are restricting the market and slowing down an already lengthy 
drug development process. 
 
Despite the regulatory issues, there is now new optimism regarding bringing 
these drugs to market and greater recognition is given to the challenges of 
translating the research and design of AMPs into a new class of antibiotics. 
Omiganan (Sader et al. 2004) has entered phase III trials for the once-daily 
treatment of severe papulopustular rosacea. Iseganan is in phase III trials for the 
treatment of oral mucositis in patients with head and neck malignancy (Mahlapuu 
et al. 2016a). In February 2019, NovaBiotics (UK) was awarded a £1.8 million 
grant for the advancement of the development of Novamycin (NP339) for the 
treatment of fungal infections caused by Aspergillus,  Cryptococcus and Candida 
species.  
 
1.9.2 Designing new peptide analogues 
 
AMPs are promising alternatives to antibiotics, but many of the AMPs derived 
from natural sources are not optimal for therapeutic usage due to limited supply, 
susceptibility to acidic/enzymatic degradation and high production costs as well 
as eukaryotic haemolytic and cytotoxic activities. The information obtained from 
sequence and structural analyses of natural AMPs is providing a template for the 
design of more potent and less cytotoxic AMPs to be synthetically produced in 
order to improve the therapeutic indices (Ong and Wiradharma 2014). 
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There is a gap in the knowledge as to how the structure of AMPs can influence 
function and cytotoxicity. One method of investigating the contribution of amino 
acids to overall function and toxicity is to use a template-based approach to AMP 
design. This involves site-directed mutagenesis (SDM) of an AMP to enhance 
therapeutic properties. By this method, the contribution of single amino acid 
residues to overall function and toxicity can be determined (Panteleev et al. 
2015). This de novo design approach allows increased understanding of how 
factors such as amphipathicity, cationicity and structural class contribute to the 
antimicrobial and cytotoxic properties of AMPs. Using this method, basic amino 
acid residues (histidine, lysine, arginine) are included to increase electrostatic 
interactions and are combined with non-polar amino acids (tryptophan, tyrosine, 
alanine) to facilitate insertion into the lipid bilayer. This approach is of great drug 
development interest, as it enables the identification of motifs responsible for 
antimicrobial activity to aid the optimisation of novel AMPs (Ong and Wiradharma 
2014, Pal et al. 2016). The effects of structural changes have mostly been noted 
in terms of influence on antibacterial activity, but eukaryotic cytotoxicity is an 
important factor to consider if these peptides are ever to be marketed as future 
therapeutics (Irazazabal et al. 2016, Memariani, Shahbazzadeh, Ranjbar, et al. 
2016). 
 
Most peptide therapeutics (not limited to AMPs) are approved for delivery via the 
parenteral route, with 75% administered via injection (Fosgerau and Hoffmann 
2015). Some AMPs are being investigated for topical administration however, it 
is of greater convenience for patients if orally available drugs are developed 
(Dean et al. 2011, Samy et al. 2015). The challenge of such drug design is 
susceptibility to acidic and enzymatic degradation by both the gastrointestinal 
tract and when crossing the intestinal mucosa alongside pharmacokinetic and 
pharmacodynamic parameters. As such, chemical strategies to stabilise the 
secondary structure must be considered when designing antimicrobial peptides 
for therapeutic use (Fosgerau and Hoffmann 2015). Several AMPs have been 
verified for their antimicrobial activity and are being used in the pharmaceutical, 
enzyme and food industries, demonstrating AMPs have a place in the therapeutic 




1.10 Strategies for AMP production 
 
In addition to the pharmaceutical challenges relating to regulation, reducing AMP 
inactivation and making AMPs more drug-like, another challenge facing AMP 
introduction into the clinical setting is developing a strategy for large-scale protein 
production. AMPs are isolated from numerous organisms, but for experimental 
evaluation AMPs are generally synthesised by solid-phase synthesis (Lee et al. 
2002, Edwards et al. 2016). Solid-phase peptide synthesis (SPPS) is considered 
the most mature technology available for the chemical production of peptides up 
to 50 amino acids in length (Mahlapuu et al. 2016b). Although this method can 
efficiently produce low quantities of peptides at high purity, it is a lengthy and 
expensive process that is not sustainable for large-scale production of 
commercial drugs. 
 
Production systems for recombinant peptides include bacteria, yeast, insect and 
mammalian cells. However, these systems can require extensive optimisation 
and often have a long and extensive research and design phase (Mahlapuu et al. 
2016b). Despite this, AMPs have been successfully produced recombinantly 
which provides optimism for up-scaling and potential drug production on a 
pharmaceutical scale. Plectasin has been successfully produced recombinantly 
in Aspergillus oryzae (Mygind et al. 2005). Snakin-1 has been recombinantly 
produced in Pichia pastoris and purified from inclusion bodies which yielded 
approximately 40 mg of pure snakin-1 from a one litre bacterial culture (Kuddus 
et al. 2016). Tanhaiean et al., (2018) described a methodology for the 
recombinant production of a His-tagged camel milk lactoferrin in E. coli, which 
produced an average yield of 0.42 g of protein from a litre of bacterial culture. 
These studies highlight that recombinant technologies can be utilised for AMP 




All species are subject to microbial challenge, as such numerous mechanisms to 
combat bacterial attack have developed (Sharma and Nagaraj 2015). The search 
for novel antimicrobial compounds was led by the investigations in to the bacterial 
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defence strategy in organisms which lack an adaptive immune system. Defensins 
are naturally occurring cationic, cysteine-rich polypeptides which have been 
isolated from numerous organisms, including mammals, insects and plants (Ye 
et al. 2010). Similarity between insect defensins and scorpion venom toxins led 
to the isolation of the first scorpion defensin from the haemolymph of the North 
African scorpion Leiurus quinquestriatus (Cociancich et al. 1993). This scorpion 
peptide shared a high degree of homology with insect defensins in the order 
Odonata, it also demonstrated antimicrobial activity against Micrococcus luteus 
(Cociancich et al. 1993). The isolation of antimicrobial compounds from 
venomous animals was not unexpected; during the envenomation process in 
snakes, the fangs and oral cavity is exposed to a large quantity of potentially 
pathogenic bacteria but despite this, snake envenomation is associated with a 
low level of bacterial infection (de Lima et al. 2005, de Latour et al. 2010). 
Fosgerau and Hoffmann, (2015), established an infection model in scorpions and 
detected antimicrobial activity upon bacterial challenge. This research 
demonstrated the expression of antimicrobial compounds in venoms may have 
evolved to protect the venom gland from bacterial attack (Fosgerau and 
Hoffmann 2015). 
 
The venom of venomous animals represents a rich source of substances of 
therapeutic interest, such as AMPs, neurotoxins, defensins, antiepileptic peptides 
and ion-specific toxins amongst others (Zhu, Peigneur, et al. 2014, Memariani et 
al. 2016, Valdez-Velazquéz et al. 2016).  Antibacterial properties of venoms had 
been suspected for many years, with the first reports of these venom properties 
emerging in 1948 and 1968 from species of Elapidae and Viperidae snakes (de 
Lima et al. 2005, de Latour et al. 2010). Numerous snakes have demonstrated 
potent antimicrobial activity in their crude venom, such as the venom of Naja naja 
oxiana which has potent antimicrobial activity towards both Gram positive and 
Gram negative bacteria (Samy et al. 2016). It has also been demonstrated that 
scorpion venoms are an abundant source of AMPs and the presence of such 
peptides in the venom may contribute to the protection of the venom gland from 
infection whilst also facilitating the action of neurotoxins (Hernández-Aponte et 




Components of venoms have been used as therapeutic agents since the isolation 
of a bradykinin-potentiating peptide from the snake Bothrops jararaca in the latter 
half of the twentieth century. This peptide was developed in to captopril® (a small 
molecule angiotensin converting enzyme-inhibitor) as a result of the study of 
structure-function relationship analysis and design, thus demonstrating that 
therapeutic molecules can be developed from natural venom. (Reeks et al. 2015) 
Similarly, native AMPs derived from venoms are not optimal for therapeutic 
application and require modification to improve the therapeutic index (Datta et al. 
2015). Such modifications may include the substitution of amino acids or 
truncation to optimise the peptide to maximise antimicrobial activity and decrease 
host cytotoxicity (Memariani, et al. 2016). A greater understanding of the 
relationship between the structure and function of AMPs could also aid future 
development of novel therapeutics from naturally derived AMPs from venoms 
(Datta et al. 2015)  
 
1.11.1 Scorpion venom 
 
Scorpions are ancient animals and are considered one of the oldest forms of 
arachnids. Scorpions are characterised by an elongated body and the presence 
of a telson, which holds the venom glands (Abdel-Rahman et al. 2015). Scorpions 
now inhabit virtually all terrestrial habitats, except Antarctica. Over 1700 species 
have been described to date, with the key to their success being the production 
of potent venom (Ortiz et al. 2015). The venom of scorpions has evolved as a 
sophisticated weapon to aid in the capture of prey and self-defence (Abdel-
Rahman et al. 2015) whilst also providing a means of deterring possible 
competitors (Ortiz et al. 2015). Scorpion venom provides a rich source of 
biological components with a range of pharmaceutical activities (Ramírez-Carreto 
et al. 2015). Venom analyses have revealed that the venom from each individual 
scorpion species may contain over 500 different peptides ranging from 1 to 9 kDa 
in mass (Newton et al. 2007). Peptides derived from scorpion venoms can be 
loosely divided in to two separate groups: disulphide-bridged peptides (DBPs) 
which include neurotoxins and the non-disulphide bridged peptides (NDBPs) 
which possess anti-cancer, immunomodulatory and antimicrobial activities 
(Ramírez-Carreto et al. 2015).  
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The DBPs have been more widely explored, due to the medical relevance of 
envenomation (Ramírez-Carreto et al. 2015). The majority of DBPs are cross-
linked by 3-4 disulphide bridges and can specifically interact with ion channels 
(Machado et al. 2016). DBPs make up the largest constituent of scorpion venom 
and have been characterised as peptides which interact with ion channels 
(Harrison et al. 2014). Of the DBPs, neurotoxins have been the driving force of 
natural venom components. The neurotoxins can block or modify the targeted ion 
channels, which results in autonomic excitation, whilst α-toxins can also initiate a 
massive release of catecholamines. These two events combined can create a 
cascade of physiological events which can progress to tachycardia, heart failure 
and death (Ortiz et al. 2015).  
 
Scorpion stings are a notorious health issue in certain countries, with over 1.2 
million stings registered annually. However, scorpions have been traditionally 
used in medicine in Asia and Africa since the emergence of ancient cultures. 
(Ortiz et al. 2015) The isolation and chemical and functional characterisation of 
scorpion venom is expected to lead to the discovery of new molecules of 
therapeutic interest (Valdez-Velazquéz et al. 2016). 
 
There has been a growing interest in the NDBPs and to date, over 40 scorpion 
NDBPs have been identified and functionally characterised (Ramírez-Carreto et 
al. 2015). Most of the NDBPs characterised from scorpion venom are 
antimicrobial peptides, which are amphipathic and generally α-helical (Machado 
et al. 2016). These peptides have been demonstrated to modify their structural 
conformation depending on the environmental conditions, which can facilitate 
their interactions with bacterial membranes and contribute to antibiotic activity 
(Daniele-Silva et al. 2016). In addition to antimicrobial properties, the NDBPs 
have shown multiple activities, including; insecticide, antiviral, antifungal, 
antimalarial, haemolytic, anti-proliferation, bradykinin-potentiating and 
immunomodulatory (Daniele-Silva et al. 2016, Machado et al. 2016).  AMPs 
derived from scorpion venoms generally have a small size (13-56 amino acids), 
a cationic charge (+1 to +7) and distinct hydrophobic domains (Harrison et al. 
2014).  Bacteria have demonstrated a reduced ability to develop resistance to the 
NDBP- class of scorpion AMPs, which further demonstrates the potential of these 
molecules to provide a scaffold for the development of novel peptides to treat 
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infectious disease (Ramírez-Carreto et al. 2015, Daniele-Silva et al. 2016, 
Machado et al. 2016). 
 
1.11.2 Scorpio maurus palmatus 
 
The scorpion Scorpio maurus palmatus belongs to the family Scorpionidae which 
is commonly found in the Mediterranean, Middle East, Saudi Arabia and Jordan. 
S. m. palmatus is not dangerous to humans, but its venom possesses toxins 
which have neurotoxic and cytotoxic properties towards insects. Transcriptomic 
study of the venom milked from the venomous glands of S. m. palmatus has 
revealed the presence of antimicrobial peptides (Abdel-Rahman et al. 2013). 
 
Four antimicrobial peptides have been identified and characterised from the 
venom of S. m. palmatus. Of these, Smp24 and Smp43 are of greatest interest, 
as Smp13 and Smp76 demonstrated no detectible antimicrobial activity (Abdel-
Rahman et al. 2013). Smp24 and Smp43 share broad-spectrum antimicrobial 
activity and are promising candidates for development in to future therapeutics. 
Smp43 contains a helix-hinge-helix region, which is present in the group of 
longer-chain antimicrobial peptides all of which have high therapeutic indices. 
This group of AMPs has significant potential for development in to future 
antimicrobial therapeutics. Smp43 has demonstrated low levels of haemolysis, 
but it caused significant ATP release when assayed in HepG2 cells (Harrison et 
al., 2016). Modifications to the peptide to limit the host cytotoxicity would further 




Smp24 is 24 amino acids in length, bactericidal, cytotoxic and belongs to the mid-
chain family of scorpion antimicrobial peptides. It demonstrates broad-spectrum 
antimicrobial activity, including activity against methicillin-resistant 
Staphylococcus aureus (MRSA) isolates, Enterobacteriaceae and Candida 




Smp24 has demonstrated multiple modes of action, which vary depending upon 
the lipid composition of the target membrane (Harrison, et al. 2016). It operates 
by a membrane disruptive mechanism but has also demonstrated activity upon 
intracellular targets via disruption of DNA synthesis. Previous circular dichroism 
(CD) analysis determined Smp24 to be unordered in aqueous solution but adopts 
an α-helical structure in membrane mimetic conditions in the presence of 60% 
trifluoroethanol (TFE) with two helical regions of approximately 59% and 22% 
predicted (Harrison, et al. 2016). 
 
The disruptive effects of Smp24 on membranes have been determined via 
numerous methodologies, which concluded the mechanisms of membrane 
disruption are dependent on the membrane composition (Harrison et al. 2016). 
Atomic force microscopy (AFM) is a technique which enables the visualisation of 
live cells in situ, which makes it a valuable tool for the study of mechanisms of 
action of AMPs on bacterial cell membranes (Meincken et al. 2005). Electrostatic 
interaction and lipid defect sensing may be responsible for the initial attraction of 
Smp24 to prokaryotic (PC:PG) and eukaryotic (PC:PE) membrane surfaces, the 
precise nature of peptide induced membrane disruption is different. In anionic 
PC:PG bilayers, pores of varying size were observed by AFM, with pores ranging 
between 20 and 150 nm in width and a depth of 2 – 4 nm which remained stable 
over a 30 minute period. Increased peptide concentration resulted in complete 
membrane disruption within 5 minutes. Combined with liposome leakage data, 
this suggests that total membrane collapse does not happen and therefore 
favours a pore forming mechanism as opposed to a carpet mechanism (Harrison 
et al. 2016).  
 
Quartz crystal microbalance-dissipation (QCM-D) is a technique that enables the 
examination of interactions between an AMP and a biological membrane in real 
time and in situ, which provides information about the mass and structural 
changes occurring in the membrane (McCubbin et al. 2011). QCM-D data also 
supports the toroidal pore theory as increased peptide accumulation and 
increased dissipation was observed which is consistent with peptide induced 
membrane disruption. The dissipation event could be due to the peptide threshold 
concentration being overcome and peptide molecules mixing with the bilayer and 
thus resulting in reduced interaction with the aqueous phase. In conclusion, the 
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proposed mechanism of action for Smp24 is the classical pattern observed for 
AMPs: initial electrostatic interaction, peptide accumulation and membrane 
insertion upon meeting the threshold concentration. The collected data suggests 
Smp24 produces a toroidal pore, due to the presence of pores of varying sizes 
upon increased peptide concentration leading to complete destruction of the 
bilayer as opposed to increased pore formation (Harrison et al. 2016).   
 
For zwitterionic PC:PE bilayers, it is proposed that Smp24 operates via a different 
mechanism due to observation of stratifications via AFM. Liposome leakage was 
also less pronounced for PC:PE membranes and combined with QCM-D data, 
this supports that accumulation of peptides at the bilayer does not occur. Smp24 
has demonstrated the ability to cause disruption of PC:PE bilayers, forming pores 
between 200 and 350 nm in width depending upon Smp24 concentration, 
however, this does not lead to complete membrane disruption (Harrison et al. 
2016).   
 
Native Smp24 has a high percentage of haemolysis. Mutations have previously 
been applied to the structure of Smp24 to limit the percentage haemolysis. The 
truncation of the peptide to remove the 4 amino acids at the C-terminus (Smp24T) 
reduced haemolysis by 43%, but a high level of cytotoxicity was still observed 
(Harrison et al., 2016). Despite this, the decrease in haemolysis resulted in 
Smp24T demonstrating a higher therapeutic index overall. The incorporation of a 
glycine-valine-glycine (GVG) hinge has previously been postulated to reduce the 
haemolytic properties of venom-derived AMPs (Rodríguez et al. 2014b) but for 
Smp24 this resulted in increased haemolytic activity, increased toxicity towards 
HepG2 cells and decreased antimicrobial activity compared with native Smp24. 
For Smp24, the GVG hinge slightly decreased the selectivity of the peptide, 
suggesting whilst AMPs can share structural and functional characteristics, they 
may not be molecules which can adopt a shared strategy for therapeutic 
enhancement. Resultantly, this suggests further investigations in to the 
contribution of individual amino acids to the overall mechanism of action and 
cytotoxicity is required in order to fully understand how these molecules function 






Smp43 is a 43 amino acid peptide, which demonstrates broad-spectrum 
antimicrobial activity and a low level of haemolysis and cytotoxicity (Harrison, 
Abdel-Rahman, et al. 2016). Circular Dichroism (CD) analysis of Smp43 
demonstrated that like Smp24, the peptide was disordered aqueous solution and 
adopted its helical structure in membrane mimetic conditions. Smp43 adopted a 
di-helical structure in the presence of 60% TFE with two helical regions of 
approximately 70% and 25% (Harrison, et al. 2016). 
 
The mechanistic activity of Smp43 has been investigated by liposome leakage 
assays, AFM of anionic and zwitterionic membranes, QCM-D and intracellular 
reporter gene assays in Bacillus subtilis. No evidence of intracellular effects was 
observed for Smp43, with the stress response identified in B. subtilis reporter 
strains being limited to the cell envelope. The mechanistic information obtained 
by AFM analysis concluded that Smp43 is approximately 6.5 nm in length and 
therefore too large to span the membrane bilayer. The membrane-binding 
properties of Smp43 include initial binding and nucleation, defect growth by two-
dimensional diffusion of surface bound peptides to existing defect sites and the 
convoluted geometry of the observed defects suggests Smp43 dwells at the 
defect boundary where it stabilises the high edge energies associated by 
exposing the hydrophobic phospholipid tails (Heath et al. 2018).  
 
Smp43 shares 80% homology with Pandinin 1, an AMP derived from the venom 
of the scorpion Pandinus imperator (Rodríguez et al. 2014a). The observation of 
the mechanism of action of Smp43, combined with the sequence homology with 
Pandinin 1 suggests a mechanism by which there is initial electrostatic interaction 
at the membrane surface and the stabilisation of peptide-lipid bonds by the π-
electron cloud of the conserved tryptophan indole groups. A threshold 
concentration is then reached which enables peptide insertion in to the 
membrane, a stable pore is formed and additional peptides are able to diffuse in 
to the membrane defect which results in the removal of lipid micelles. This is a 
rapid process, which is potentially limited by the arrival of more peptide molecules 
to the defect site and the probability of peptide-peptide interactions and lipid 
removal (Heath et al. 2018). Whilst it has previously been established that the 
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insertion of peptides in to the lipid bilayer occurs at a critical concentration 
(Yandek et al. 2007), the data obtained for Smp43 was insufficient to determine 
if the peptide insertion occurred before or after diffusion to the observed 
membrane defects (Heath et al. 2018).  
 
The mechanism of action of Smp43 has been postulated as “diffusion limited 
disruption” which describes the growth of membrane defects as a result of peptide 
diffusion and accumulation. The speed and scope of this mechanism of action 
differs depending on membrane composition, with membrane defect growth 
occurring at a 30-fold faster rate in anionic PC:PG membranes than zwitterionic 
PC:PE membranes (Heath et al. 2018). 
 
To date, no studies have investigated the relationship between structure and 
function of Smp43 via a mutagenesis strategy. Although Smp43 does 
demonstrate broad spectrum antimicrobial activity, the obtained minimum-
inhibitory concentration (MIC) values for the Gram negative isolates tested were 
quite high (128 – 256 µg/ml) (Harrison et al. 2016). Modifications to the structure 
of Smp43 to enhance the antimicrobial properties of the peptide or truncation of 
the peptide in a similar methodology to that taken for Smp24 would be an 






1.12 Scope of the present study 
 
This present study aims to improve the understanding of the relationship between 
structure, function and cytotoxicity of venom-derived AMPs. The study also aims 
to develop a recombinant protein production system for AMPs to produce large 
quantities of peptide "in house" and ultimately create a library of peptides. 
 
The objectives were to: 
 
• Characterise the relationship between structure and antimicrobial activity 
by performing single amino-acid substitutions in Smp24 and Smp43. 
 
• Characterise the relationship between the Smp24 and Smp43-derived 
peptides and cytotoxicity and haemolytic activity with eukaryotic cells. 
 
• Determine the effects of the amino acid substitutions on the secondary 
structure of the peptides via biophysical techniques. 
 
• To develop a recombinant expression system for the over production of 
Smp24. 
 
• Optimise a site-directed mutagenesis (SDM) strategy to create a library of 

















All chemicals were purchased from Sigma Aldrich (Dorset, UK) unless otherwise 
stated. 
 
2.2 Peptide synthesis 
 
Smp24, Smp43 and all derived modifications were synthesised via solid-phase 
synthesis by David's Biotechnologie GmbH, Regensberg, Germany to a purity of 
90-99%. 
 
2.3 Minimum inhibition concentration (MIC) assay 
 
The MIC of the antimicrobial peptides was determined against a variety of 
organisms using the broth microdilution method described by Andrews (2001) 
and performed on the Clariostar plate reader (BMG labtech, Offenburg, 
Germany). The following microbes were used throughout this study: Escherichia 
coli JM109, Staphylococcus aureus SH1000, Pseudomonas aeruginosa 2056 
(H085180216), Bacillus subtilis sub species subtilis (NCIMB 3610).   
 
Overnight cultures were diluted in Muller Hinton (MH) broth (Sigma Aldrich, 
Dorset, UK) to produce a bacterial suspension for antimicrobial susceptibility 
testing. Doubling dilutions of antimicrobial peptides (AMPs) were added to the 
bacterial suspension at a 1:10 ratio with a final well volume of 200 µL. AMPs were 
examined at a concentration of 0 - 512 µg/ml, with MH broth as a growth control.  
Plates were incubated statically for 18 - 24 hours at 37°C and read using a plate 
reader. The MIC was defined as the lowest concentration of antimicrobial peptide 
at which growth was inhibited when viewed as turbidity against a negative broth 
control. The MIC was determined by performing the assay in triplicate (or 
duplicate if quantity was extremely limited) on two different occasions and 






2.4 Minimum bactericidal concentration (MBC) assay 
 
5 µL aliquots were taken from the wells of the 96-well MIC plate and spot plated 
on to MH agar in triplicate. The plates were incubated statically for 18 - 24 hours 
at 37°C.  The MBC was defined as the lowest concentration at which the visible 
growth was completely inhibited by the antimicrobial peptides (Henly et al. 2019). 
 
2.5 Minimum biofilm eradication concentration (MBEC) assay 
 
Overnight cultures of bacterial isolates (E. coli JM109 or E. coli EC2) were 
prepared in MH broth by inoculating 2 to 3 colonies of bacteria in 10 ml MH broth 
and incubating at 37°C, 200 rpm for 18 – 24 hours.  Overnight cultures were 
diluted to OD600 0.008 and 100 µl was added to a 96 well plate. A peg lid was 
added (NUNC, Warrington, UK) and the plate was incubated at 37°C for 18 - 24 
hours to enable biofilm formation.  
 
The peg lid was twice-washed with 200 µl PBS (Gibco, Warrington, UK) for 10 
seconds before being added to the “challenge plate.” The challenge plate was 
prepared by adding doubling dilutions of antimicrobial peptide in a 1:10 ratio with 
sterile MH broth to give a final well volume of 150 µl. The plate was incubated at 
37°C, 100 rpm for 24 hours. The minimum biofilm inhibition concentration (MBIC) 
was defined as the lowest concentration at which growth was inhibited versus the 
turbidity of a negative broth control and determined by measuring the OD600 of 
the 96-well plate. The peg lid was then transferred to 96-well plate containing 200 
µl of sterile MH broth and incubated for 24 hours at 37°C, 100 rpm. The minimum 
biofilm eradication concentration (MBEC) was determined as the lowest 
concentration required to cause no growth by reading the OD600 and comparing 
turbidity to a sterile MH broth control (Cowley et al. 2015). 
 
MBEC assays were performed in triplicate on two separate occasions. Data 





2.6 Haemolysis assay 
 
The haemolytic activity of the peptides was tested using sheep erythrocytes as 
described by Corzo et al, (2001). A 10% (v/v) suspension of phosphate buffered 
saline (PBS) washed sheep erythrocytes was incubated in a 96 well plate with 
the antimicrobial peptides at a concentration range of 0 – 512 μg/ml. The plate 
was incubated at room temperature with intermittent shaking for 1 hour. 
Haemolysis was determined by measuring the absorbance of the supernatant at 
an optical density of 570 nm on a Wallac Victor2 1420 plate reader (Marshall 
Scientific, New Hampshire, USA). 10% Triton X-100 was used as a positive 
control and deionised water was used as a negative control. All samples were 







Haemolysis assay results represent the average of three technical repeats. Due 
to the limitation of the quantity of peptide available for analysis, it was not possible 
to perform a biological repeat for haemolysis data. 
 
2.7 Cytotoxicity assays 
2.7.1 Eukaryotic cell culture line maintenance 
 
All cell lines were routinely screened for the presence of mycoplasma. Cells were 
grown in Dulbecco's modified Eagle's medium (DMEM) with 10% foetal calf 
serum (FCS) and 1% penicillin-streptomycin. Cells were incubated in T-75 flasks 
at 37˚C in a 5% CO2 atmosphere. Culture media was changed twice a week and 
cells were trypsinised upon reaching 90% confluence.  
 
Human urothelial epithelial cells (HUEPC) were purchased from Provitro (Berlin, 
Germany). HUEPC cells are a primary cell line, which were cultured without the 
addition of antibiotics in the media. Cells were grown in urothelial cell growth 
media (Provitro) at 37°C with 5% CO2 until cells reached 90% confluence. Cells 
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were twice washed with PBS, trypsinised using TrypLe (Gibco, UK) and 
neutralised with trypsin neutralising solution (Provitro). The cells were centrifuged 
at 300 x g for 5 minutes and re-suspended in urothelial growth medium. Culture 
media was changed every other day until cells reached 90% confluence.  
 
2.7.2 Cytotoxicity assays 
 
Cellular toxicity was determined by measuring lactate dehydrogenase (LDH) 
release by Pierce LDH release assay kit (Life Technologies, Paisley, UK). 
Peptides were assayed at a concentration range of 0.5 – 512 μg/ml against a 
human liver cell line (HepG2), kidney cell line (HEK-293) and keratinocyte cell 
line (HaCaT) to determine the potential toxic effects in vitro. 
 
Cells were seeded in a 96 well plate at a density of 2 x 105 cells per well (HepG2 
and HEK-293) and 1.6 x 105 cells per well (HaCaT) and 1.4 x 105 cells per well 
(HUEPC) in 90 µL of culture media and incubated for 24 hours. Peptides were 
then added and incubated for a further 24 hours. To determine LDH release, 50 
µL of culture media was incubated with 50 µL of reaction buffer at room 
temperature for 30 minutes as per manufacturer’s instructions. The absorbance 
of was measured at 490 nm and 680 nm using CLARIOstar microplate reader 
(BMG Labtech, Ortenberg, Germany). Deionised water was used as a 
spontaneous LDH control and 10% Triton X-100 was used as maximum LDH 
control. Prior to calculating percentage cytotoxicity, the background LDH 
absorbance (680 nm) was subtracted from the 490 nm absorbance. Cytotoxicity 






All cytotoxicity assays were performed in triplicate on two separate occasions. 





2.7.3 LD50 calculations 
 
The LD50 was defined as the concentration which resulted in 50% cell death. This 
was calculated by plotting AMP concentration versus cytotoxicity on a dose-
response curve and extrapolating the value which caused 50% cell death. 
 
 
2.7.4 T-test on data 
 
A T-test (De Winter 2013) was carried out on the calculated LD50 values. The 
LD50 of modified peptides was compared with that of the LD50 of the parental 
peptide. p-values of less than 0.05 were deemed to be statistically significant. A 
T-test was chosen for the method of statistical analysis due to the usage of this 
test in the field of drug research and development to compare the performance 
of drugs. In this study, the T-test was used to assess the performance of modified 
Smp analogues to the parental peptides (Smp24 and Smp43) to determine 
superiority of inferiority.  
 
2.7.5 Therapeutic index 
 
Therapeutic index (TI) is a widely accepted parameter to represent the specificity 
of antimicrobial peptides for prokaryotic versus eukaryotic cells. Larger TI values 
represent greater specificity for prokaryotic cells. Therapeutic index values were 
calculated as the ratio of cytotoxicity and antimicrobial activity by dividing LD50 
and HC50 values by the MIC for each peptide against E. coli (Jiang et al. 2014). 
 
2.8 Circular dichroism 
2.8.1 Methodology 
 
All circular dichroism (CD) work was carried out at the Department of Molecular 
Biology and Biotechnology, University of Sheffield. The secondary structures of 
antimicrobial peptides were determined via CD spectroscopy. Samples were 
prepared to a 100 µM concentration in water and 200 µl of the peptide was added 
53 
 
to the cuvette. Trifluoroethanol (TFE) was titrated in the experiment in a 0 - 70% 
concentration (v/v). The absorbance was corrected for the changes in volume 
over the assay. Analysis was performed on a JASCO J-810 spectropolarimeter  
(Jasco, Maryland, USA) at 22°C using a 0.1 cm path-length cell.  
 
2.8.2 Data analysis 
 














Data was analysed using the following equation: 
 
JFO>=	8OO;9:;B;:D =




Where observed ellipticity = degrees, Mr = kDa, concentration = mg/ml, path 
length = 0.1 cm and nA is the number of amino acids. 
 
2.9 Modelling 
2.9.1 Helical wheel projections 
 
Helical wheel projections were produced for all the peptides in this study using 






2.9.2 Ab-initio modelling 
 
Initial 3D-modelling was performed by inputting sequences into the Quark online 
server at https://zhanglab.ccmb.med.umich.edu/QUARK/. The software 
generated a secondary structure model and produced a file format which was 




3D-modelling of AMPs and derived modifications was achieved using PyMOL 2.3 
software by Schrödinger (https://pymol.org/2/). Structures were generated to 
display the amino acids of interest. 
 
2.9.4 Hydrophobic moment 
 
Hydrophobic moment and surface polarity was calculated using the software 
developed by Reißer et al., 2014, accessed at 
http://www.ibg.kit.edu/HM/?page=paper 
 
2.10 Gene synthesis 
 
STII/Smp24 gene sequences were designed based upon native peptides isolated 
from Scorpio maurus palmatus venom (Harrison, Abdel-Rahman, et al. 2016). 
Smp24 sequences were adapted for E. coli codon usage and fused to a signal 
peptide from heat-stable E. coli as per Lyukmanova, et al, (2007). The 
STII/peptide inserts were synthesised and fused between the HindIII and NdeI 
sites of the vector pET22b (+) by Eurofins (Ebersberg, Germany). 
 
Plasmids for the expression of FLAG-tagged peptides were designed using the 
same methodology listed above. The codon usage for the amino acid sequence 
for the FLAG tag (DYKDDDDK) and the cleavage sequence (LVPRGS) was 
adapted for codon usage in E. coli. The gene inserts were spliced in to a pET22b 
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(+) vector between the NdeI and HindIII restriction sites by Eurofins (Ebersberg, 
Germany). 
 
2.10.1 Transformation of plasmids 
 
E. coli BL21 was prepared in 10 ml Luria Burtani (LB) broth and incubated 
overnight at 37°C with moderate shaking (200 rpm). To produce electro-
competent cells, the overnight culture was diluted 1:500 in to 50 ml of LB broth 
and placed in a 37°C incubator for 90 - 120 minutes until the cells reached mid-
log phase (OD600 0.5). The cells were pelleted by centrifugation at 4800 x g, 4°C 
for 10 minutes. The cell pellet was re-suspended in 20 ml ice cold sterile dH2O 
and centrifuged again under the same conditions. The cell pellet was twice 
washed with ice cold water before a final resuspension in 2.5 ml sterile dH2O.  
 
Plasmids were transformed by the addition of 1 µl of plasmid to 100 µl of electro-
competent E. coli cells and pulsing for 1 second using an electroporator (Bio-Rad, 
Watford, UK). 1 ml of LB broth was added to the transformed cells and the cells 
were incubated at 37°C for 1 hour prior to plating out the cells on LB agar 
containing 100 µg/ml ampicillin and incubating at 37°C overnight. A negative 
control was prepared by transforming 1 µl of sterile dH2O into electro-competent 
cells. 
 
2.10.2 Polymerase chain reaction (PCR) to confirm transformation 
 
Following transformation, the presence of plasmids was confirmed via extraction, 
PCR and analyses of T7 PCR fragments via agarose electrophoresis. Overnight 
cultures were prepared by adding one colony of transformed bacteria to 5 ml LB 
broth containing 100 μg/mL ampicillin. Plasmids were extracted via GeneJET 
Miniprep kit (Thermo Fisher Scientific, Hemel Hempstead, UK) as per 
manufacturer's instructions.  
 
1 μl of plasmid was added to a PCR tube containing 47 µL MegaMix (Microzone, 
Stourbridge, UK), 1 µl T7 forward primer (5'-TAATACGACTCACTATAGGG-3') 
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and 1 μl T7 reverse primer (5'- GCTAGTTATTGCTCAGCGG-3') (Sigma-Aldrich, 
Dorset, UK). Amplification was performed on a Techne TC-3000 PCR thermal 
cycler with the following conditions: initial denaturation 95°C 3 minutes, followed 
by 30 cycles of 95°C 30 seconds, 42°C 1 minute, 72°C 1 minute and final 
extension 72°C for 5 minutes. The PCR products were visualised on a 1% 
agarose gel containing 0.01% Ethidium Bromide. All constructs were sent for 
sequencing confirmation at Eurofins (Ebersberg, Germany). 
 
2.10.3 Agarose gel electrophoresis 
 
PCR products were visualised on a 1% agarose gel made up in 30 ml TAE buffer 
containing 0.01% Ethidium bromide. The PCR product was mixed with 5 x loading 
dye (Bioline, London, UK) and 10 μl of this was added to the gel. A 1 kb DNA 
HyperLadder (Bioline, London, UK) was used as a marker to determine the size 
of the fragments. Gels were visualised and photographed under UV light using 
the NU Genius gel dock system (Syngene, Cambridge, UK). 
 
2.11 Production of Smp24 with the STII leader sequence 
 
An overnight culture of E. coli BL21 λDE3 containing the pET22b/STII/Smp24 
vector was prepared by inoculating 1 colony of bacteria in to 50 ml of LB broth 
containing 100 µg/ml ampicillin. The culture was incubated at 37°C with moderate 
shaking (200 - 250 rpm) for 18 hours. The overnight culture was diluted 1:100 in 
to minimal mineral M9 media (0.4% glycerol, 3 g/litre KH2PO4, 6 g/litre Na2HPO4, 
0.5 g/litre NaCl, 0.24 g/litre MgSO4, 0.01 g/litre CaCl2, 2 g/litre NH4Cl, 1% 
thiamine chloride, 0.2% yeast extract) containing ampicillin (100 µg/ml). The cells 
were cultivated at 37°C with shaking at 250 rpm until the cells reached mid-log 
phase with an optical density of 0.6 at 600 nm. Gene expression was induced by 
the addition of isopropyl-1-thio-β-D-galactopyranoside (IPTG) to a final 
concentration of 0.05 mM. After 15 hours of cultivation, the growth culture was 
centrifuged at 14,000 x g for 30 minutes at 4°C. The growth media was then 
acidified to pH 4.5, heated to 70°C for 30 minutes and then centrifuged again at 




Following the overproduction of Smp24, the culture was centrifuged at 14,000 x 
g for 30 minutes. The supernatant was acidified to pH 4.5, heated to 70°C and 
centrifuged under the same conditions. 
 
2.12 Purification of the STII/Smp24 peptide 
2.12.1 Cation exchange I 
 
Peptides were purified via Akta Design using a 20 ml Sepharose Fast Flow resign 
column (GE Healthcare, Buckinghamshire, UK) equilibrated with 10 mM 
CH3COONa, pH 5.0 (buffer A). All buffers, the expressed protein diluted in buffer 
A, were de-gassed and passed through a 0.22 µM filter. 
 
The column was equilibrated with 5 column volumes (CVs) of buffer A. The 
culture supernatant was diluted in 1 L of buffer A and applied to the column via 
peristaltic pump at a flow rate of 38. The column was washed with 5 CVs of buffer 
A prior to elution. Samples were eluted from the column using the Akta Design 
via a gradient from a range of 0 - 1 M NaCl. This was achieved via gradient elution 
with 10 mM CH3COONa, 1 M NaCl pH 5.0 (buffer B) over 20 CVs. The elution of 
peptides and/or proteins was determined by monitoring the UV range at 215 nm 
and 280 nm. Fractions containing proteins were collected, freeze-dried and re-
dissolved in 1 ml dH2O (Lyukmanova et al. 2007a).  
 
2.12.2 Cation exchange II 
 
The sample was de-salted by membrane dialysis, lyophilised and re-suspended 
for further purification to remove any additional impurities. The sample was 
purified using a second cation exchange column, a MonoS HR5/5 column (GE 
Healthcare, Buckinghamshire, UK) equilibrated with 10 mM CH3COONa pH 5.0. 
Samples were to be eluted against an NaCl gradient over 20 CVs. Purification 




2.13 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 
SDS-PAGE was carried out using the Bio-Rad Mini Protean system following 
manufacturer's instructions. Samples for SDS-PAGE were prepared by adding 
30 µl of protein sample to 30 µl of sample buffer (table 2.1) and heated at 95°C 
for 5 minutes. The reagents used for SDS-PAGE are listed in table 2.1. 
 





45 ml 10% SDS, 2.5 ml 0.5 M TRIS pH 6.8, 5 ml dH2O, 2.5 ml 
glycerol, 200 µl 5% Bromophenol blue, 250 µl β-mercaptoethanol 
Separating 
gel (10%) 
3.33 ml 30% Acrylamide-bis solution (Bio-Rad laboratories Ltd, 
Herts, UK), 2.5 ml 1.5 M TRIS pH 8.8, 100 µl 10% SDS, 4 ml dH2O, 
200 µl APS, 20 µl TEMED. 
Stacking gel 750 µL Acrylamide-bis solution (Bio-Rad), 1.5 ml 0.5 M TRIS pH 
6.5, 60 µl 10% SDS, 3 ml dH2O, 150 µl APS, 10 µl TEMED 
Running 
buffer 
14.4g glycine (Fisher Scientific, Loughborough, UK), 1g SDS, 3g 
TRIS made up to 1 litre with dH2O 
Stain 200 ml methanol (Fisher Scientific) 75 ml acetic acid (Fisher 
Scientific), 0.1% Coomassie blue R-250, made up to 1 litre with 
dH2O. 
Destain 200 ml methanol (Fisher Scientific), 75 ml acetic acid (Fisher 
Scientific) made up to 1 litre with dH2O. 
 
A resolving gel solution of 10% acrylamide was poured between two glass plates 
which had previously been cleaned with iso-propanol. 100 µl of water saturated 
butanol was added to the top of the gel to allow the gel to set with an even surface. 
Once set, the butanol and non-polymerised acrylamide was poured off and the 
gel washed with dH2O. The stacking gel was poured on to the resolving gel and 
the plastic comb inserted. Once the gel was set, the comb was removed and the 
wells washed with dH2O. The gel was then assembled in a tank with the running 
buffer and the samples were loaded. The gel was run at 200V with 30 µl of sample 
running against the Precision Plus Protein Dual Xtra ladder (Bio-Rad 
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Laboratories Ltd, Hertfordshire, UK). Gels were stained overnight and then 
adequately de-stained. 
 
If AMPs were not resolved via a 10% resolving gel, an optimised gel was used 
with an increased concentration of acrylamide. The final gel composition is stated 
in table 2.2. 
 





1.5 ml dH2O, 16 ml 30% acrylamide-bis solution (Bio-Rad), 6 ml 
1.5 M TRIS pH 8.8, 240 µL 10 % SDS, 240 µl 10 % APS, 24 µl 
TEMED. 
Stacking gel 7.9 ml dH2O, 3 ml acrylamide-bis solution (Bio-Rad), 3.375 ml 0.5 
M TRIS pH 6.8, 150 µl 10% SDS, 150 µl 10% APS, 15 µl TEMED. 
 
Gels were prepared as previously described. Samples (30 µl) were loaded in to 
the gel and run against the Precision Plus Dual Xtra ladder at 200V.  
 
2.14 Tris-tricine PAGE 
 
Despite increasing the acrylamide concentration, the resolution of the gel 
remained poor in the low molecular weight range. TRIS-tricine gels were utilised 
to achieve better resolution at a lower molecular weight. 
 
2.14.1 TRIS-tricine gel composition (12%) 
 














Cathode buffer 0.1 M TRIS (Fisher Scientific), 0.1 M tricine (Fisher Scientific), 0.1 
% SDS made up to 1 litre with dH2O. 
Anode buffer 0.2 M TRIS (Fisher Scientific) pH 8.9 made up to 1 litre with dH2O. 
Separating gel 
(12%) 
3 ml acrylamide-bis solution (75.5:1, 40%) (Bio-Rad), 303 ml TRIS 
3 M pH 8.45, 1 ml glycerol, 3.2 µl TEMED, 80 µl APS, 2.2 ml dH2O 
Stacking gel 0.43 ml acrylamide-bis solution (Bio-Rad), 1.24 ml TRIS 3 M, 3.32 
ml dH2O, 5 µl TEMED, 50 µl APS. 
 
Gels were prepared as per section 2.12 using the Bio-Rad Mini Protean system. 
The gel was then assembled in a tank with the anode buffer applied to the upper 
tank and the cathode buffer applied to the lower tank. Samples were mixed in a 
1:1 ratio with sample buffer and loaded to the gel. The gel was run at 200V with 
30 µl of sample running against the Precision Plus Protein Dual Xtra ladder (Bio-
Rad Laboratories Ltd, Hertfordshire, UK). Gels were stained overnight and then 
adequately de-stained as per section 2.12. 
 
2.14.2 Pre-cast gels 
 
As an alternative to the TRIS-Tricine gels, pre-cast gels from Bio-Rad were 
purchased. Initially, the 16.5% Mini Protean TRIS-Tricine gel (Bio-Rad) was 
purchased. The gel was assembled in the Mini Protean tank and filled with TRIS-
tricine running buffer (Bio-Rad). Protein samples were mixed with tricine sample 
buffer for protein gels (Bio-Rad) in a 1:1 ratio and applied to the gel. Gels were 
run at 200V against the Precision Plus Dual Xtra ladder. Samples were stained 






2.14.3 Pre-cast gradient gel 
 
10 - 20% gradient Mini Protean TRIS Tricine gels were also used for the 
identification of Smp24. Samples were run as per section 2.13.2 at 200V under 
the same conditions and stained using the Pierce Silver Stain kit (Life 




α-cyano-4-hydroxycinnamic-acid (CHCA) was used as the sample matrix and 
prepared to a concentration of 5 mg/ml in 70:30 ratio of acetonitrile: 0.5% 
trifluoroacetic acid (TFA). 0.5 μl of sample was added to 0.5 μl of matrix on the 
target plate and dried until the matrix and protein co-crystallised. The plate was 
analysed on the Bruker Autoflex III Smartbeam MALDI-TOF (Bruker, 
Massachusetts, United States). Spectra were processed using mMass software 
to visualise peaks. 
 
2.16 Immunological detection of Smp24 by anti-Smp24 antibodies 
2.16.1 Raising antibodies in rabbits 
 
As Smp24 is not a commercially available peptide, antibodies were raised by 
immunisation of animals with the antigen of interest. Polyclonal antibodies 
against Smp24 were raised in rabbits following a SuperFast 28 day immunisation 
schedule by David's Biotechnologie (Regensberg, Germany). The 28-day 
protocol yields antibodies with titres comparable to standard 63 or 90 day 
procedures.  
 
2.16.2 Dot blot 
 
1 µl of sample or controls was added to nitrocellulose membranes (Abcam, 
Cambridge, UK) and allowed to air dry. Bovine serum albumin (BSA) at a 
concentration of 1 mg/ml was used as a negative bind control. Samples were 
blocked in 5% milk in TBST (20 mM TRIS, 150 mM NaCl, 0.05% Tween-20, pH 
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7.5) for 1 hour in a petri dish, with gentle agitation (65 rpm) at room temperature. 
The blot was incubated with primary antibody (1:10,000) dissolved in 2% milk in 
TBST and incubated at room temperature for 1 hour with gentle agitation. After 1 
hour, the blot was washed with TBS (20 mM TRIS, 150 mM NaCl, pH 7.5) for 3 x 
10 minute washes. A goat anti-rabbit secondary antibody IRDye 800CW (Licor, 
Cambridge, UK) was added at a 1:10,000 dilution in 2% milk in TBST and 
incubated in the dark, at room temperature with gentle agitation for 1.5 hours. 
The blot was then washed for 5 minutes in TBS prior to being visualised on an 
Odyssey imaging system (Licor, Cambridge, UK). 
 
2.17 Galleria mellonella pathogenicity assay 
2.17.1 Preparation of larvae 
 
Final larval stage G. mellonella larvae (Whole Foods Ltd, Sheffield, UK) were 
stored in the dark at 4˚C for less than 7 days before being randomly assigned to 
each construct-containing bacterial isolate. The larvae were assigned 12 to each 
condition and the death was monitored over a 7 day period.  
 
2.17.2 Pathogenicity assay 
 
The larvae were incubated at 37˚C for 30 minutes prior to injection. Overnight 
cultures of each test bacteria were centrifuged at 12000 x g and twice washed 
with sterile PBS (Gibco, Paisley, UK). Samples were diluted to an OD600 of 0.1 (5 
x 108 to 8 x 108 CFU/ml) in 1ml. 5 µl of each suspension was injected in to the 
hemocoel of each larva via the second to last left proleg with a Hamilton syringe. 
Larvae were incubated at 37˚C in sealed petri dishes and the numbers of 
surviving larvae were recorded daily. A non-injected group and a group injected 
with sterile PBS were used as negative controls. 
 
The experiment was run for a 7 day period or until 2 of the control group had died, 
whichever came first. Two independent bacterial replicates were used to 




2.17.3 Log rank reduction test. 
 
A log-rank reduction test was performed on the data to determine the statistical 
significance. Log-rank reduction tests (LRRTs) are used to compare the survival 
between different groups. LRRTs are widely used in clinical trials to establish the 
efficacy of a new treatment compared with a control when the measurement is 
the time to event. In the scope of this study, the event is death of the larvae. The 
significance in death rate was calculated using a log rank reduction test (p ≤0.05).  
 
2.18 Affinity tagged protein over production 
2.18.1 Protein overproduction 
 
A 50 ml culture of E. coli BL21 λDE3 containing the vector of interest was 
prepared in 250 ml conical flask in LB broth containing 100 µg/ml ampicillin and 
incubated at 37°C, 200 rpm overnight. The overnight culture was diluted 1:200 in 
to 1L of fresh LB broth containing 100 µg/ml ampicillin and incubated at 37°C with 
orbital shaking at 200 rpm until the OD600 reached 0.5 - 0.6. The culture was 
rested at room temperature for 30 minutes prior to the addition of IPTG to a final 
concentration of 1 mM. The culture was incubated at room temperature with 
moderate shaking (225 rpm) overnight.  
 
Cells were harvested by centrifugation at 5000 x g for 30 minutes at 2 - 8°C. The 
supernatant was discarded and the pellet was frozen at -20°C. The frozen cells 
were lysed by adding 10 ml of CellLytic B (Sigma-Aldrich, Dorset UK) per gram 
of frozen cell paste. The lysis buffer and protein pellet solution was incubated at 
room temperature with rocking as per manufacturer’s instruction for 15 minutes 
to fully extract the soluble proteins from the cells. Following protein extraction, the 
cells were centrifuged at 16,000 x g for 10 minutes to remove the insoluble 
material. The supernatant (soluble) fraction was separated from the pellet 
(insoluble) fraction. Both fractions were analysed by dot blot to determine the 




2.18.2 Identification of fusion protein by dot blot 
 
Expressed protein samples (1 µl) were added to nitrocellulose membrane 
(Abcam PLC, Cambridge, UK) and air dried. BSA at a concentration of 1 mg/ml 
was used as a negative bind control. Samples were blocked in 5% milk in TBST  
for 1 hour in a petri dish, with gentle agitation (65 rpm) at room temperature. The 
blot was incubated with anti-FLAG antibody produced in rabbit (Millipore, 
Watford, UK) dissolved in 2% milk in TBST incubated at room temperature for 1 
hour with gentle agitation.  
 
After 1 hour, the blot was washed with TBS for 3 x 10 minute washes. A goat anti-
rabbit secondary antibody IRDye 800CW (Licor, Cambridge, UK) was added at a 
1:10,000 dilution in 2% milk in TBST and incubated in the dark, at room 
temperature with gentle agitation for 1.5 hours. The blot was then washed for 5 




2.19 Affinity-tagged protein purification 
 
M2 affinity gel was prepared as per manufacturer's instructions. The protein 
containing supernatant was added to M2 affinity gel and incubated on a rocking 
platform with protease inhibitors (Fisher Scientific, Leicestershire, UK) at 4°C 
overnight to enable the fusion proteins to bind to the agarose beads. The 
following morning, the gel was centrifuged at 1000 x g for 5 minutes to separate 
the gel from the unbound supernatant. The supernatant was removed and stored 
for dot blot analysis; the gel was washed by adding 2 ml of TBS and centrifuging 
at 500 x g for one minute. This process was repeated until the A280 reached 0.05. 
The bound protein was eluted from the gel using 0.1 M glycine HCl pH 3.5. The 
gel was incubated with the glycine at room temperature with gentle agitation (200 
rpm) for 5 minutes. This was centrifuged at 800 x g for 1 minute, the supernatant 
(eluted protein) was eluted in to three 1 ml fractions in to tubes containing 20 µl 




2.19.1 Further optimisation 
 
Where no protein was detected to have eluted from the affinity gel, the cell 
lysate was diluted 2-fold in to lysis buffer before binding to the M2 affinity gel at 
4°C overnight. The gel was pelleted by centrifugation, the supernatant was 
again kept for dot blot analysis and the gel washed with TBS until to A280 
reached 0.05. Any bound protein was eluted from the gel by incubation with 0.1 
M glycine pH 3.5 with gentle rocking at room temperature for 15 minutes. The 
gel was again centrifuged and the eluted proteins were assayed for FLAG-
content via dot blot. 
 
2.20 Site-directed mutagenesis 
 
Site-directed mutagenesis (SDM) was performed using the Agilent Quik Change 
II mutagenesis kit (Agilent Technologies, Cheshire, UK). Primers were designed 
using Agilent Primer Design software and synthesised by Life Technologies Ltd, 
(Paisley, UK).  
 
Mutagenesis reactions were optimised from the initial manufacturer's instructions, 
with the addition of 5% DMSO to prevent the formation of primer secondary 
structures. Mutagenesis conditions were as follows: 
 
§ 5 µl of 10 x reaction buffer 
§ X µl of pET22b/STII/Smp24 plasmid  (to add ~45 ng) 
§ 1.25 µl forward primer (100 ng/µl) 
§ 1.25 µl reverse primer (100 ng/µl) 
§ 1 µl dNTP mix 
§ 2.5 µl dimethyl sulfoxide (DMSO) 
§ dH2O to a final volume of 50 µl 
§ 1 µl PfuUltra High Fidelity DNA polymerase (2.5 U/µl) 
 
Amplification was performed on a Techne TC-3000 PCR amplifier under the 




Table 2.4: PCR cycling conditions for site-directed mutagenesis 
 
Segment Cycles Temperature Time 
1 1 95°C 30 seconds 
2 16 95°C 30 seconds 
55°C 1 minute 
68°C 6 minutes 
 
 
Following amplification, a restriction digest was performed. 1 µl of DpnI restriction 
enzyme (10 U/µl) was added to each amplification reaction, mixed, centrifuged 
via micro-centrifuge for 1 minute and then incubated at 37°C for 2 hours.  
 
For the transformation, 2 µl of DpnI treated DNA (the plasmid with the introduced 
mutation) was added to a 50 µl aliquot of XL1-Blue cells and incubated on ice for 
30 minutes before heat-shocking the samples at 42°C for 45 seconds and re-
incubating on ice for 2 minutes. 500 µl of S.O.C. media (2% tryptone, 0.5% yeast 
extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20mM glucose) 
pre-heated to 42°C was added to the transformation reaction and incubated at 
37°C for 1 hour with moderate shaking (225-250 rpm). 250 µl of reaction was 
added to an LB agar plate containing 100 µg/ml ampicillin and incubated 






Elucidating the relationship between structure 




3.1  Introduction 
 
With the ever-increasing development of resistance to conventional antibiotics, 
there is an urgent need to develop novel compounds for infection management 
and treatment (Ciumac et al. 2019). As such, antimicrobial peptides (AMPs) are 
attracting increased therapeutic interest with a long-term aim of optimising the 
peptides to enhance potency whilst delivering safe therapeutics with minimised 
risk of antimicrobial resistance (AMR) development (Schmidtchen et al. 2014). 
There are currently 60 Food and Drug Administration (FDA) approved peptide 
drugs, with a further 140 candidates in various phases of clinical trials, 
highlighting the potential for novel antimicrobial peptide-based drug development 
(Hazam et al. 2019). Pharmaceutical companies are making efforts to 
commercialise AMPs (Alencar-Silva et al. 2018). 
 
Despite the promising nature of peptide-based antimicrobial drugs, factors 
limiting their potential utility as therapeutic agents include a limited spectrum of 
activity, low cell-membrane permeability and low oral-bioavailability (Hazam et al. 
2019). Approaches are being taken to design novel AMPs, including peptide  
truncation, and deletion and substitution of amino acids from the peptide chain 
(Harrison et al., 2016a; Hilpert et al., 2006; Rathinakumar et al., 2009). Structure-
activity relationship studies can be used to systematically modify naturally 
occurring peptides or design new synthetic peptides de novo to determine the 
relationship between structure and function (Torres et al. 2019). The overall goal 
of this approach is to produce improved AMPs with enhanced antimicrobial 
activity and reduced mammalian cytotoxicity. 
 
Over 5000 AMPs have been identified to date (Fan et al. 2016), with over 40 
peptides being biologically categorised from scorpion venom alone (Harrison et 
al. 2014). Some of the peptides demonstrate strong antimicrobial activity whilst 
others demonstrate more species specific antimicrobial activity (Harrison et al. 
2014, Miyashita et al. 2017, Li et al. 2019a).   
 
Although AMPs demonstrate structural diversity, they are commonly defined as 
short (10-50 amino acids), cationic (+2 to +9) and have been classified in to three 
main groups. Linear peptides which form alpha-helices, cysteine-rich peptides 
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which contain one or more disulphide bonds and peptides with an over-
representation of one or two amino acids (Hancock and Lehrer 1998, Zasloff 
2002), such as glycine, proline, tryptophan or histidine (Koehbach and Craik 
2019). As AMPs are biological molecules,  some of the peptides are derived from 
larger pre-cursor proteins, which consist of a signal peptide, prosequence and a 
mature peptide (Abdel-Rahman et al. 2013, Kim, Go, et al. 2018). 
 
Four α-helical antimicrobial peptides (Smp13, Smp24, Smp43 and Smp76) have 
been characterised from the venom of the Egyptian scorpion Scorpio maurus 
palmatus (Abdel-Rahman et al., 2013). Of these four peptides, Smp24 and 
Smp43 demonstrated broad-spectrum antimicrobial activity (Harrison et al., 
2016). Smp24 is a 24-amino acid peptide carrying a charge of +3 and shares 
54% sequence homology with Pandinin 2, an AMP from the venom of the 
scorpion Pandinus imperator. Smp24 displays cytotoxic and haemolytic activity 
which in its native form, decreases the therapeutic application of the peptide. 
Smp43 is a 43-amino acid peptide, which carries a charge of +4 and has broad-
spectrum antimicrobial activity, though not as a potent as the sister peptide 
Smp24, and a more favourable cytotoxicity profile (Harrison et al., 2016a) . Both 
peptides are of therapeutic interest, Smp24 for its broad-spectrum antimicrobial 
activity and Smp43 for its lower level of haemolysis and cytotoxicity compared 
with Smp24. 
 
3.2 Study aims 
 
The experiments in this chapter aim to improve the antimicrobial activity of Smp24 
and Smp43. Structural modifications were performed on both peptides by 
introducing single, double or triple amino acid substitutions and determining the 
effect the structural changes had on the antimicrobial function of the peptides. 
 
This chapter also aims to investigate the mechanism of action of the modified 
(daughter) peptides compared with the native peptides using homology modelling 
and structural investigation using circular dichroism (CD) spectroscopy. 
Successful candidate molecules for further development in the clinical setting 




3.3 Experimental design 
 
The two peptides used within this study (figure 3.1) have been modified on the 
basis of improving the antimicrobial activity. Single amino acid substitutions are 
a common methodology for investigating the relationship between structure and 
function (Zhu, Dong, et al. 2014) with strategies varying between research 
groups. A systematic approach to mutagenesis is required to cover as much of 
the sequence space as possible. Previously, increasing the charge of 
antimicrobial peptides has been linked with increased antimicrobial activity 
(Huang et al. 2015, Torres et al. 2019).  
  
Helical wheel diagrams can be used to display the sequence of helical peptides, 
in this case Smp24 and Smp43. Helical wheels present the theoretical structure 
of alpha-helical peptides and how the helix “stacks” when looking down through 
the different turns of the helix. This enables the clusters of amino-acids to be 
visualised, to determine if the peptide adopts an area of hydrophobicity, 
hydrophilicity and charge (amphipathic structure). This information can be used 
to determine how to enhance the peptides by increasing the amphipathic 












Figure 3.1: Helical wheel projections. Helical wheel diagrams were produced for Smp24 (A) and Smp43 (B) using 
the rzlab software from the University of California (www.rzlab.ucr.edu). Hydrophilic (circles), hydrophobic 
(diamonds), potentially positively charged (pentagons), potentially negatively charged (triangles). Hydrophilicity is 
depicted proportionally by a red-orange colour scheme, with red symbolising the greatest hydrophilic (uncharged). 
Hydrophobicity is shown using a green-yellow colour scheme with green being the most hydrophobic fading 




A strategy was taken to substitute serine residues (polar uncharged) for lysine 
residues (positively charged) to increase the overall charge of the peptides by +1. 
This methodology was used by (Huang et al. 2015) which determined increasing 
the charge of a porcine antimicrobial peptide resulted in increased antimicrobial 
activity. As such, this formed the basis for the initial mutagenesis strategy for both 
Smp 24 and Smp43.  
 
Alanine  scanning is a methodology commonly implemented to investigate  the 
side chains responsible for  binding and activity (Jamieson et al., 2013; Torres et 
al., 2019). Tryptophan residues have been demonstrated to be important for pore 
formation (Travkova et al. 2017), an approach was taken to substitute tryptophan 
residues for alanine across both peptides. The role of tryptophan residues in the 
antimicrobial peptide Pandinin-2, which shares sequence homology with Smp43, 
was demonstrated in a study by (Ramírez-Carreto et al. 2015). The substitution 
of tryptophan residues for alanine residues resulted in a loss of antimicrobial 
function. Due to the high sequence homology between Pandinin-2 and Smp43 
(70%), it was an interesting research direction to determine the role of tryptophan 
residues in the Smp peptides. As such this could provide structural and functional 
information as to whether peptides with similar sequence homologies can be 
mutated using the same strategy and yield similar results. 
 









In total, 10 modifications of Smp24 were produced and 8 modifications of Smp43 
were produced. A double charge modification of Smp24 (S3K/S15K) was 
produced to determine if charge could be increased to produce more 
antimicrobial activity or if charge could ultimately become a limiting factor.  
 
A triple alanine knockout of Smp43 (W3A/W5A/W14A) was produced to 
determine whether tryptophan residues were essential for function following initial 
single substitutions by alanine scanning. Aspartic acid residues (D) were 
Figure 3.2: Mutation strategy for scorpion AMPs. Modifications were made to increase 
the charge of Smp24 (A) and Smp43 (C). Modifications were also made to increase the 
hydrophobicity of Smp24 (B) and Smp43 (D). 
74 
 
substituted for phenylalanine (F) to simultaneously increase the charge and 
hydrophobicity of the peptides. 
 
Prior to peptide production, the charge, stability, PI and grand average of 
hydropathy (GRAVY) of the peptides were calculated using the ProtParam tool 




The peptide sequences and induced changes to the charge, isoelectric point (PI) 
and hydrophobicity are shown in table 3.1 for Smp24 variants and table 3.2 for 
Smp43 derived peptides. Isoelectric point is the pH at which a protein has no net 
charge; significant changes to the PI can affect the charge of the peptide at 
physiological conditions. Proteins carry a positive charge at pH values lower than 
the PI, in the case of Smp24 and Smp43, the peptides are positively charged at 
physiological pH. Hydrophobicity is displayed as the GRAVY, which is calculated 
by adding the hydropathy value for each amino acid  residue and dividing by the 
length of the peptide (Kyte and Doolittle 1982). Hydrophobicity scores below 0 
are more likely globular (hydrophilic) and scores above 0 are more likely 
membranous (hydrophobic) (Maeda et al. 2012). Therefore, the higher the 








3.4.1 Peptide sequences 
 
Table 3.1: Sequence and parameter data for Smp24 and derived modifications. 
 
Peptide Charge GRAVY Molar Mass (Da) pI Sequence 
Smp24 +3 0.31 2578 10.0 IWSFLIKAATKLLPSLFGGGKKDS 
Smp24 W2A +3 0.43 2462 10.0 IASFLIKAATKLLPSLFGGGKKDS 
Smp24 S3F +3 0.46 2638 10.0 IWFFLIKAATKLLPSLFGGGKKDS 
Smp24 S3K +4 0.18 2619 10.2 IWKFLIKAATKLLPSLFGGGKKDS 
Smp24 S3K/S15K +5 0.05 2573 10.3 IWKFLIKAATKLLPKLFGGGKKDS 
Smp24 F4A +3 0.27 2502 10.0 IWSALIKAATKLLPSLFGGGKKDS 
Smp24 K7S +2 0.44 2537 9.7 IWSFLISAATKLLPSLFGGGKKDS 
Smp24 K7F +2 0.59 2597 9.7 IWSFLIFAATKLLPSLFGGGKKDS 
Smp24 S15K +4 0.18 2619 10.2 IWSFLIKAATKLLPKLFGGGKKDS 
Smp24 D23F +4 0.58 2610 10.5 IWSFLIKAATKLLPSLFGGGKKFS 
Smp24 S24K +4 0.18 2619 10.2 IWSFLIKAATKLLPSLFGGGKKDK 
 








Table 3.2: Sequence and parameter data for Smp43 and derived modifications. 
 
Peptide Charge GRAVY Molar Mass 
(Da) 
PI Sequence 
Smp43 +4 -0.32 4654 9.9 GVWDWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS 
Smp43 W3A +4 -0.25 4539 9.9 GVADWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS 
Smp43 D4F +5 -0.17 4686 10.1 GVWFWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS 
Smp43 W5A +4 -0.25 4539 9.9 GVWDAIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS 
Smp43 W14A +4 -0.25 4539 9.9 GVWDWIKKTAGKIANSEPVKALKSQALNAAKNFVAEKIGATPS 
Smp43 W3A/W5A/W14A +4 -0.13 4310 9.9 GVADAIKKTAGKIANSEPVKALKSQALNAAKNFVAEKIGATPS 
Smp43 S16K +5 -0.39 4695 10.0 GVWDWIKKTAGKIWNKEPVKALKSQALNAAKNFVAEKIGATPS 
Smp43 S24K +5 -0.39 4695 10.0 GVWDWIKKTAGKIWNSEPVKALKKQALNAAKNFVAEKIGATPS 
Smp43 S43K +5 -0.39 4695 10.0 GVWDWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPK 
 
Amino acid modifications are highlighted in bold. 
77 
 
The results of the charge modifications on both peptides yielded peptides with 
decreased GRAVY scores and thus made the peptides more hydrophilic. The 
most hydrophilic peptide for Smp24 was the S3K/S15K modification, which 
carried the highest charge. The increases in charge on Smp43 did increase the 
hydrophilicity of the peptides but to a lesser extent than the effect observed in 
Smp24.  
 
All of the hydrophobic mutations introduced to both peptides increased the 
GRAVY score. For the most part, the hydrophobic mutations were performed 
without altering the charge properties of the peptides; the two exceptions to this 
are the K7F and K7S modifications of Smp24 which reduced the charge of the 
peptide to +2 due to the substitution of the positively charged lysine residue for 
uncharged residues. 
 
3.4.2 Minimum inhibitory concentrations and Minimum bactericidal 
concentrations 
 
3.4.2.1  Smp24 antimicrobial activity 
 
The minimum inhibitory concentrations (MICs) of Smp24 and derived daughter 
peptides were determined by a broth microdilution method (Andrews 2001). 
Peptides were assayed in the range of 0 - 512 µg/ml, with the MIC defined as the 
lowest concentration of AMP which caused inhibition of bacterial growth. Strains 
were as follows: Escherichia coli JM109, Pseudomonas aeruginosa H085180216 
and Staphylococcus aureus SH1000.  
 
In addition to the inhibitory effects of the peptides, it was important to investigate 
the mechanistic effects of the peptides by determining if the peptides were 
bacteriostatic or bactericidal. The bactericidal activity of all the peptides was 
investigated by inoculation of MH agar with 5 µL aliquots from the MIC well plate. 
The minimum bactericidal concentration (MBC) was defined as the concentration 




To determine the therapeutic potential of the modified peptides, the MICs were 
to be compared with two commercially available lipopeptide antibiotics 
(polymyxin B and daptomycin). 
 
The results for MIC and MBC determination of Smp24 and the derived 


















nc = not calculable due to the mixed population of polymyxins
Peptide Charge GRAVY MIC (µg/ml) MBC (µg/ml) 
E. coli P. aeruginosa S. aureus E. coli P. aeruginosa S. aureus 
Smp24 +3 0.31 32 64 8 32 64 8 
Smp24 W2A +3 0.43 64 128 32 64 256 64 
Smp24 S3F +3 0.46 32 64 16 64 128 64 
Smp24 S3K +4 0.18 1 32 0.5 8 128 1 
Smp24 S3K/S15K +5 0.05 16 16 16 16 32 16 
Smp24 F4A +3 0.27 32 128 16 64 256 16 
Smp24 K7S +2 0.44 64 128 16 128 256 32 
Smp24 K7F +2 0.59 >512 >512 >512 >512 >512 >512 
Smp24 S15K +4 0.18 8 32 4 8 32 8 
Smp24 D23F +4 0.58 32 64 32 32 64 32 
Smp24 S24K +4 0.18 8 32 4 8 128 8 
Daptomycin -6 -1.93 >512 >512 4 >512 >512 8 
Polymyxin B +5 nc 2 2 32 4 8 64 
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3.4.2.2 Smp24 microbial inhibition  
 
The most potent antimicrobial activity was demonstrated by the S3K modification, 
which resulted in a 32-fold increase in bacterial inhibitory activity to 1 μg/ml 
against E. coli and a 16-fold increase in inhibition to 0.5 μg/ml against S. aureus. 
Despite the dramatic increase in activity against E. coli and S. aureus, only a 2-
fold increase was observed for anti-Pseudomonal activity, with an MIC of 32 
μg/ml. In contrast, the greatest decrease in antimicrobial activity was observed 
for the K7F modification which showed no activity at the concentrations tested 
against any of the organisms in this study.  
 
All of the single charge modifications yielded peptides with increased 
antimicrobial activity against the Gram positive and Gram negative isolates 
tested, with the peptides showing the greatest increases in activity against E. coli. 
Both the S15K and S24K modifications resulted in a 4-fold increase in anti-E. coli 
activity with an MIC of 8 μg/ml and a 2-fold increase in anti-Staphylococcal and 
anti-Pseudomonal activity with MICs of 4 μg/ml and 32 μg/ml respectively. 
 
The double charge modification S3K/S15K demonstrated an interesting anti-
bacterial profile, with the same inhibitory value (32 μg/ml) observed for all isolates 
tested. S3K/S15K demonstrated a 2-fold increase in activity against E. coli, a 2-
fold decrease in anti-Staphylococcal activity but demonstrated the greatest 
increase in anti-Pseudomonal inhibition with a 4-fold increase in activity. 
 
The hydrophobicity modifications did not result in increased inhibitory activity 
against any of the isolates tested. Loss of activity was observed for the K7S, W2A 
and F4A modifications, which demonstrated reduced activity against the isolates 
tested. Two-fold reductions in activity were observed against E. coli (MIC 64 
μg/ml) and P. aeruginosa (MIC 128 μg/ml) for K7S and W2A, with K7S and F4A 
showing a 2-fold reduction in anti-staphylococcal activity (16 μg/ml) and the W2A 
modification resulting in a 4-fold reduction in activity (32 μg/ml).  
 
The D23F modification yielded a peptide with both increased charge and 
increased hydrophobicity. The activity of the peptide was similar to that of the 
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parental peptide with the exception of S. aureus activity which was a 4-fold 
decrease with an MIC of 32 μg/ml.  
 
Daptomycin is commercially licensed for the treatment of skin infections caused 
by very specific Gram positive organisms (such as MRSA and vancomycin-
resistant Enterococci), the inhibition data from this experiment demonstrates 
daptomycin is only effective against the Gram positive isolates tested. 
Promisingly, modified peptides derived from Smp24 showed inhibitory values 
equal to that of daptomycin (S15K and S24K), with the S3K modification 
demonstrating greater activity. 
 
Polymyxin B (PMB) is primarily used for the treatment of resistant Gram negative 
infections, but the results of this assay demonstrate the antibiotic also possesses 
activity against some Gram positive species. Only one of the modified peptides 
demonstrated activity greater than PMB against Gram negative species, which 
was S3K against E. coli. All of the modifications of Smp24 except K7F and native 
Smp24 demonstrated anti-Staphylococcal activity equal to or greater than that of 
PMB. 
 
3.4.2.3 Smp24 bactericidal activity 
 
Unsurprisingly, no detectable bactericidal activity was observed with the K7F 
modification, which held no inhibitory activity. All of the charge modifications 
resulted in increased bactericidal activity against E. coli; despite the 32-fold 
increase in inhibitory activity of S3K, only a 4-fold increase in bactericidal activity 
was observed, a change equal to that of the other two single lysine substituted 
peptides. Against S. aureus however, an 8-fold increase in bactericidal activity 
was seen by S3K and the MBC value (1 μg/ml) was the lowest value observed 
across all modifications. Despite the increased inhibitory activity S3K and S24K 
against P. aeruginosa, both peptides demonstrated a 2-fold reduction in 
bactericidal activity with an MBC of 128 μg/ml. 
 
With the exception of D23F (64 μg/ml), all of the hydrophobic modifications 
demonstrated reduced bactericidal activity against P. aeruginosa and E. coli 
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compared with native Smp24. The greatest loss of activity against E. coli was a 
4-fold reduction by K7S (128 μg/ml), whilst K7S, W2A and F4A all demonstrated 
4-fold reduction in bactericidal activity against P. aeruginosa (256 μg/ml). All of 
the hydrophobic modified peptides demonstrated reduced bactericidal activity 
against S. aureus, with the greatest loss of activity being an 8-fold reduction by 
W2A and S3F (64 μg/ml). 
 
With the exception of B. subtilis, the lipopeptide antibiotics demonstrated a similar 
pattern to that observed with the AMPs with higher MBC values than the MIC. 
Polymyxin B demonstrated potency against E. coli at 4 μg/ml, a value which was 
not met by any of the peptides in the study, with the lowest MBC against E. coli 
being 8 μg/ml. Similarly, none of the peptides demonstrated potency against P. 
aeruginosa equal to that of PMB. Against S. aureus, all of serine-lysine 
substitutions demonstrated lethality equal to that of daptomycin. With the 
exception of K7S and K7F, all of the Smp24 modifications had lethality equal to 
or greater than that of PMB against S. aureus.  
 
These results highlight that whilst some of the peptides have activity lower than 
that of the commercial peptide antibiotics, like antibiotics, the specificity of the 
peptides could be restricted. Some of the peptides demonstrated increased 
potency against some bacterial classes compared with others, such as S3K 
which demonstrated increased potency against E. coli and S. aureus but not B. 
subtilis. 
 
3.4.2.4 Comparison between MIC and MBC 
 
To determine the efficacy of the peptides to kill bacteria relative to the 
concentration required to inhibit growth, a ratio between the MIC and MBC was 







Table 3.4: MIC: MBC ratios for Smp24 and derived modifications 
 
Peptide Charge GRAVY MIC:MBC ratio 
E. coli P. aeruginosa S. aureus 
Smp24 +3 0.31 1 1 1 
Smp24 W2A +3 0.43 1 2 2 
Smp24 S3F +3 0.46 2 2 4 
Smp24 S3K +4 0.18 8 4 2 
Smp24 S3K/S15K +5 0.05 1 2 1 
Smp24 F4A +3 0.27 2 2 1 
Smp24 K7S +2 0.44 2 2 2 
Smp24 K7F +2 0.59 *NC *NC *NC 
Smp24 S15K +4 0.18 1 1 2 
Smp24 D23F +4 0.58 1 1 1 
Smp24 S24K +4 0.18 1 4 2 
Daptomycin -6 -1.93 *NC *NC 2 
Polymyxin B +5 nc 2 4 2 
 
nc - not calculable due to the mixed population of polymyxins; *NC - not calculable due 
to the values exceeding the limit of detection of the study 
 
The results in table 3.4 display the increased concentration required to kill 
bacteria relative to the concentration to inhibit growth, e.g. the MIC of S3K is 1 
μg/ml for E. coli but the MBC is 8 μg/ml, equal to an 8 fold increase in 
concentration required for bactericidal activity relative to inhibition. The 
differences observed could indicate mechanistic changes arising as a result of 
structural changes, such as a change in the pore-forming abilities of the modified 
peptides relative to the parental peptide. 
 
For Smp24, all of the modifications resulting in increased charge yielded peptides 
with enhanced bacterial inhibition when compared with the parental peptide. For 
native Smp24, the MBC was equal to the MIC for all of the bacterial isolates 
studied. 
 




3.4.3 Smp43 antimicrobial activity 
 
Table 3.5: Antimicrobial activity of Smp43 and modified peptides as determined by broth microdilution assay. 
 
Peptide Charge GRAVY MIC (µg/ml) MBC (µg/ml) 
E. coli P. aeruginosa S. aureus B. subtilis E. coli P. aeruginosa S. aureus B. subtilis 
Smp43 +4 -0.32 32 64 >512 8 32 64 >512 8 
Smp43 W3A +4 -0.25 16 32 >512 16 16 128 >512 16 
Smp43 D4F +5 -0.17 64 32 >512 8 64 32 >512 16 
Smp43 W5A +4 -0.25 8 64 >512 8 8 64 >512 8 
Smp43 W14A +4 -0.13 4 64 >512 8 8 128 >512 8 
Smp43 W3A/W5A/W14A +4 -0.13 >512 >512 >512 NT* >512 >512 >512 NT* 
Smp43 S16K +5 -0.39 32 32 >512 16 32 64 >512 16 
Smp43 S24K +5 -0.39 32 16 256 4 64 64 512 8 
Smp43 S43K +5 -0.39 16 16 >512 8 32 32 >512 8 
Daptomycin -6 -1.93 >512 >512 4 8 >512 >512 8 8 
Polymyxin B +5 nc 2 2 32 2 4 8 64 2 
 
Nc - not calculable due to the mixed populations of polymyxins; NT* - not tested. 
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3.4.3.1 Smp43 microbial inhibition 
 
The effects of charge modifications on Smp43 were less effective than the 
modifications observed in Smp24. This could be attributed to differences in 
structure between the two peptides. Whilst Smp24 and Smp43 are both derived 
from the venom of Scorpio maurus palmatus, the peptides assemble differently. 
Smp24 adopts a single alpha helix, whereas Smp43 adopts a di-helical protein 
structure (see sections 5.4.2 and 5.4.3).  
 
None of the peptides demonstrated activity against S. aureus, except S24K which 
had an MIC of 256 μg/ml. Due to the lack of activity against S. aureus, the 
peptides were assayed against B. subtilis subsp subtilis (NCIMB 3610) to 
determine if the peptides held activity against Gram positive organisms.  All of the 
peptides demonstrated anti-Bacillus activity, suggesting the spectrum of activity 
is more restricted for Smp43 compared with Smp24. The S24K modification was 
the only peptide which demonstrated increased activity against B. subtilis with an 
MIC of 4 μg/ml.  
 
S24K and S43K modifications resulted in significant 4-fold increases in anti-
Pseudomonal activity resulting in MICs of 16 μg/ml. The peptides with single 
tryptophan to alanine substitutions demonstrated increased activity compared 
with the parental peptide. The greatest increase in activity was observed for the 
W14A modification which demonstrated an 8-fold increase in activity against E. 
coli to gain an MIC of 4 μg/ml. Two-fold increases in activity were observed for 
the W3A and D4F modifications against P. aeruginosa, but these modifications 
also resulted in a 2-fold decrease in activity against E. coli (D4F) and B. subtilis 
(W3A). 
 
The triple tryptophan alanine modified peptide demonstrated no detectable 
antimicrobial activity across the three isolates tested. The antimicrobial activity 
assessment of the peptide was restricted due to the small quantity of peptide 
synthesised and therefore the antimicrobial activity could not be assessed 




All of the peptides except S16K and W3A had anti-Bacillus activity equal to that 
of daptomycin, with S24K Smp43 demonstrating a lower MIC at 4 µg/ml. None of 
the Smp43 modifications resulted in anti-Staphylococcal activity equal to or 
greater than that of daptomycin. 
 
When comparing the activity of Smp43 and derivatives with PMB, none of the 
peptides demonstrated antimicrobial activity at the same range of inhibition as 
PMB. 
 
3.4.3.2 Smp43 bactericidal activity 
 
The charge modifications had little effect on the bactericidal activity of Smp43, 
with the peptides mostly retaining the bactericidal activity demonstrated by the 
parental peptide. The exceptions to this are S24K with a 2-fold decrease against 
E. coli (64 μg/ml) and detectible bactericidal activity against S. aureus (512 
μg/ml). S43K demonstrated a 2-fold increase in activity against P. aeruginosa (32 
μg/ml) and S16K with a 2-fold decrease in bactericidal activity against B. subtilis 
(16 μg/ml). 
 
The hydrophobicity modifications had a more significant outcome, with increased 
bactericidal activity against both the Gram negative isolates tested. The greatest 
increases in activity were observed for W5A and W14A modifications which 
resulted in 4-fold increased activity (8 μg/ml) against E. coli. A 2-fold reduction in 
bactericidal activity against P. aeruginosa was observed for W3A and W14A (128 
μg/ml), whilst a 2-fold increase in activity was observed for D4F (32 μg/ml). Only 
two of the hydrophobicity modifications resulted in a 2-fold reduction in activity 
against Bacillus, which are W3A and D4F. 
 
Many of the Smp43 modified peptides had MBC values equal to that of 
daptomycin against B. subtilis, but none of the peptides demonstrated lytic activity 
against S. aureus equal to that of daptomycin. Polymyxin B was more potent than 
the modified Smp43 peptides used within this study, but the W5A and W14A 
modifications demonstrated MBC's within a 2-fold range of PMB. This is a 
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promising result, as the peptide is close to a therapeutic range of a commercially 
licensed treatment. 
 
3.4.3.3 MIC: MBC ratios for Smp43 
 
The bactericidal activity of native Smp43 is equal to the MIC value for all the 
isolates tested in this study. This did not remain consistent with the modified 
peptides. Despite showing increased inhibitory activity, not all of the peptides 






Table 3.6: MIC: MBC ratios for Smp43 and derived modifications 
 
Peptide Charge GRAVY MIC:MBC ratio 
E. coli P. aeruginosa S. aureus B. subtilis 
Smp43 +4 -0.32 1 1 *NC 1 
Smp43 W3A +4 -0.25 1 4 *NC 1 
Smp43 D4F +5 -0.17 1 1 *NC 2 
Smp43 W5A +4 -0.25 1 1 *NC 1 
Smp43 W14A +4 -0.13 2 2 *NC 1 
Smp43 W3A/W5A/W14A +4 -0.13 *NC *NC *NC NT* 
Smp43 S16K +5 -0.39 1 2 *NC 1 
Smp43 S24K +5 -0.39 2 4 2 2 
Smp43 S43K +5 -0.39 2 2 *NC 1 
Daptomycin -6 -1.93 *NC *NC *NC 1 
Polymyxin B +5 nc 2 4 2 1 
 





The results from the table above demonstrate the concentration of the peptides 
required to kill bacteria relative to the concentration required to inhibit growth. 
Despite the MBC being higher than the MIC for some of the modifications, 
peptides were produced which overall showed improved activity compared with 
native Smp43. As shown in the antimicrobial assays across all of the modified 
peptides, there are wide differences in MIC values, with the lower MIC values 
typically observed against Gram positive bacteria, which mimics the activity 
observed by other α-helical peptides derived from scorpion venom (Bao et al., 
2015; Bea et al., 2015; Miyashita et al., 2017b). 
 
3.5 Anti-biofilm activity 
 
In addition to the antimicrobial assays performed, the anti-biofilm properties of 
the peptides were investigated as per the methods highlighted in chapter 2, 
section 2.5. Briefly, biofilms were grown on peg lids which were transferred in to 
a "challenge plate" containing doubling dilutions of AMPs in the range of 0 - 512 
µg/ml (table 3.7). 
 
Table 3.7: Anti-biofilm activity of Smp24 and Smp43 as defined by MBIC and MBEC 
values 
 
  Biofilm (μg/ml) Planktonic (μg/ml) 
Peptide Strain MBIC MBEC MIC MBC 
Smp24 E. coli EC2 64 256 8 16 
Smp24 E. coli JM109 32 256 32 32 
Smp43 E. coli EC2 8 256 8 64 
Smp43 E. coli JM109 32 256 32 32 
Daptomycin E. coli EC2 >512 >512 >512 >512 
Daptomycin E. coli JM109 >512 >512 >512 >512 
Polymyxin B E. coli EC2 32 64 2 4 
Polymyxin B E. coli JM109 8 >512 2 4 
 
 
The anti-biofilm activity of the parental peptides was assayed against an E. coli 
laboratory strain (JM109) and clinical strain (EC2). EC2 is an uropathogenic E. 
coli (UPEC) strain which demonstrates antibiotic resistance against ampicillin and 
trimethoprim which are commonly prescribed antibiotics for urinary tract 
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infections (UTIs). EC2 has been previously classified as a biofilm-forming strain 
(Henly et al. 2019) and was chosen for comparison of the anti-biofilm activity of 
the peptides against laboratory and clinical strains. 
 
3.5.1 Biofilm vs planktonic MICs 
 
The MBIC for both of the peptides was markedly lower than the concentration 
required for eradicating the biofilm against both isolates tested. Interestingly, 
whilst a 2-fold increase in concentration was required to inhibit the growth of the 
biofilm on the biofilm-forming strain for Smp24, the MBEC remained constant. 
Against EC2, there was a 4-fold difference in concentration required for 
eradication of the biofilm compared with inhibition, whereas as an 8-fold 
difference was observed for JM109. When comparing the MBIC to the planktonic 
MIC, the values remained constant at 32 µg/ml for both AMPs against E. coli 
JM109. This could be attributed to the pore-formation mechanism of action of the 
AMPs, which could be uninhibited by the complexity of a biofilm in terms of growth 
inhibition. Differences were observed when comparing the concentration required 
to eradicate biofilm growth which was an 8-fold increased concentration.  
 
Smp43 demonstrated an enhanced ability to inhibit biofilm formation compared 
with Smp24, but the concentration required to eradicate the biofilm was the same. 
The lowest MBIC of the study was noted at 8 µg/ml by Smp43 against E. coli 
EC2, equal to the anti-biofilm effect of polymyxin B. The difference in MBIC 
between Smp24 and Smp43 could suggest mechanistic differences between the 
two peptides and suggest differences in the properties possessed by both 
peptides. Promisingly, the activity of Smp43 is superior to that of polymyxin B, 
whilst both held an MBIC of 8 µg/ml, the lytic activity of Smp43 was superior (256 







3.5.2 Comparison of anti-biofilm activity of Smp24 and Smp43 with 
commercially available lipopeptide antibiotics 
 
The lowest MBIC values within this study were observed by Smp43 against E. 
coli EC2 and Polymyxin B against E. coli JM109 both of which were 8 µg/ml. 
Polymyxin B demonstrated the greatest ability to eradicate biofilm growth, with 
an MBEC of 64 µg/ml, though this was not consistent as Polymyxin B performed 
worse than the Smp peptides when eradicating growth of E. coli JM109.  
 
Unsurprisingly, the anti-biofilm activity of daptomycin was not detectable for the 
isolates tested due to the limitation of efficacy of daptomycin’s spectrum of activity 
being limited to Gram positive pathogens. 
 
3.6 Structural investigations: Circular Dichroism 
 
Circular dichroism (CD) spectroscopy is a technique which can be used to 
determine the secondary structure of proteins with 3-dimensional insights (Li and 
Arakawa 2019). Briefly, 100 µM concentrations of peptides dissolved in dH2O 
were added to a cuvette and the absorbance was read across a 190-250 nm 
wavelength on a JASCO J-810 spectropolarimeter (Maryland, USA). The 
structure of the peptides was investigated in an aqueous environment and by 
titration of trifluoroethanol (TFE) to a concentration of 60% to create membrane 
mimetic conditions. CD spectroscopy was used to determine if the induced amino 
acid substitutions had affected the structure of the peptides.  
 
3.6.1 CD spectroscopy of Smp24 
 
CD spectra were obtained for Smp24 (see chapter 2, section 2.8) and the most 
and least potent modified variants (S3K and K7F) to determine if the amino acid 








Figure 3.3: Helical propensity of Smp24, S3K and K7F in aqueous (0% TFE) and 
membrane mimetic (60% TFE) conditions. 
 
As shown in figure 3.3, the peptides are disordered in an aqueous solution and 
adopt a helical conformation in the presence of 60% TFE, characterised by the 
presence of two minima around 208 and 222 nm (Kang et al. 2017a). There are 
some structural difference between the modified peptides and native Smp24, as 
shown by the differences in the state of the disordered peptides in aqueous 
solution compared with native Smp24. S3K appears to adopt a structure similar 
to that of Smp24, with a random coil in the presence of water and a characteristic 
α-helix in the presence of 60% TFE. K7F however, demonstrates some 
differences compared with native Smp24. The random coil demonstrates a 
different MRE trace compared with native Smp24 and the minima at 208 and 222 





















K7F H2OSmp24 H2O S3K H2O
S3K 60% TFE K7F 60% TFESmp24 60% TFE
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3.6.2 TFE titration of Smp24 
 
To further elucidate the differences in structures observed in figure 3.3, the helical 
propensity of the peptides was determined by the titration of TFE over a 0 to 60% 
percentage range. More spectra were obtained over the 0 - 30% range in order 
to determine the percentage at which the peptides adopt their final alpha-helices. 
 
The results of the structural investigations by the titration of TFE for Smp24, 








As shown in figure 3.4, the point at which the peptides adopt their final α-helices 
differs between the native and modified peptides. Native Smp24 adopts its α--
helical structure in 25% TFE, Smp24 S3K adopts its α-helix at a higher TFE 
concentration (30%) and Smp24 K7F adopts α--helix at a lower concentration of 
TFE (20%).  
 
3.6.3 CD spectroscopy of Smp43 
 
CD spectra were obtained for Smp43 in the presence of 0% TFE and membrane 
mimetic (60% TFE) conditions (see chapter 2, section 2.8). The helical propensity 




Figure 3.5: The helical propensity of Smp43 in water (0% TFE) and in membrane 
mimetic conditions (60% TFE). 
 
Spectral analysis of the CD data revealed Smp43 is present as an unordered 
structure in aqueous conditions (H2O) and adopts a helical structure in the 
presence of 60% TFE. Data analysis (Perez-Iratxeta and Andrade-Navarro 2008) 
revealed Smp43 held 95.39% helical content in 60% TFE. 
















0% TFE 60% TFE
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Despite differences between Smp24 and Smp43, both peptides analysed by CD 
spectroscopy demonstrated a disordered structure in solution and adopted α-
helical conformations in membrane mimetic environments, with the minor 
structural modifications resulting in small changes in helical formation. The data 
supports the hypothesis that peptides are disordered in solution (i.e. the 
extracellular environment) and adopt their final helical conformations upon 




Smp24 and Smp43 have both been previously characterised in terms of biological 
activity (Harrison et al., 2016). Limited modifications have previously been 
performed on Smp24 in attempts to enhance the antimicrobial activity, including 
the truncation of Smp24 to remove the last 4 amino acid residues. The truncation 
was based on previous modifications to Pandinin 2 (Rodríguez et al. 2014a) 
which shares 54% sequence homology with Smp24. The truncation of Smp24 
(IWSFLIKAATKLLPSLFGGG) resulted in a reduction in charge at the C-terminus 
to +2 and an overall 2-fold decrease in antimicrobial activity was observed against 
S. aureus and E. coli. Smp24 was also modified by the insertion of a glycine-
valine-glycine (GVG) hinge, a modification which yielded a 2-fold decrease in 
potency against Gram positive species and a 4-fold reduction in activity against 
Candida albicans but retained the activity of native Smp24 against the Gram 
negative isolates tested (Harrison et al., 2016). These results highlight the effect 
structural changes can have on the antimicrobial activity but specific changes to 
the mechanism of action have not been elucidated. Whilst the mechanism of 
action of drugs may not be required for therapeutic licensing purposes, as 
demonstrated by the lack of understanding of the mode of action of daptomycin 
(Anderson 2008, Taylor and Palmer 2016); a greater understanding of the 
relationship between structure and function of AMPs could lead to the design and 
development of molecules with enhanced therapeutic indices.  
 
Increases in charge have been linked to enhanced antimicrobial activity (Huang 
et al. 2015). The main lipid components of bacterial cell membranes are anionic 
phospholipids, such as phosphatidylglycerol (PG) and cardiolipin (CL), with the 
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predominant zwitterionic lipid phosphatidylethanolamine (PE) (Ciumac et al. 
2019) which leads to an overall negative charge across the external face of the 
cell membrane. However, membrane composition differs between bacterial 
species. For example, the predominant components of E. coli  cell membranes 
are PE (75%) and PG (20%) with a lower concentration of CL (5%) (Sohlenkamp 
and Geiger 2016, Hu and Tam 2017). The S. aureus membrane, however, is 
composed of cardiolipin (22.5%), PG (43.1%) and lysyl-PG (L-PG) (30%) 
(Hayami et al. 1979, Young et al. 2019) and is therefore less negative overall than 
the membrane of E. coli. The composition of the E. coli membrane results in an 
overall anionic charge, with a resting membrane potential of -220 mV during early 
exponential phase, which reduces to -140 mV in late exponential phase (Bot and 
Prodan 2010). The electrical potential across the membrane of S. aureus is -130 
mV at pH 7.5 (Mates et al. 1982), making the resting membrane potential less 
negative than that of E. coli.  
 
The overall negative charge of the outer bilayer in most models is considered to 
be responsible for the initial electrostatic interaction with the positively charged 
peptide (Torcato et al. 2013). Increases in the charge of AMPs increases the 
electrostatic binding between the peptide and cell membrane, which in turn may 
increase the potency of AMPs (Tossi et al. 2000b). This was observed in this 
study, as shown by the increased potency of the increased charge variants.  
 
3.7.1 Structural differences between modified peptides 
 
To determine the structural effect the modifications which resulted in the most 
and least potent antimicrobial activity, Smp24, Smp24 S3K and Smp24 K7F were 
analysed by CD spectroscopy. Smp24 demonstrated a disordered structure in 0 
– 15% TFE and began to adopt its α-helical structure in the presence of 25% 
TFE, with the greatest defined helix observed in the presence of 60 – 70% TFE 
(conditions which mimic the cell membrane environment). Smp24 S3K 
demonstrated a similar structural content, with a disordered structure observed 
in the presence of 0 – 15% TFE, with the peptide beginning to adopt α-helical 
structure in the presence of 20% TFE leading to the final α-helical structure 
forming in the presence of 50% TFE. As Smp24 S3K adopted its helical structure 
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in the presence of a lower percentage of TFE, this demonstrates Smp24 S3K has 
a greater propensity to form an α-helical structure than native Smp24. As greater 
antimicrobial potency was observed for Smp24 S3K, this could be attributed to 
the increased ability to form α-helices due to the requirement for AMPs to adopt 
their final structures to exhibit antimicrobial activity (Willcox et al. 2008).  
 
For Smp24 K7F the minima and maxima at 208 and 222 nm respectively are 
much less pronounced compared with native Smp24, suggested Smp24 K7F 
adopts a less defined helix. Smp24 K7F remains disordered in solution at 25% 
TFE, but begins to fold in to its final structure at 30% TFE. The differences in 
structure between native Smp24 and Smp24 K7F could provide mechanistic 
insights, suggesting the helical content of Smp24 is imperative for function. In the 
case of Smp24 K7F, a loss of helical content has resulted in a loss of antimicrobial 
activity. 
 
3.7.2 Comparison of AMPs to commercially available lipopeptide 
antibiotics 
 
In this study, the results of the structural modifications were compared with native 
peptides, but it is also important to consider the efficacy of the peptides alongside 
commercially available therapeutics. Daptomycin is a cyclic lipopeptide antibiotic 
with potent bactericidal activity against most Gram positive organisms, including 
vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococci 
(Galar et al. 2018). Whilst the mechanism of daptomycin remains unclear, it is 
known the mechanism involves the cytoplasmic membrane, is dependent on 
calcium concentration and is restricted to Gram positive bacteria (Taylor and 
Palmer 2016). Under broth microdilution assays, daptomycin demonstrated anti-
Staphylococcal activity at an MIC of 4 μg/ml. 
 
Although many of the peptides within this study did not demonstrate bacterial 
potency at similar concentrations to the lipopeptide antibiotics, there are a few 
candidate peptides that merit further consideration. Smp24 S3K demonstrated 
MIC values of 1 and 0.5 μg/ml against E. coli and S. aureus respectively. Smp24 
S15K and S24K both demonstrated MIC values within a 2-fold range of 
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daptomycin, with MICs of 8 μg/ml for S. aureus. The Smp43 modifications did not 
yield peptides with anti-Staphylococcal activity within an equivalent range to 
daptomycin, but the MIC of the S24K and W14A modifications was equal to the 
activity of polymyxin B. Whilst the MIC of susceptible isolates by the European 
Committee for Antimicrobial Susceptibility Testing (EUCAST) is usually deemed 
to be 2 mg/litre (2 μg/ml), this is based on colistin which has different 
pharmacokinetics to polymyxin B despite belonging to the same antibiotic class 
(Chew et al. 2017). A study by Sader et al, 2015 concluded that 41.3% of the 
isolates tested for MIC values against colistin and polymyxin B demonstrated 
higher MIC values for polymyxin B. (Albur et al. 2015). 
 
3.7.3 AMPs and anti-biofilm activity 
 
Whilst antibiotic resistance is of growing concern and new therapeutic agents are 
required, there is an increased observation of biofilm associated infections which 
contribute to 65 - 80% of all diagnosed microbial infections. Biofilms are surface-
attached microbial communities able to attach to biotic or abiotic surfaces 
(Parrino et al. 2019).  Biofilms are often recalcitrant to both the immune response 
and antimicrobial treatment, making biofilm-associated infections difficult to treat 
(Henly et al. 2019). As a result of this, new molecules are required with biofilm 
targeting activity. Improvements have been made to the AMPs in terms of 
antimicrobial activity, which is promising in the search for new antimicrobial 
compounds (Macià et al. 2018). 
 
Several studies have reported AMPs can successfully inhibit biofilm formation. 
LL-73 from the cathelicidin family of AMPs showed potent inhibition of the 
production of biofilms by S. aureus at concentrations as low as 3 μg/ml (Dean et 
al. 2011) The AMP WLBU2 has demonstrated anti-biofilm activity against 
ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacter species) pathogens including the inhibition of growth and initial 
biofilm formation. In the case of WLBU2, biofilm inhibition was demonstrated to 
be more effective than the assayed antibiotics (including colistin) at preventing 




The parental Smp peptides both demonstrated anti-biofilm activity, with the 
biofilm inhibition concentration being markedly lower than the concentration 
required for biofilm eradication, in keeping with other anti-biofilm studies. For 
example, Japonicin-2LF demonstrated an MBIC of 25 µg/ml and an MBEC of 800 
µg/ml against E. coli biofilms (Yuan et al. 2019). Smp43 demonstrated greater 
potency than Japonicin-2LF with MBIC of 8 μg/ml against E. coli JM109. Both 
Smp24 and Smp43 demonstrated a greater ability to eradicate biofilm growth 
than Japonicin-2LF with MBEC values of 256 µg/ml. This highlights the potential 
to use the peptides as anti-biofilm agents in addition to antimicrobial compounds.  
 
The rapid killing activity and membrane-targeting ability makes AMPs attractive 
molecules for antimicrobial applications, where AMPs are believed to reduce the 
likelihood of resistance development by bacteria. Due to this, many groups are 
looking at the surface immobilisation of AMPs as anti-biofilm agents (Lim and 
Leong 2018). Studies have demonstrated that retention of AMP secondary 
structure has been critical for activity and therefore the immobilisation of AMPs 
must be carefully considered to preserve the bactericidal activity (Willcox et al. 
2008). As bacterial adhesion to biomaterials remains a major problem in the 
medical device field, the development of novel antimicrobial coatings with a 
reduced propensity for resistance would be worthwhile (Costa et al. 2011). 
 
Future directions to investigate the anti-biofilm properties of the Smp peptides 
would include further screening of the compounds (particularly S3K, to ascertain 
if the anti-biofilm activity was more potent than that of Smp24). The incorporation 
of the peptides in to a coating which could potentially be used to prevent biofilm 
adherence on indwelling devices would also present an interesting future 
direction. Catheter coatings can be categorised into two groups; antifouling 
coatings which do not kill microbes directly but instead prevent the attachment of 
bacteria on the surfaces which would usually allow biofilm formation (Campoccia 
et al. 2013) and biocidal properties which are designed to kill the microbes on 
contact as the active compounds are not eluted from the coating (Williams and 
Worely 2000). The former uses steric repulsion and electrostatic repulsion to 
prevent the formation of conditioning films for planktonic bacteria that ultimately 
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form biofilms (Singha et al. 2017), though this could be problematic for AMP 
coatings due to the positive charge of the peptides. 
 
The investigation of the anti-biofilm properties of the peptides by incorporation 
into a sol gel eluting the peptides into solution would be a logical next-stage 
approach following the observed anti-biofilm activity. Peptides could be 
incorporated into a sol gel and applied to the pegs of a peg lid and the abilities of 
the peptide sol gel to inhibit biofilm growth as per the method described in chapter 
2. Alternatively, the anti-fouling properties of an AMP sol gel could be investigated 
by crystal violet biofilm formation assays which enable the quantification of 
biofilms and thus the concentration of AMP in the sol gel required to prevent 




Both Smp24 and Smp43 demonstrate anti-biofilm activity, with biofilm inhibition 
being equal to the planktonic MIC, highlighting the potential for the peptides as 
anti-biofilm agents. 
 
The S3K, S15K and S24K modifications to Smp24 produced peptides with 
enhanced antimicrobial activity compared with native Smp24. The S3K/S15K 
modification also demonstrated an interesting 4-fold increase in antimicrobial 
activity against pseudomonads. As such, these modifications are of interest for 
further study. 
 
For Smp43, the W3A, W5A and W14A modifications yielded peptides with 
enhanced activity against E. coli whilst the S24K and S43K modifications resulted 
in increased anti-Pseudomonal activity compared with native Smp43. As such, 
these peptides are interesting candidates for further investigations. 
 
Future work would involve a more intensive antimicrobial screen of the peptides 
of interest encompassing more bacterial strains (such as Klebsiella spp, Candida 
spp, clinical MRSA isolates and clinical carbapenem-resistant 
Enterobacteriaceae isolates).  Due to cost limitations with the synthesis of 
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peptides by solid-phase synthesis, the antimicrobial characterisation of the 
peptides was restricted to two Gram positive and two Gram negative strains. 
 
Whilst a strategy has been adopted to increase the antimicrobial properties of the 
peptides, it is also important to determine the effect the modifications to the 
peptides will have on mammalian tissues. AMPs do preferentially interact with 
prokaryotic membranes, but numerous venom-derived AMPs have demonstrated 
haemolytic properties (Yang et al. 2013, Hong-Ling et al. 2016) and significant 
cytotoxic effects (Lai et al. 2002). In order to calculate the therapeutic indices of 
the peptides, mammalian cytotoxicity must be performed. Calculation of the 
therapeutic indices will enable the peptides with significantly improved or reduced 







Investigating the relationship between 





4.1  Introduction 
 
The antimicrobial activity of the parental Smp peptides and the derived 
modifications has been discussed in chapter 3. Whilst improvements to 
antimicrobial activity have been observed, it is also important to characterise the 
effects of the peptides on mammalian membranes. A common limitation for the 
use of antimicrobial peptides (AMPs) therapeutically is the disruption of 
eukaryotic membranes and haemolytic side effects (Semreen et al. 2018). 
 
The toxic effects of AMPs are a limiting factor for AMP drugs already in clinical 
usage. Polymyxins demonstrate high nephrotoxicity, neurotoxicity and 
neuromuscular blockage at therapeutic doses (Conway et al. 1997). Due to this, 
the usage of polymyxins and colistin is restricted to patients with serious 
infections caused by multi-drug resistant (MDR) Gram negative bacteria for which 
all other therapeutic options have been exhausted (Mirski et al. 2017).  
 
A major application for AMPs in clinical usage is topical administration (Naafs 
2018). Consequently, the ability of the Smp peptides and derived modifications 
will be assessed against a eukaryotic skin cell line to evaluate the potential the 
peptides may have for topical application. Additionally, the peptides will also be 
screened against liver and kidney cell lines to assess the cytotoxic properties of 
the peptides against the systems typically responsible for the processing and 
excretion of drugs delivered systematically. 
 
4.2 Study aims 
 
The experiments in this chapter aim to characterise the haemolytic and cytotoxic 
activity of the antimicrobial peptides Smp24 and Smp43. Structural modifications 
were performed on both peptides via introducing single, double or triple amino 
acid substitutions and the effect the structural changes had on the antimicrobial 




The HaCaT cell line was unfortunately found to contain mycoplasma, as such the 
results within this chapter for the HaCaT cell line represent only 3 technical and 
1 biological repeats.  
 
Due to cost limitations with the synthesis of peptides via solid-phase synthesis, 
the cytotoxicity profiles of some of the peptides were restricted. For the 
tryptophan knockout modification, only haemolysis data could be collected.  
 
4.3 Experimental design 
 
The two peptides used within this study (figure 4.1) have been modified on the 









In total, 10 modifications of Smp24 were produced and 8 modifications of Smp43 



















The haemolytic potential of the peptides was assessed by incubation of the 
peptides (0 - 512 μg/ml) with sheep erythrocytes over a one hour period according 
to the method of Corzo et al, (2002). HC50 values were calculated as the 
concentration resulting in 50% haemolysis (refer to chapter 2, section 2.6).  
 
As the antimicrobial activity of two commercially available AMP-like antibiotics 
(daptomycin and polymyxin B) was assessed in chapter 3 (section 3.4.2), it was 
deemed important to assess the activity of the AMPs used in this study compared 
with commercially licensed drugs. 
 
4.4.1.1  Haemolytic activity of modified Smp24 peptides 
 
The HC50 values for Smp24 and derived modified peptides are shown below in 
table 4.1. 
 
Table 4.1: Haemolytic activity presented as HC50 values for Smp24 and derived 
modifications used within this study.  
 
Peptide Charge GRAVY HC50 (μg/ml) 
Smp24 +3 0.31 76 
Smp24 W2A +3 0.43 >512* 
Smp24 S3F +3 0.46 52 
Smp24 S3K +4 0.18 11* 
Smp24 S3K/S15K +5 0.05 23* 
Smp24 F4A +3 0.27 423* 
Smp24 K7S +2 0.44 36 
Smp24 K7F +2 0.59 442* 
Smp24 S15K +4 0.18 26* 
Smp24 D23F +4 0.58 33* 
Smp24 S24K +4 0.18 15* 
Daptomycin -6 -1.93 >512 
Polymyxin B +5 nc >512 
 
Statistical significance was determined by performing a T-test.  
* p-value ≤0.05; nc - not calculable 
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Native Smp24 exhibits moderate to high haemolytic activity, with an HC50 
concentration of 76 μg/ml. All of the modifications performed to enhance the 
charge (which in turn enhanced the antimicrobial activity) resulted with enhanced 
haemolytic activity and lower HC50 concentrations. Interestingly, S3K which 
demonstrated the most potent antimicrobial activity also demonstrates the most 
haemolytic activity out of the peptide modifications assayed. 
 
Unsurprisingly, both of the lipopeptide antibiotics demonstrated a low level of 
haemolytic activity, with HC50 values above the limit of detection of this study. 
One of the peptides within this study, W2A, demonstrated a low level of 
haemolysis which was observably similar to that of the lipopeptide antibiotics with 
a HC50 beyond the limit of detection (>512 µg/ml). Two of the other peptides also 
demonstrated a lower level of haemolysis (F4A and K7F) with HC50s of 423 and 
442 µg/ml respectively. 
 
4.4.1.2 Haemolytic activity of modified Smp43 peptides 
 
The haemolytic activity of the modified Smp43 peptides was also determined 
(table 4.2). 
 




Charge GRAVY HC50 (μg/ml) 
Smp43 +4 -0.32 >512 
Smp43 W3A +4 -0.25 >512 
Smp43 D4F +5 -0.17 92* 
Smp43 W5A +4 -0.25 >512 
Smp43 W14A +4 -0.13 >512 
Smp43 W3A/W5A/W14A +4 -0.13 >512 
Smp43 S16K +5 -0.39 >512 
Smp43 S24K +5 -0.39 >512 
Smp43 S43K +5 -0.39 >512 
Daptomycin -6 -1.93 >512 
Polymyxin B +5 nc >512 
 
Statistical significance was determined by performing a T-test.  
* p-value ≤0.05; nc - not calculable 
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The haemolytic activity of Smp43 and derived modifications demonstrates a low 
level of haemolysis, with increased charge demonstrating no observable increase 
in haemolytic activity within the concentration range investigated in this study. 
Interestingly, one of the peptides within this study produced an HC50 value within 
the limit of detection. The D4F modification demonstrated significantly increased 
haemolytic activity, demonstrating a higher charge than Smp43 (+5) and 
increased hydrophobicity, which appears to have resulted in a peptide with an 
increased propensity to interact with sheep erythrocyte membranes. The activity 
to all of the modified Smp43 peptides, except the D4F modification, was found to 
be equivalent to that of the lipopeptide antibiotics within the concentration range 
used within this study. 
 
4.4.2 Cytotoxicity against liver and kidney cells 
 
Cytotoxicity testing was carried out to assess the effect the peptides would have 
on mammalian cell lines. As all systemic drugs pass through the liver and a 
significant proportion of drug metabolism occurs in the liver, a liver cell line 
(HepG2) was used to assess the toxicity of the peptides. The excretion of the 
drug must also be considered when developing potential novel antimicrobials; as 
such the cytotoxicity of the peptides was also assessed on a kidney cell line 
(HEK-293).  
 
Both cell lines were routinely tested for mycoplasma and determined to be 
mycoplasma free. Cytotoxicity was assessed by incubation of the cell lines with 
AMPs over the concentration range of 0 - 512 µg/ml and determining LDH release 
by a Pierce LDH assay (Life Technologies, Paisley, UK) (chapter 2, section 
2.7.2). LD50 values were calculated by plotting AMP concentration against 
observed percentage cytotoxicity to determine the concentration of peptide to 
cause 50% cell death. 
 
As the haemolytic activity of daptomycin and polymyxin B had been determined, 
the same approach was taken with cytotoxicity screening to compare the activity 




4.4.2.1 Cytotoxic activity of modified Smp24 peptides 
 
The cytotoxic activity of Smp24 and Smp24-derived modified peptides was 





Table 4.3: Cytotoxic activities of Smp24-derived peptides against liver and kidney cell 
lines.  
 
Peptide Charge GRAVY LD50 (μg/ml) 
HepG2 HEK-293 
Smp24 +3 0.31 37 39 
Smp24 W2A +3 0.43 121* 72* 
Smp24 S3F +3 0.46 51* 32 
Smp24 S3K +4 0.18 34 38 
Smp24 S3K/S15K +5 0.05 42 29* 
Smp24 F4A +3 0.27 63* 56* 
Smp24 K7S +2 0.44 30 15* 
Smp24 K7F +2 0.59 >512* >512* 
Smp24 S15K +4 0.18 38 13* 
Smp24 D23F +4 0.58 >512* 38 
Smp24 S24K +4 0.18 36 23* 
Daptomycin -6 -1.93 >512 >512 
Polymyxin B +5 nc >512 351 
 
Statistical significance was determined by performing a T-test,  
* p-value ≤0.05; nc - not calculable. 
 
As shown by the results in table 4.3 above, significant changes have been made 
to the cytotoxicity profiles of the peptides. For the cytotoxicity profiles against 
HepG2 cells, only one modification (K7S) resulted in a non-significant increase in 
cytotoxicity. Four of the peptides within this study resulted in significant decreases 
in liver toxicity. F4A and S3F had LD50 concentrations at higher concentrations 
than that of native Smp24 and two of the modifications in this study K7F and 
D23F demonstrated LD50 concentrations beyond the limit of detection of the 




The cytotoxicity results against the HEK-293 cell line demonstrated a different 
pattern, with the peptides generally having increased levels of toxicity against the 
HEK-293 cell line when compared with the HepG2 cell line. The peptide which 
exhibited the greatest degree of cytotoxicity against the kidney cell line was S15K, 
with an LD50 concentration of 13 µg/ml. Conversely, the least cytotoxic peptide 
within this study was K7F which again demonstrated an LD50 value above the 
limit of detection within the confines of the study. Significant decreases in 
cytotoxicity were observed by the W2A and F4A modifications, although the LD50 
concentrations were both lower than those observed against HepG2 cells. Some 
of the peptides within this study also demonstrated significant increases in 
cytotoxicity, S15K, S24K, S3K/S15K and K7S all possessed lower LD50 
concentrations compared with native Smp24. 
 
Both daptomycin and polymyxin B demonstrated low levels of toxicity against 
mammalian cell lines with LD50 values above the concentration range limit used 
within this study. The exception to this was the assessment of polymyxin B 
against the HEK-293 cell line, which demonstrated an LD50 within the limit of 
detection at 351 µg/ml. Two of the modified Smp24 peptides (K7F and D23F) 
demonstrated low levels of cytotoxicity equal to that of both polymyxin B and 
daptomycin. Against the kidney cell line, one of the peptides within the study 
demonstrated less cytotoxicity than polymyxin B and equal cytotoxicity to 
daptomycin, which was the K7F modification. 
 
4.4.2.2 Cytotoxic activity of modified Smp43 peptides 
 
Following the characterisation of the Smp24 peptides, the LD50 of Smp43 and 









Table 4.4: Cytotoxic activities of Smp43 and derived modifications against liver and 
kidney cell lines.  
Peptide Charge GRAVY LD50 (μg/ml) 
HepG2 HEK293 
Smp43 +4 -0.316 162 36 
Smp43 W3A +4 -0.25 172 76* 
Smp43 D4F +5 -0.17 68 40 
Smp43 W5A +4 -0.25 46* 39 
Smp43 W14A +4 -0.13 77* 29 
Smp43 W3A/W5A/W14A +4 -0.13 ND ND 
Smp43 S16K +5 -0.39 49 31 
Smp43 S24K +5 -0.39 29* 17 
Smp43 S43K +5 -0.39 39* 21 
Daptomycin -6 -1.93 >512 >512 
Polymyxin B +5 nc >512 351 
Statistical significance was calculated by performing a T-test,  
* p-value ≤0.05;  ND - not determined; nc - not calculable. 
 
Native Smp43 shares a relatively low level of cytotoxicity against the HepG2 cell 
line when compared with that of Smp24. The characterisation of the Smp43 
modifications within this study demonstrated many peptides with significant 
increases to the LD50. S24K, S43K, W5A and W14A modifications all yielded 
peptides with increased cytotoxicity compared with native Smp43. None of the 
Smp43 modifications produced peptides with significantly decreased cytotoxicity. 
 
Similar to the results obtained from Smp24, lower LD50 concentrations were 
observed for the HEK-293 cell line compared with the HepG2 cell line. Native 
Smp43 demonstrated a much lower LD50 concentration against the kidney cell 
line compared with that observed for the liver cell line. Only one of the 
modifications made to Smp43 resulted in a significant change to the LD50, with 
W3A demonstrating a significant improvement to the LD50 with a concentration of 
76 μg/ml. 
 
Neither native Smp43 nor any of the modified Smp43 peptides demonstrated 
cytotoxicity equal to the limited cytotoxicity of daptomycin or polymyxin B. The 
cytotoxicity of the W3A/W5A/W14A could not be determined due to the small 




4.4.3 Cytotoxicity of AMPs against skin cell lines 
 
Following the assessment of the AMPs against liver and kidney cell lines, the 
cytotoxicity of the peptides was assessed against a human skin cell line for the 
consideration of topical application of the peptides. Cytotoxicity was determined 
according to previously discussed methods (chapter 2, section 2.7.2). 
 
4.4.3.1 Cytotoxicity of modified Smp24 peptides against human skin cells 
 
The cytotoxicity profiles of Smp24 and the derived modifications against a human 
keratinocyte cell line are shown below in table 4.5. 
 
Table 4.5: LD50 concentrations for modified Smp24 peptides against an immortalised 
human keratinocyte cell line (HaCaT). 
 
Peptide Charge GRAVY LD50 (μg/ml) 
Smp24 +3 0.31 34 
Smp24 W2A +3 0.43 104* 
Smp24 S3F +3 0.46 >512* 
Smp24 S3K +4 0.18 18* 
Smp24 S3K/S15K +5 0.05 18* 
Smp24 F4A +3 0.27 57* 
Smp24 K7S +2 0.44 22 
Smp24 K7F +2 0.59 >512* 
Smp24 S15K +4 0.18 18* 
Smp24 D23F +4 0.58 137* 
Smp24 S24K +4 0.18 142 
Daptomycin -6 -1.93 >512 
Polymyxin B +5 nc >512 
Statistical significance was calculated by performing a T-test,   
* p-value £0.05; nc - not calculable 
 
Native Smp24 demonstrates a moderate to high level of cytotoxicity against the 
HaCaT cell line with an LD50 concentration of 34 μg/ml. The modifications to 
Smp24 yielded mixed results, with the exception of S24K, all of the serine to 
lysine substitutions produced peptides with significantly increased cytotoxicity 
profiles. Interestingly, the peptide with the highest charge (S3K/S15K) carried the 




Increasing the hydrophobicity of the peptides generally resulted in significant 
decreases in cytotoxicity, with the K7S modification being the only exception to 
this rule. The modifications which incorporated phenylalanine residues into the 
sequence all resulted in significant decreases in cytotoxicity against HaCaT cells. 
Both K7F and S3F modifications demonstrated LD50 values above the detection 
limit within the scope of this study, whilst D23F and W2A modifications both 
produced peptides with LD50 values above 100 µg/ml. 
 
Two of the peptides demonstrated cytotoxicity equal to that of daptomycin and 
polymyxin B within the detection limits of this study. The S3F and K7F 
modifications demonstrated cytotoxicity of >512 µg/ml. Whilst other modifications 
may not have demonstrated cytotoxicity comparable to that of the two lipopeptide 
antibiotics within the concentration range of this study, 3 of the other peptides 
(W2A, D23F and F4A) demonstrated significantly reduced cytotoxicity. This is 
promising when looking to reduce cytotoxicity of the peptides overall. 
 
4.4.3.2 Cytotoxicity of modified Smp43 peptides against immortalised 
keratinocytes 
 
The results of the cytotoxicity assessment of Smp43 and the derived 















Table 4.6: Cytotoxicity profiles of Smp43 and derived modifications displayed as LD50 




Charge GRAVY LD50 (μg/ml) 
Smp43 +4 -0.32 179 
Smp43 W3A +4 -0.25 194 
Smp43 D4F +5 -0.17 327 
Smp43 W5A +4 -0.25 37* 
Smp43 W14A +4 -0.13 53* 
Smp43 W3A/W5A/W14A +4 -0.13 ND 
Smp43 S16K +5 -0.39 328 
Smp43 S24K +5 -0.39 >512* 
Smp43 S43K +5 -0.39 99* 
Daptomycin -6 -1.93 >512 
Polymyxin B +5 nc >512 
Statistical significance was calculated by performing a T-test  
* p-value £0.05; ND - not determined; nc - not calculable. 
 
As shown by the results in table 4.6, native Smp43 demonstrates a low level of 
cytotoxicity against keratinocytes compared with Smp24. Unlike the results 
obtained for the modification to Smp24, no pattern was observed for the changes 
in cytotoxicity for Smp43 in relation to the modifications performed.  
 
Four of the modifications made to Smp43 demonstrated reduced cytotoxicity. 
D4F and W3A modifications both resulted in peptides with increased 
hydrophobicity and decreased cytotoxicity against HaCaT cell line, although 
these differences were not determined to be statistically significant.  
Two of the modifications which produced peptides with increased charge (S16K 
and S24K) demonstrated reduced cytotoxicity against the HaCaT cell line. The 
S24K modification demonstrated a statistically significant decrease in 
cytotoxicity, with an LD50 greater than 512 µg/ml.  
 
One of the peptides within this study demonstrated a low level of cytotoxicity 
equal to that of daptomycin and polymyxin B. The S24K modification 
demonstrated cytotoxicity >512 µg/ml and was the least cytotoxic variant of 
Smp43. Whilst the D4F and S16K modifications didn't have the low haemolysis 
observed for the lipopeptide antibiotics, both modifications demonstrated reduced 
cytotoxicity compared with the parental peptide. 
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4.4.3.3 Human Urothelial Epithelial Cells (HUEPC) 
 
Following the observation of a detectable LD50 for the cytotoxicity of polymyxin B 
against HEK-293 cells, the properties of the cell membranes of the cell lines was 
investigated and interesting differences in the resting membrane potential of the 
cell lines were noted. The HEK-293 cell line has a considerably more negatively 
charged membrane when compared with the other cell lines; as such the 
cytotoxicity of the two parental peptides was re-assessed against a cell line 
related to excretion with a more neutral membrane potential. Primary human 
uroepithelial cells (HUEPCs) were used for this investigation. Differences in 
membrane potential between the cell lines used in this study are shown in table 
4.7. 
 
Table 4.7: Membrane potential differences between primary and secondary cell lines 
 
Cell line Designation Membrane potential (mV) 
Sheep erythrocytes Primary 28-39 
HepG2 Secondary -18.25 
HEK-293 Secondary -40 
HUEPC Primary -14.3 
 
 
Following the observations that there may be an association between cell 
membrane potential and peptide cytotoxicity, the cytotoxicity of the parental 
peptides was assessed against HUEPCs (table 4.8). 
 
Table 4.8: Cytotoxicity assessment of native Smp24 and Smp43 against HUEPC cells 
 




As shown in table 4.10, both peptides demonstrated LD50 profiles beyond the limit 
of detection of the study when assayed against the HUEPC cell line. The results 
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of this study are interesting, as variations in membrane charge and composition 




Previous structural modifications to Smp24 include the insertion of a GVG hinge, 
increasing the peptide length to 26 amino acids and the truncation of the last 5 
amino acids of the chain to reduce the peptide sequence to 19 amino acids. The 
results of the modifications yielded contrasting outcomes; the Smp24GVG 
modification resulted in greater haemolytic activity compared with native Smp24 
whilst Smp24T demonstrated reduced haemolytic activity (Harrison, et al. 2016). 
Cytotoxicity of the peptides has previously been determined by ATP release 
assay and all the peptides demonstrated cytotoxic properties. The insertion of the 
GVG hinge led to dramatically increased cytotoxicity whilst the truncation of the 
peptide resulted in a small reduction in cytotoxicity (Harrison, Abdel-Rahman, et 
al. 2016). The truncation modification resulted in an increased hydrophobicity of 
the peptide with a GRAVY score of 1.05 and a charge reduction to +2. One of the 
peptides within this study with similar physicochemical properties, K7F, 
demonstrated a similar level of haemolysis but was much less cytotoxic than 
Smp24T. 
 
4.5.1 Haemolysis of Smp24 
 
Most of the Smp24 modifications within this study resulted in a high level of 
haemolysis, which is in keeping with haemolytic properties of scorpion venom-
derived antimicrobial peptides in the literature. BmKn2-7 is an antimicrobial 
peptide derived from the venom of Buthus martensii karsch and natively 
demonstrates a HC50 of 17 µg/ml (Li et al. 2019b). Modifications to the structure 
of this peptide which resulted in increased charge, reduced the HC50 to 90 µg/ml  
(Li et al. 2019a). The effects of increased charge on Smp24 resulted in increased 
haemolysis, but the charge modifications to Smp43 resulted in a non-detectable 




As a general rule, the Smp24 peptides which demonstrated improved 
antimicrobial activity also demonstrated increased haemolytic activity. Similar 
results have previously been observed for antimicrobial peptides extracted from 
Australian tree frogs, with improvements in antimicrobial activity accompanied by 
4-fold increases in haemolytic activity (Fernandez et al. 2008).  
 
Whilst Smp24 and Smp43 are both isolated from the same venom, the 
differences in haemolytic and cytotoxic profiles highlight the relationship between 
structure and function. Smp43 is a much larger AMP, with a di-helical structure 
which is predicted to be globular due in aqueous solutions by the GRAVY value. 
Smp24 is a smaller peptide which behaves similarly to other smaller venom-
derived AMPs within the literature and is predicted to be membranous in 
structure. VmCT1 is a 13 amino acid peptide derived from the venom of the 
scorpion Vaejovis mexicanus. The influence of charge on the antimicrobial 
activity of VmCT1 was investigated by the incorporation of lysine residues in to 
the structure. (Pedron et al. 2019). Similar to the results observed in this study 
for Smp24, the structural modifications which resulted in reduced antimicrobial 
activity resulted in reduced haemolytic activity, as evidenced by the reduced 
cytotoxicity of the W2A and K7F modifications.   
 
 
4.5.2 Haemolysis of Smp43 
 
Smp43 has previously been shown to possess a low level of haemolysis against 
sheep erythrocytes (Harrison, et al. 2016), which is thought to be related to the 
structure. Smp43 adopts a di-helical structure in the presence of 60% TFE and 
belongs to the longer-chain AMP family. Other peptides in this class with the 
helix-hinge-helix topology include Pandinin 1 and cecropin A (Holak et al. 1988, 
Corzo et al. 2001) which offer attractive therapeutic indices for future therapeutic 
development. Additionally, the suggested globular state of Smp43 could 
contribute to the behavioural differences between Smp24 and Smp43. The 
modifications made to the Smp43 peptides resulted in non-detectable changes 
to the haemolytic potential, with the HC50 exceeding the limit of detection at >512 
µg/ml. The exception to this is the D4F modification which resulted in a HC50 of 
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92 μg/ml. Interestingly, the D4F modification did not demonstrate an improved 
antimicrobial pattern compared with native Smp43. D4F has a slightly increased 
activity against Pseudomonas (32 µg/ml) but decreased potency against E. coli 
(64 µg/ml) and therefore the increased haemolytic activity demonstrated by this 
modification created a less therapeutically appealing peptide. 
 
4.5.3 Haemolysis as a measure of cytotoxicity 
 
Haemolysis has previously been used to determine the cytotoxic properties of 
AMPs, though methods used differ between research groups. Types of blood 
used for the assays can vary tremendously, with blood derived from species 
ranging from fish (rock bream) to human (Bae et al. 2018, Rončević et al. 2019). 
The membrane composition can influence the percentage haemolysis (or HC50) 
observed, as the fatty acid content of red cell membranes can vary greatly 
between species (Al-Qarawi and Mousa 2004). Sheep erythrocytes are 
commonly used to determine the HC50 of AMPs due to ease of availability and no 
requirement for ethical approval to run the assays, but the membrane 
composition differs to that of human red blood cells. Zwitterionic 
phosphatidylcholine (PC) is responsible for 1.6% of the membrane for sheep red 
blood cells and 39.5% of the membrane of human red blood cells (Dennison and 
Phoenix 2014). As lower levels of peptide insertion have been observed in the 
presence of the PC (Dennison and Phoenix 2014), the usage of sheep 
erythrocytes as a marker of haemolysis may result in an inaccurate 
representation of the HC50 which could be observed in human red blood cells. It 
is anticipated, due to differences in phospholipid content of red cell membranes 
between different species, that a lower level of haemolysis would be observed if 
the peptides were tested against human blood.  
 
As a result of the membrane composition affecting the perceived haemolysis of 
the peptide, the modifications to the structure of the peptides could produce 
misleading haemolysis results when determining suitability for human application. 
For future investigations, haemolysis assays could be performed on human red 
blood cells to determine if the membrane composition of the cells is a critical 




Limited investigations have been made in to the membrane potential of sheep 
erythrocytes and the resting membrane potential of the cells has been linked to 
ion dependency. The membrane potential of sheep erythrocytes was determined 
to be 33-39 mV in the presence of high potassium and 28-37.8 mV in the 
presence of low potassium (Andreoli et al. 1967). Alternatively, the haemolytic 
propensity of the peptides could be more complex. It has previously been 
postulated that the interaction between AMPs and mammalian cell membranes 
is mostly the result of hydrophobic interactions (Mahlapuu et al. 2016a). As 
Smp24 and the derived modifications are more hydrophobic than Smp43, this 
could also contribute to the increased cytotoxicity observed against mammalian 
cells.  
 
4.5.4 Eukaryotic cytotoxicity 
 
Differences in LD50 concentrations were observed between two cell types (HEK-
293 and HepG2) used within this study for both native peptides. This could offer 
some mechanistic insights as to how peptides interact with mammalian 
membranes and the importance of the ratio between AMP charge and the 
electrical potential of the cell membrane. Greater cytotoxicity was observed 
against the HEK-293 cell line than HepG2 for all of the peptides tested.  
 
Primary cells (such as the HUEPC cells) are isolated directly from tissues, have 
a finite lifespan and limited expansion capacity, which can make the cell line 
challenging to work with in the laboratory. Primary cells have “normal” cell 
morphology and maintain many of the important markers and functions observed 
in vivo (Alge et al. 2006, Pan et al. 2009). Secondary cell lines, which are often 
derived from tumours are immortalised by chemical carcinogens or viruses which 
enable virtually unlimited proliferation. A question of major importance is whether 
the mechanism of immortalisation affects the genotype and phenotype of the cells 
(Smith et al. 1992).  
 
The human embryonic kidney cell line (HEK-293) was obtained by exposing 
human embryonic kidney cells to mechanically sheared fragments of adenovirus 
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type 5 DNA. This resulted in 11% of the adenovirus genome being incorporated 
in to the 19q13.2 chromosome of the HEK cells, which is required for the genomic 
coding of E1A and E1B proteins for immortalisation (Stepanenko and Kavsan 
2012). HepG2 cells are a human teratocarcinoma cell line obtained from a 15 
year old Caucasian male and frequently used as in vitro alternatives to primary 
hepatocytes due to an unlimited lifespan, stable phenotype, high availability and 
ease of handling (Donato et al. 2015). Studies have determined gene expression 
can differ between primary cell lines and the relevant immortalised cell lines. 
Wilkening et al., (2003) demonstrated the expression of Phase 1 enzymes in the 
HepG2 cell line was considerably lower than that observed in primary liver cells. 
The study concluded that the HepG2 cell line could be useful for the study of 
drug-metabolising enzymes (such as LDH within the confines of this study) but it 
does pose questions about the reliability of data obtained from secondary cell 
lines. Resultantly, the data obtained from using primary cells has been 
demonstrated to be more relevant and reflective of the in vivo environment (Alge 
et al. 2006, Pan et al. 2009).  
 
4.5.4.1 Membrane composition 
 
HEK-293 cells have high (~35%) phosphatidylcholine (PC), high (~25%) 
phosphatidylserine (PS) and a moderate (~15%) phosphatidylethanolamine (PE) 
content compared with HepG2 cells which have a PC (~30%) enriched 
membrane with PE and PS almost excluded from this leaflet (Müller et al. 1996). 
Additionally, both cell lines demonstrated marked differences in cell membrane 
potential, with HepG2s  exhibiting a membrane potential of -18.2 mV (Liu et al. 
2003) and HEK-293 cells holding a membrane potential of -40 mV (Stott et al. 
2015).  Together these results could indicate the importance of membrane 
composition when determining cytotoxicity. The licensed drug Polymyxin B 
demonstrated a detectable LD50 value (351 µg/ml) against the HEK-293 cell line 
but no activity against the HepG2 cells, which could indicate mechanistic 
interactions between a positively charged peptide and more negatively charged 
cell membranes. The membrane of HaCaT cells is composed of 37% PC, 6.7% 
sphingomyelin (SM) and 18% PE/PS/phosphatidylinositol (PI) (Schurer et al. 
1993). The HaCaT cell membrane is composed of a greater percentage of neutral 
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phospholipids compared with the HEK-293 cell line which could contribute to the 
differences observed in cytotoxicity between the cell lines. 
 
The increased propensity for cell death with a more negatively charged 
membrane is perhaps unsurprising, due to the initial electrostatic interactions 
between positive charged AMPs and negatively charged bacterial membranes 
being the driving force for antimicrobial activity (Mihajlovic and Lazaridis 2010). 
 
4.5.4.2 Cytotoxicity of Smp24 
 
For Smp24-derived peptides, cytotoxicity against the HepG2 cell line remained 
constant for all peptides with modifications that increased the net charge, with 
LD50 concentrations around 37 µg/ml. Some of the modifications which resulted 
in increased hydrophobicity (and decreased antimicrobial activity) resulted in 
reduced cytotoxicity against HepG2 cells. The incorporation of phenylalanine 
residues significantly reduced the cytotoxicity. Phenylalanine substitutions were 
performed at the N-terminus (S3F), mid-chain (K7F) and C-terminal (D23F), with 
the latter two resulting in the greatest reduction in cytotoxicity to >512 µg/ml. 
Whilst the reduction of the cytotoxicity of K7F modification is statistically 
significant, the lack of antimicrobial activity demonstrated by this modification 
renders this peptide therapeutically unattractive, though this could suggest the 
antimicrobial activity and the cytotoxicity activity of Smp24 could be linked.  
 
The reduction of cytotoxicity upon incorporation of phenylalanine residues in to 
the AMP structure has been observed previously (Saint Jean et al. 2018). The 
modification of the AMP C18G where leucine residues were substituted with 
phenylalanine residues improved the percentage viability of the HEK-293 cell line 
(Saint Jean et al. 2018). As with many studies investigating modified AMPs (Oddo 
et al. 2015, Bae et al. 2018, Rončević et al. 2019), the cytotoxicity screen was 
limited to one cell line which creates difficulties when observing cytotoxicity 
patterns. For Smp24, the incorporation of phenylalanine residues reduced 
cytotoxicity against the HepG2 and the HaCaT cell lines but the effect on HEK-
293 cells was more varied, with only the K7F modification demonstrating a 




Modifications to the C-terminal of Smp24 appeared to result in contrasting 
outcomes. The D23F modification was less cytotoxic against HepG2 and HaCaT 
cells, whilst the S24K modification resulted in increased cytotoxicity against HEK-
293 cells and non-significant differences against the HepG2 and HaCaT cell lines. 
Rodríguez et al., (2014) determined the cytotoxicity of Pandinin 2 was linked with 
the KKD residues at the C-terminal. As Smp24 shares sequence homology with 
Pandinin 2, the results from this study suggest the KKD residues at the C-terminal 
of Smp24 are also linked with cytotoxicity and substitution of these peptides 
results in contrasting outcomes. 
 
4.5.4.3 Cytotoxicity of Smp43 
 
For Smp43, the incorporation of phenylalanine (D4F) had a more varied result. 
Reduced cytotoxicity against HaCaT cells and non-significant changes against 
the HepG2 and HEK-293 cell lines were observed though the LD50 of the D4F 
modification when compared with native Smp43. Though the changes were not 
statistically significant, the biological relevance can be determined by calculating 
the therapeutic index (see chapter 5, section 5.6). 
 
All of the modifications to Smp43, with the exception of the W3A modification, 
resulted in increased cytotoxicity against the HepG2 cell line. Interestingly, the 
W3A modification resulted in an enhanced antimicrobial profile compared with 
native Smp43 and therefore a more therapeutically attractive peptide was 
produced when comparing the ration of antimicrobial activity to cytotoxicity. The 
most cytotoxic peptides within the study were S24K and S43K, both of which 
contain increased charge within the second helix of the peptide and increased 
clustering of charged residues within the helix. As the HepG2 membrane has a 
slight negative charge, the increased polarity of the peptide could have aided 
interaction with the membrane and the resultant cytotoxicity. Against the HEK-
293 cell line, all of the modifications except the W3A modification resulted in 
enhanced cytotoxicity. Polymyxin B, which has a charge of +5, demonstrated a 
detectable LD50 value against this cell line suggesting the cytotoxicity profile of 




4.5.5 Therapeutic applications 
 
The results in this study demonstrate technical limitations within the AMP field. 
Firstly, the screening of AMP cytotoxicity by means of haemolysis assay is not 
necessarily conclusive. Differences in haemolysis vs mammalian cytotoxicity 
have been observed for the variants of Smp24 and Smp43 against the numerous 
cell lines used. For example, the HC50 of Smp43 is >512 µg/ml but the LD50 
against HEK-293 cells is 36 µg/ml which would have a significant impact when 
calculating the therapeutic index. Erythrocyte membrane composition differs 
between species, thus making data sets between studies directly incomparable. 
Dennison and Phoenix, (2014) determined the effect of the antimicrobial peptide 
modelin 5 on sheep, pig and human erythrocytes. The study determined that the 
greatest haemolysis was observed against sheep erythrocytes (12% at 500 µM) 
and much lower haemolysis was observed against human erythrocytes (<2% at 
500 µM). Taking the results of this study and the results of Dennison and Phoenix, 
(2014) in to account, the data suggests the activity of AMPs is much more 
complicated than initially anticipated and a more comprehensive screen of AMPs 
is required in order to gain a cytotoxicity profile that may be representative against 
relevant cell types in humans.  
 
Secondly, the choice of cell lines can affect the cytotoxicity. This study highlights 
that differences in the membrane potential of eukaryotic cell lines can affect the 
observed cytotoxicity, with cell lines that have a more negative membrane 
potential demonstrating greater susceptibility to AMPs. This could potentially lead 
to peptides being labelled as more cytotoxic if a single cell line is used in 
validating drug leads. For this study, the cell line hypothesis was tested by 
performing cytotoxicity screening of the parental peptides against the HUEPC cell 
line. The resting membrane potential of HUEPC is -14.3 mV (Laaris et al. 2012), 
which is less negative than the membrane potential of both the HepG2 and HEK-
293 cell lines (Liu et al. 2003, Stott et al. 2015). This resulted in calculated LD50s 
of >512 µg/ml for both Smp24 and Smp43, which was not observed against the 




Thirdly, a general strategy to reduce cytotoxicity across AMPs may not be 
possible. The results of this study highlight how similar modifications introduced 
to peptides derived from the same venom have had contrasting effects. For 
example, tryptophan to alanine substitutions in Smp24 resulted in reduced 
cytotoxicity, but typically result in an increase in cytotoxicity following equivalent 
substitutions in Smp43. From this it can be concluded that it is essential to 
perform numerous modifications on parent peptides to determine which residues 
can be modified to produce enhanced peptides, but that this can be varied and a 




Peptides with reduced cytotoxicity have been produced for both Smp24 and 
Smp43. The K7F, D23F, W2A and S3F modifications to Smp24 produced 
peptides with reduced cytotoxicity against kidney, liver and skin cells. Of these 
modifications, the D23F peptide is of interesting due to retaining the antimicrobial 
activity profile of native Smp24 whilst demonstrating reduced cytotoxicity. The 
W3A modification of Smp43 demonstrated reduced cytotoxicity against the 
kidney cell line whilst reduced cytotoxicity against the skin cell line was observed 
for the D4F, S16K and S24K modifications. Whilst both the S16K and S24K 
modifications of Smp43 resulted in increased cytotoxicity, both of these 
modifications demonstrated enhanced antimicrobial activity compared with native 
Smp43. 
 
All of the modifications to Smp24 produced peptides with enhanced haemolysis, 
except W2A, F4A and K7F which all demonstrated statistically significant reduced 
HC50 values. With the exception of D23F, these modifications also resulted in 
decreased antimicrobial activity. The modifications to Smp43 resulted in non-
detectable changes to the haemolysis, with HC50 values exceeding the limit of 
detection of the study. Resultantly, all of the peptides which demonstrated 
increased antimicrobial activity also demonstrated non-detectable changes in 
haemolysis and thus enhanced peptides were produced. The one exception to 
this was the D4F modification which was detectably and significantly more 




The results of this study highlight the importance of a comprehensive screen for 
cytotoxicity and how the effects of modifications can appear to have unpredictable 
effects on cytotoxicity. Additionally, this study has revealed it could be pertinent 
to assess cellular cytotoxicity against both primary and secondary cell lines. 
 
The next step of the investigation is to analyse the structural modifications made 
to Smp24 and Smp43 and the effects these have had on function. Additionally, 
calculating the therapeutic indices of the peptides will enable candidate peptides 
















5.1 Structural investigations relating to antimicrobial activity 
 
The antimicrobial activity of Smp24, Smp43 and derived modifications has been 
assessed in chapter 3 and the cytotoxic and haemolytic properties have been 
assessed in chapter 4. Initial structural investigations were performed on the most 
and least active antimicrobial peptides (Smp24 S3K and Smp24 K7F) to 
determine if it was possible to visualise structural differences by circular dichroism 
(CD) spectroscopy (chapter 3, section 3.6). Smp24 was chosen for the focus of 
CD work due to the greatest increased and decreased antimicrobial activity 
observed across this investigation. 
 
Computational modelling can be utilised to investigate the relationship between 
structure and the observed effects on function. Ab-initio modelling can be utilised 
to generate a 3-dimensional structure based upon the amino acid sequence. 
Whilst the accuracy of computational modelling could be subjective, when used 
in combination with CD spectroscopy, the experimental data enables the models 
generated via modelling software to be either supported or rejected. 
 
5.2 Study aims 
 
This chapter aims to investigate the relationship between structure and 
antimicrobial and cytotoxicity activity of the daughter peptides compared with the 
native peptides via homology modelling of both Smp24 and Smp43. The chapter 
will be identifying structural changes via helical wheel, three-dimensional 
structure and hydrophobic and electrostatic potential modelling. 
 
Therapeutic indices have been calculated to identify which peptide modifications 
demonstrate an enhanced antimicrobial and cytotoxicity profile when compared 







5.3 Experimental design 
 
To investigate the effects of the modifications of the peptides on the structure, 
computational modelling was used. Initially, helical wheels were generated to 
visualise the organisation of the peptides in terms of charge and hydrophobicity 
(section 2.9.4). Ab-initio modelling was then used to generate 3-dimensional 
helices. Structural files were generated using QUARK software by Zhanglab, but 
to obtain more complex models, the output file format from QUARK was used to 
process samples using PyMOL Molecular Graphics System, Version 2.0 
Schrödinger, LLC (section 2.9.3). 
 
5.4 Structural investigations relating to antimicrobial activity 
 
Initially, structural investigations were made to determine the effects of structural 
changes on the antimicrobial activity of the peptides. The modifications resulting 
in >8 fold reductions or improvements to the antimicrobial activity of the peptides 
were investigated via helical wheel, surface polarity and 3-dimensional structural 
analysis. 
 
5.4.1 Structural investigations of Smp24 K7F  
 
The increased hydrophobicity of the peptides generally led to a reduction in 
antimicrobial activity. This has been observed in the literature before; 
modifications to Pandinin 2 which resulted in a GRAVY increase from 0.32 to 0.57 
yielded a peptide with no detectable antimicrobial activity against the isolates 
tested, which included S. aureus, E. coli and B. subtilis (Rodríguez et al., 2011). 
The most hydrophobic Smp24 modification was K7F, which demonstrated no 
antimicrobial activity against the same species of bacteria. Structurally, this 






Figure 5.1: Structural analysis of Smp24 and modifications. Helical wheel analysis of (A) 
Smp24, (B) Smp24 K7F and 3D structural analysis of (C) Smp24 and (D) Smp24 K7F 
using PyMOL (Schrödinger, LLC). Differences between the modified peptide and native 
peptide are highlighted by rings and boxes.  
 
From the helical wheel structures (figure 5.1 panels A and B), the K7F 
modification resulted in a change in the amphipathicity of the peptide compared 
with Smp24. The addition of the phenylalanine led to the incorporation of a 
hydrophobic residue towards the polar N-terminal region of the helix. The 3D 
modelling of the peptide also suggests significant structural changes to the 
peptide, with the helix region of K7F being reduced and the disordered region 
being more predominant. The structural changes could imply the importance of 









5.4.2 Structural investigations of Smp24 S3K 
 
The S3K modification to Smp24 resulted in the most potent AMP within this study, 
with an MIC of 0.5 µg/ml against S. aureus and 1 µg/ml against E. coli. The 
structural analysis of the S3K modification demonstrates the effect of 
incorporation of a slightly longer chain and positively charged lysine residue to 




Figure 5.2: Structural analysis of N-terminal charge modification of Smp24. Helical wheel 
analysis of Smp24 (A) and Smp24 S3K (B); 3D structural analysis of Smp24 (C) and 
Sm24 S3K (D). Differences between the modified peptide and native peptide are 
highlighted by rings and boxes.  
 
From helical wheel analysis, the incorporation of the lysine residue at position 3 








peptides is widely reported as the most important physicochemical property of 
AMPs, as it enables the peptides to attack the cell membrane by selectively 
interacting with the hydrophobic-hydrophilic domains of the phospholipids 
(Edwards et al. 2016). With the S3K modification, there is an increase in charge 
on one side of the helix whilst the hydrophobicity on the other side of the helix 
remains equal to that of Smp24. This can be most readily seen in the space-filling 
models (figure 5.4). The change in polarity of the peptide could contribute to the 
observed increase in antimicrobial activity. 
 
5.4.3 Structural investigations for Smp43 W3A/W5A/W14A 
 
The W3A/W5A/W14A modification to Smp43 resulted in no detectable 
antimicrobial activity (section 3.4.3). The structural analysis of the 
W3A/W5A/W14A modification of Smp43 demonstrates the effect of incorporation 










Figure 5.3: Structural analysis of tryptophan substitutions in Smp43. Helical wheel for 
Smp43 (A) and Smp43 W3A/W5A/W14A (B) 3D structural analysis of peptides of Smp43 
(C) and Smp43 W3A/W5A/W14A (D). Differences between the modified peptide and 
native peptide are highlighted by rings and boxes.  
 
From helical wheel analysis, the substitution of 3 tryptophan residues for alanine 
has decreased the hydrophobicity of the peptide, as demonstrated by the 
increase in orange circular residues. From analysis of the 3D structure, no 
substantial changes can be observed. The incorporation of the alanine residues 
has decreased the length of the side chains, but overall the peptide exhibits the 
same di-helical structure as the parental peptide. The decrease in the 
antimicrobial activity of the modification could be attributed to the decrease in 
hydrophobicity. Whilst the W3A/W5A/W14A modification carries the same charge 
as native Smp43, it retains the same propensity for electrostatic interactions with 









essential component for insertion in to the membrane (Zasloff 2002, Matsuzaki 
2009). The decreased hydrophobicity of the peptide could be responsible for the 
lack of antimicrobial activity shown, as the peptide could form the initial 
electrostatic interactions but be unable to insert in to the membrane to create 
pores and the resulting cell death. 
 
5.4.4 Relating structure to function: Smp24 S3K and Smp24 K7F 
 
For short antimicrobial peptides, deletion or substitution of single amino acids can 
induce notable changes in the secondary structure (Ciumac et al. 2019). 
Numerous methods were taken to observe the effects the modifications would 
induce on the structure of the peptides. Structural predictions for the helical 
formation of Smp24 were performed using Jpred4, an update of Jpred3 
previously used for the prediction of helical and coil regions of peptides (Cole et 
al. 2008). The software predicted Smp24 formed a single helix region, extending 
from I1 to S15 with the remaining 9 amino acids adopting an unordered structure. 
The most potent peptide in the study, S3K and the least potent peptide, K7F were 
both predicted to retain a helical structure.  
 
Large changes to the structure were not expected from single amino acid 
substitutions, but small changes in the structure could affect the mechanism of 
action. Due to changes in the charge and hydrophobicity of the peptides, the 
amphipathicity and charge distribution would both be affected. Spatial 
distributions of the peptides were modelled using the 3D hydrophobic moment 
vector calculator (Reißer et al. 2014).  
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Figure 5.4: Spatial distribution of Smp24 (A, D), S3K, (B, E) and K7F (C, F) using the 3D hydrophobic moment calculator (Reißer et al. 2014). 
Polar facets are highlighted in blue and non-polar facets are highlighted in red. The rings on the images demonstrate areas of the peptides which 




5.4.5 Polar angles and hydrophobic moments 
 
Compared with Smp24 (figure 5.4, panels A and D), both the S3K and K7F 
modifications demonstrated structural changes in terms of polarity. Structural 
differences between the peptides are highlighted in figure 5.3, with the S3K 
peptide demonstrating increased polarity at the N-terminus, as expected due to 
the increased charge at residue 3. The hydrophobic moment (HM) vector of S3K 
is slightly higher when compared with native Smp24, this can be more easily 
visualised in figure 5.5. The angle between the HM vector and the z-axis is 127.0° 
for Smp24 and 139.0° for S3K. Slight structural changes can be observed around 
the HM vector for S3K, with other polar residues of the peptide appearing at the 
surface around the HM vector angle.  
 
Increased hydrophobic moment angles have been associated with increased 
antimicrobial activity in previous studies. Irazazabal et al., (2016) observed that 
a modification to mastoparan, which increased the charge from +3 to +4 whilst 
simultaneously increasing the hydrophobic moment, yielded a peptide with 
enhanced antimicrobial activity compared with the parental peptide.  Kim et al 
observed the inclusion of lysine residues which increased the charge and 
hydrophobic moment of AMPs also yielded peptides with enhanced activity 
against Pseudomonas, which was also observed in this study (Kim, Kang, et al. 
2018). The S3K modification also follows this trend, by demonstrating an 




Figure 5.5: Atomic representations of Smp24 and derived modifications. Hydrophobic moment vector is shown as a black arrow. (A) Smp24, (B) K7F and (C) 
S3K. Observable differences in the hydrophobic moment of the daughter peptides are highlighted with by red boxes. 
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For K7F, the overall polarity of the peptide is reduced compared with native 
Smp24 (figure 5.4 panels C and F). The polarity of K7F is particularly reduced 
around the N-terminus, which demonstrates a significant structural change from 
the substitution of a single amino acid. This could contribute to the lack of activity 
shown, if less surface charge is available to bind with the membrane the initial 
electrostatic interactions would be weaker and therefore may not lead to pore 
formation and the resultant antimicrobial activity. K7F has a reduced HM vector 
angle of 111.4° as shown in figure 5.5 (panel B). Decreases in surface charge 
have previously been associated with a decrease in antimicrobial activity (Bluhm 
et al. 2015), which is supported by the data from this study. Both Smp24 peptides 
with a reduced charge (K7S and K7F) demonstrated reduced antimicrobial 
activity compared with the parental strain. The results highlight the importance of 
the initial electrostatic interaction for the overall mechanism of action. 
 
As shown in figure 5.5, the polar angles of Smp24, S3K and K7F appear at 
different angles. The angle between the HM vector and the z-axis is 127.0° for 
Smp24 with a 12 degree increase in the polar angle resulting in the dramatic 
increase in antimicrobial activity of S3K.  Conversely, a 16 degree decrease in 
the polar angle resulted in a dramatic decrease in antimicrobial activity, as the 
K7F peptide demonstrated no detectable antimicrobial activity. The results 
highlight the importance of polar angle for membrane insertion and resultant pore 
formation which lead to the antimicrobial activity. 
 
The charge at the N-terminal of toroidal-pore forming peptides is thought to be 
critical for pore formation (Mihajlovic and Lazaridis 2012). Smp24 has previously 
been demonstrated to cause membrane disruption by toroidal pore formation 
(Harrison et al., 2016). When lysine 7 of melittin was replaced with glutamine or 
alanine, this resulted in the initial formation of a cylindrical pore but did not lead 
to full toroidal pore formation or membrane depletion when investigated using 
computer simulation experiments. The modification resulted in a change in the 
mechanism of action of the peptide and reduced the efficacy compared with 
native melittin. The results obtained for N-terminal modifications of Smp24 
provide functional data which support the hypothesis that charge at the N-terminal 
is important for the mechanism of action of peptides which operate via toroidal 
pore. The S3K modification demonstrated increased propensity for bacterial 
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activity, whereas the K7F modification demonstrated reduced activity. 
Additionally, the data from this study suggests the structure of the peptide could 
also be important for function. Whilst S3K has a greater N-terminal charge 
density, it shares a similar structure to native Smp24 (figure 5.2, panel D). K7F 
however demonstrated reduced charge density and therefore a lower propensity 
for electrostatic interactions with the anionic bacterial cell membranes. The 
increase in disordered structure of K7F (figure 5.1, panel D) could also contribute 
to the lack of activity seen, as the data suggests the peptide does not adopt a full 
alpha-helix and therefore is unable to insert in to bacterial membranes as 
efficiently as native Smp24.   
 
To investigate the effect of the N-terminal charge modifications on pore-
formation, future work would involve observing the effect of the peptides on 
synthetic phospholipid vesicles.  
 
The activity of the S3K/S15K modification could be attributed to the increased 
charge. Increasing the charge of antimicrobial peptides has been shown to be 
restrictive to antimicrobial peptides above a particular threshold due to 
electrostatic screening. The highly charged and hydrophilic peptides lose much 
of their effect at increased ionic strength (Schmidtchen et al. 2014). The 
protonation states of the positively charge amino acids (lysine, arginine and 
histidine) differs in the membrane environment (Li et al. 2017).  Theoretical 
calculations have also shown that lysine becomes deprotonated in the bilayer 
centre (Yoo and Cui 2008, Gleason et al. 2013), which could explain the 
restriction of antimicrobial activity observed by the double lysine substitution. The 
presence of salt causes deactivation of AMPs and reduces the initial electrostatic 
interactions required for pore formation and antimicrobial activity (Aoki and Ueda 
2013). This does highlight one of the limitations of AMPs in terms of therapeutics, 
however, although clearly AMPs are biologically effective, playing an important 







5.4.6 Relating structure and function: Smp43 S24K, Smp43 S43K and 
Smp43 W14A 
 
For Smp43, the effect of the modifications were less clear. In general, the S24K 
modification yielded the greatest increase in antimicrobial activity, with increased 
activity against P. aeruginosa, B. subtilis and S. aureus (section 3.4.3).  
Structurally, this modification led to an increase in charge density around the mid 
chain of the peptide, which can be seen in figure 5.6 along with a decreased 
hydrophobic moment (9.0 A*kT/e) compared with native Smp43 (9.8 A*kT/e). The 
modification also resulted in an alteration of the orientation of the C-terminus of 
the peptide (figure 5.6). The S43K modification resulted in an increase in the 
spread of the charge density across the peptide, as shown in figures figure 5.6 





Figure 5.6: Spatial diagrams for Smp43 (A), Smp43 S24K (B), Smp43 S43K (C) and Smp43 W14A (D). The rings highlight areas of the modified Smp43 








Figure 5.7: Polar facet representation in Smp43 and derived modifications. Smp43 (A), Smp43 S24K (B), Smp43 S43K (C) and Smp43 W14A (D). 
Regions of the modified peptides which demonstrate visible differences to the parental peptide are highlighted by the rings. 
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5.4.7 Smp43 S43K 
 
The S43K modification resulted in changes to both the N and C-terminus in terms 
of organisation and charge distribution and demonstrated a lower hydrophobic 
moment (6.8 A*kT/e) than native Smp43. The changes in polarity demonstrate 
the importance of an AMP electrostatic interaction to the prokaryotic membrane 
for the pore-forming mechanism of action. Increases in surface polarity have 
yielded peptides with enhanced antimicrobial activity. The results of increased 
charge yielding enhanced antimicrobial activity are in line with results obtained 
with the successful modification of mucroporin-M1 (Dai et al. 2008). Mucroporin-
M1 was modified to increase the charge compared with native mucroporin, Dai 
et al 2009, observed the increased charge resulted in greater increases to some 
strains tested (mostly Gram negative) and smaller fold-changes observed against 
Staphylococcus and Bacillus species, which was similar to the results found with 
this study. 
 
5.4.8 Smp43 W14A 
 
The W14A modification resulted in changes to the non-polar facets at both the N 
and C-termini (figure 5.6 and figure 5.7). The non-polar, hydrophobic components 
of peptides are thought to be important for the insertion of peptides in to the 
prokaryotic cell membrane after the initial electrostatic interaction has taken place 
(Hazam et al. 2019). The results of this study highlight a delicate balance between 
charge and hydrophobicity is required for optimum antimicrobial properties, as a 
slight increase in the hydrophobicity which resulted in small structural changes 
(W14A) yielded a peptide with enhanced antimicrobial activity. 
 
5.4.9 The role of charge and hydrophobicity on Smp43 function 
 
The hypothesis that a balance between hydrophobicity and charge is critical for 
antimicrobial activity is supported by the activity of the most hydrophobic peptide 
for the Smp43 modifications, the tryptophan knockout (W3A/W5A/W14A). The 
modification induced structural changes which can be visualised in figure 5.8. A 
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Hydrophobicity content of 50% has been stated as being desirable regarding the 
design of AMPs (Hazam et al. 2019), the W3A/W5A/W14A modification 
demonstrates 48.4% hydrophobic composition which is identical to the 
hydrophobicity content of native Smp43. With an MIC >512 µg/ml, this highlights 
the importance of investigating the parameters of individual AMPs to determine 
how each molecule can be optimised and a general approach to drug design may 






Figure 5.8: Spatial distribution of Smp43 (A and C) and Smp43 W3A/W5A/W14A (B and D). Polar facets are highlighted in blue and non-polar facets 




Interestingly, there are differences in the polar facets at the N terminal of the 
Smp43 W3A/W5A/W14A compared with native Smp43, indicating the spatial 
distribution of AMPs could also be critical for antimicrobial activity.  
 
Smp43 shares high sequence homology (75%) with Pandinin 1 (Pin 1), a 44-







Figure 5.9: Sequence homology between Smp43 and Pandinin 1. The glycine residues are at the N-terminus of the peptides and the serine and 





NMR experiments by Nomura et al., 2005 proposed Pin 1 operated by a 
detergent-like mechanism. This study suggested that Pin 1 sits within the 
interface between the hydrophobic core and the phospholipid head groups. The 
N-terminal helices of Pin 1 are tilted at a 30 degree angle relative to the lipid 
bilayer and C-terminal helices. The interactions between the tryptophan residues 
at positions 4, 6 and 15 on the tilted helix and the phospholipid head groups cause 
the membrane disruption. The knockout of the tryptophan residues at positions 
3, 5 and 14 of Smp43 resulted in a peptide with no detectable antimicrobial 
activity. This could suggest, due to the high sequence homology between the 
peptides, they both operate by a similar mechanism of action. This also implies, 
similar to Pin 1, the tryptophan residues have a crucial role in membrane 
disruption for Smp43. 
 
The effect of the individual tryptophan modifications on the bactericidal effect, in 
general resulted in either no change to the lethal activity of the peptide or resulted 
in a 2-fold reduction. The exception to this was the lytic activity of the peptides 
against E. coli, which possessed a greater propensity to cause cell death at lower 
concentrations. The activity of the single tryptophan modifications resulted in up 
to a 4-fold increase in bactericidal activity against E.coli with MBCs of 8 µg/ml. 
This could suggest mechanistic differences of activity between bacterial species, 
as despite these modifications resulting in increased antimicrobial activity against 
other isolates, the minimum bactericidal concentration was not reduced. The 
improvements in the bactericidal concentrations against E. coli is a promising 
result and could suggest AMPs can be tailored for more specific treatments of 
bacterial strains in a similar manner to antibiotics. An interesting future direction 
from this work would involve observing the pore forming abilities of the peptide to 
determine if the incorporation of the alanine residues results in increased pore 
formation or the formation of larger/deeper pores. The MIC and MBC results 
suggest the peptides are more efficient at pore formation against E. coli due to 
the 4-fold increase in lethality. Whilst the results observed may be surprising 
given the “neutral” nature of alanine, studies have previously reported the 
importance of alanine for the pore formation mechanism of action of peptides 




The MIC results suggest, for Smp43, the W3, W5 and W14 residues are important 
for the membrane activity of the peptide. In future work, a double mutation of W5 
and W14 to alanine residues would be performed in order to investigate this 
hypothesis. 
 
5.5 Structural investigations relating to eukaryotic toxicity 
 
5.5.1 Haemolysis of Smp24-derived modifications 
 
Structurally, no particular pattern was observed for haemolysis, with the 
modifications appearing to have a random effect. Contrasting information has 
been published on the effects of modifications on the haemolytic propensity of 
AMPs. Some studies have previously postulated that the interaction between 
AMPs and mammalian cell membranes is mostly the result of hydrophobic 
interactions (Mahlapuu et al. 2016a). Whilst other studies have suggested the 
effects of modifications can be random. Disruption in the hydrophobic face has 
yielded peptides with contrasting haemolysis profiles. The hydrophobic moment 
is a measure of the amphipathicity of an alpha-helix (Eisenberg et al. 1982). The 
modification of pep5 by increasing the hydrophobic moment from 0.58 to 0.74 
yielded a highly haemolytic variant (85% at 55 µM) compared with the parental 
peptide (8%). A smaller increase in the hydrophobic moment to 0.68 yielded a 
peptide with less haemolysis than the native peptide. Similar results were 
observed for the most and least haemolytic variants of Smp24. The most 
haemolytic modification to Smp24 was the S3K peptide, which has a hydrophobic 
moment vector angle of 139.0°. The least haemolytic modification was W2A, 
which has a hydrophobic moment angle of 139.0° compared with that of Smp24 






Figure 5.10: Structural  modifications of Smp24. Helical wheel projections of Smp24 (A), Smp24 S3K (B) and Smp24 W2A (C).   Structural changes as 








The similarities in the structure of the modified peptides could suggest the 
interaction between AMPs and erythrocyte membranes is more complicated than 
adjusting amino acids alone to improve parameters. The W2A modification 
demonstrates a slightly less pronounced helix upon 3D-modelling compared with 
native Smp24 (figure 5.10, panel F). As the ability of the peptides to adopt their 
helical structure is important for the mechanism of action (Jacobs and White 
1989, Shai 1999), the reduction in the helical content of the W2A modification 
could account for the observed decrease in haemolytic activity. The results 
suggest the effects of modifications on the activity of peptides could be relative 
to the effect on peptide structure in addition to changes in the hydrophobicity 
profile. In the future, CD spectroscopy could be utilised to determine the structure 
of the peptide under the presence of TFE titration (as per chapter 3, section 3.6.2) 
and this could be compared with the data for native Smp24. This would enable 
the visualisation of structural modifications on the helical propensity of the W2A 
modification.  
 
5.5.2 Haemolysis of Smp43-derived modifications 
 
As shown in figure 5.11, the D4F modification of Smp43 resulted in increased 
hydrophobicity of the peptide. The inclusion of the phenylalanine towards the N-
terminal of the peptide increased the hydrophobicity of the first helical region of 
the peptide. As hydrophobicity has been implicated with the penetration of 
mammalian cell membranes (Dennison and Phoenix 2014), this could explain the 
increase in haemolysis observed by this modification. The D4F modification also 
demonstrates an increase in charge; the relationship between charge and 
hydrophobicity has been shown to be an important factor for antimicrobial activity 
and haemolytic activity of peptide mimetics (Takahashi et al. 2017). The results 
of this study are in agreement, as the alterations to the physicochemical 
properties of D4F yielded a peptide with similar antimicrobial activity to native 






Figure 5.11: Structural modifications to Smp43. Helical wheel projections for Smp43 (A), 
Smp43 D4F (B). Structural changes as observed in the 3D structure of Smp43 (C) and 
Smp43 D4F (D). 
 
5.5.2.1 Cytotoxicity of Smp24-derived modifications 
 
Structurally, the incorporation of phenylalanine induced different changes. The 
D23F modification improved the amphipathicity of the peptide by incorporating a 
hydrophobic residue in place of a negatively charged residue, as shown in figure 
5.12 (panel D). The K7F modification (figure 5.12, panel C) introduced a 
hydrophobic modification in to the charged side of the peptide, disrupting the 
amphipathicity and in turn reducing activity against the HepG2 cell line compared 








Figure 5.12: Helical wheel projections of Smp24 (A), Smp24 S3F (B), Smp24 K7F (C) 
and Smp24 D23F (D). The substituted residues are highlighted by rings. 
 
5.5.3 Cytotoxicity of Smp43 
 
All of the modifications to Smp43, except the W3A modification, resulted in 
increased cytotoxicity against the HepG2 cell line. The most cytotoxic Smp43 
peptides within the study were S24K and S43K, both of which contain increased 
charge within the second helix of the peptide and increased clustering of charged 
residues within the helix, as shown in figure 5.13 (panels B and C). Against the 
HEK-293 cell line, all of the modifications except the W3A modification resulted 





Figure 5.13: Helical wheel projections of Smp43 (A), Smp43 S24K (B), Smp43 S43K (C) 
and Smp43 W3A (D). The substituted residues are highlighted by rings. 
 
As shown in figure 5.13, the W3A modification resulted in increased hydrophilicity 
of the helix. The reduced hydrophobic cluster of the peptide could be responsible 
for the reduced cytotoxicity observed by this modification. Tryptophan residues 
have previously been observed to be important for pore formation (Travkova et 
al. 2017), the results of this study suggest the selective substitution of tryptophan 







5.6 Therapeutic indices 
 
The therapeutic indices of the AMPs were calculated in order to assess any 
improvements or reductions to the peptides (chapter 2, section 2.7.5). 
Therapeutic indices were calculated by dividing the LD50 or HC50 by the 
calculated MIC against E. coli. 
 
5.6.1 Therapeutic indices of modified Smp24 peptides 
 
The results of the calculated therapeutic index (TI) calculations for Smp24 and 
derived modifications (figure 5.14). 
 
 
Figure 5.14: The calculated TI’s of modified Smp24 peptides against HepG2 (A), HEK-
293 (B), HaCaT (C) and sheep erythrocytes (D). Statistical significance was determined 
by performing a T-test on the data. Improvements to the TI are highlighted by the 
presence of black stars and reductions to the TI are highlighted by the presence of red 
stars .* p-value £0.05, ** p-value £0.01, *** p-value £0.001 and **** p-value £0.0001.  
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For the determination of the TI for peptides with a calculated LD50 above 512 
μg/ml, 512 was used as the LD50 value. As shown in figure 5.14, improvements 
have been made to the TI of the modified peptides. The TI of the S3K and S15K 
modifications were significantly improved against all of the cell lines tested, with 
S3K demonstrating the greatest increase in TI. Similar results were observed for 
the S24K modification, which demonstrated significant improvements against all 
tested cell lines, excluding red blood cells which resulted in a non-significant 
decrease in the TI. The D23F modification resulted in a significant increase in TI 
when measured against HaCaT and HepG2 cell lines. 
 
Conversely, significant decreases to the TI were also observed. The K7F 
modification demonstrated a reduced TI against all cell lines tested, though this 
was only deemed significant against HEK-293 and red blood cells. The K7S 
modification demonstrated significant reductions to the TI against all of the 
isolates tested. 
 
The S3K, D23F and S24K modifications would be interesting candidates for 
further investigations as these modifications demonstrated enhanced therapeutic 
profiles compared with native Smp24. 
 
5.6.2 Therapeutic indices of modified Smp43 peptides 
 
The results for the TI calculations for Smp43 and the derived structural 




Figure 5.15: The calculated TI’s of modified Smp43 peptides against HepG2 (A), HEK-
293 (B), HaCaT (C) and sheep erythrocytes (D). Statistical significance was determined 
by performing a T-test on the data. Improvements to the TI are highlighted by the 
presence of black stars and reductions to the TI are highlighted by the presence of red 
stars. * p-value £0.05, ** p-value £0.01, *** p-value £0.001 and **** p-value £0.0001. 
 
The structural modifications to Smp43 produced interesting results, with some of 
the peptides demonstrating increased TI against all cell lines tested. The W14A 
modification demonstrated a significantly increased TI against all cell lines tested. 
The W3A and W5A modifications also demonstrated increased TI against all cell 
lines tested, although statistical significance was only observed for three out of 
the four cell types for each peptide. 
 
Reductions in the TI for the modified peptides were also observed, although no 
distinctive pattern was present. All of the structural modifications which increased 
the charge of Smp43 resulted in a decreased TI against HepG2 cells. The D4F 
modification reduced the TI of Smp43 against erythrocytes, whilst all the other 
peptide modifications resulted in an increase or a non-significant change in the 




The W3A, W5A and W14A modifications would be interesting candidate peptides 
for further development as all of these peptides demonstrated increased TIs 
compared with native Smp43.  
 
5.6.3 Therapeutic indices of peptides against urothelial cells 
 
As differences in cytotoxicity were noted on the basis of membrane charge 
(section 4.4.4.3), the TI's of both parental peptides were calculated against the 
human uroepithelial cell line. As previously, the LD50 was calculated for both 
peptides using the upper limit value of 512, as the LD50 was calculated to be 




Figure 5.16: Calculated TIs for Smp24 and Smp43 against human uroepithelial cells 
(HUEPC).  
 
When compared with the LD50 concentrations obtained for Smp24 against the 
other cell lines, the TI calculated against the uroepithelial cell lines was much 
higher. For Smp43, the TI against the uroepithelial was higher than that observed 




5.6.3.1 Therapeutic indices of lipopeptide antibiotics 
 
The TI's of the lipopeptide antibiotics used within this study were also calculated. 
As daptomycin is only commercially licensed for the treatment of Gram positive 
organisms and demonstrated no activity against the Gram negative isolates 
within this study, the TI was determined against S. aureus. The TI of PMB was 





Figure 5.17: Calculated TI’s of daptomycin (A) and PMB (B) against liver, kidney, skin 
and red blood cells.  
 
As shown in figure 5.17 the calculated TI’s of the two commercially available 
AMP-like drugs are very high. The drugs demonstrate high antimicrobial activity 
and a low level of cytotoxicity, which produces a highly desirable drug profile. 
 
When comparing the TI of the modified Smp peptides to those obtained by the 
AMP-like drugs, the TI’s are considerably lower. The lipopeptide antibiotics 
demonstrate TI’s between 128 and 256, with PMB possessing the highest TI of 
the two lipopeptide antibiotics within this study. The activity of the W14A modified 
peptide produced a TI of 128 against erythrocytes, which is comparable to the 
calculated TI of 128 for daptomycin within this study. The highest TI observed 





As cytotoxicity is an important factor for the calculation of the therapeutic index, 
the TI varies greatly dependent upon the cell line used (figure 5.18). Greater TIs 
were observed for both peptides against HUEPC cells compared with the skin, 





Figure 5.18: Observable differences in TI for Smp24 (A) and Smp43 (B) against all cell 
lines used in this study. 
 
The TI of the AMPs varies greatly between the cell lines used with the urothelial 
cells producing the highest TI for both Smp24 and Smp43. This highlights the 
importance of a cytotoxicity screen encompassing numerous cell lines when pre-






In summary, two modification strategies have been employed within this study; 
one was investigating the effect of charge on function and the other investigating 
the role of hydrophobicity. AMPs have been developed with enhanced 
antimicrobial activity compared with the native peptides. Currently, the peptides 
are rather large (Smp24: 2578 Da and Smp43: 4654 Da) when compared with 
the size of small molecule compounds such as penicillin (334 g/mol), gentamicin 
(477 g/mol) and also against the lipopeptide antibiotics daptomycin (1620 Da), 
polymyxin B (1301 Da). Truncation of the peptides could enable the active moiety 
of the peptide to be determined. If the peptides can be successfully truncated, 
this would reduce production costs by solid phase synthesis and potentially 
create a drug with greater therapeutic potential. 
 
The modifications to Smp24 generally increased the haemolytic activity of the 
peptides. The only exceptions to this are the W2A, F4A and K7F modifications 
which had significantly improved HC50 concentrations. Despite the observed 
increased haemolysis, peptides with enhanced therapeutic indices have been 
produced. The S3K, F4A, D23F and S24K modifications produced enhanced TIs 
against all cell types tested and would be interesting candidates for further 
investigation. 
 
The modifications to Smp43 resulted in increased cytotoxicity towards HepG2 
cells and HEK-293 cells, with the exception of W3A. Three of the peptides within 
the study (D4F, S16K and S24K) demonstrated reduced cytotoxicity towards the 
HaCaT cell line and all of the peptides except D4F demonstrated a low level of 
haemolysis. Three peptides produced enhanced TIs against all cell lines tested, 
which are the W3A, W5A and W14A substitutions. 
 
The incorporation of unnatural amino acids in to more potent AMPs, would be an 
interesting strategy to adopt to determine if peptides with a reduced susceptibility 
to proteolytic degradation could retain the antimicrobial profile of their naturally 
occurring counterparts (Kang et al. 2017b). Whilst resistance to AMPs is not 
expected, it is important to take precautionary measures to avoid facing the same 
issues faced with antibiotic development. The ability of bacteria to develop 
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resistance to AMPs was not within the scope of the study but would be an 
interesting future direction. Resistance to the peptides could be assayed by 
multiple passages of the peptides at sub-inhibitory concentrations in liquid culture 
and observing the effect serial passaging has on the MIC of the bacteria (Perron 
et al. 2006). 
 
Cytotoxicity screening was limited due to the cost of peptide synthesis, which 
produces small quantities of peptides at high cost. The peptide synthesis also 
restricts the number of modifications that can be performed, due to the cost 
implication. The next stage of the project would be to develop a method for 
recombinant production of the AMPs to remove the cost and quantity factors that 
limit the project currently.  
 
The "in-house" production of AMPs would enable larger quantities of the peptides 
to be produced, which would in turn enable a more comprehensive antimicrobial 
and cytotoxicity screen to take place. Additionally, the peptides could be mutated 
via recombinant techniques, such as site-directed mutagenesis, to produce a 
library of mutants. This would enable more residues within the AMPs to be 
substituted to more thoroughly investigate the relationship between structure and 
function. The development of an expression system would also be of interest from 
a pharmaceutical point of view, as the scaling up of the process would enable 
large quantities of the peptide to be produced at a low cost and thus optimising 







Optimisation of the recombinant production of 






Antimicrobial peptides have previously been produced using chemical synthesis, 
with solid-phase synthesis often being the method of choice (Münzker et al. 
2017).  This methodology is capable of producing peptides with high purity 
(Wanmakok et al. 2018) however, the production of peptides in large quantities 
is limited due to the high overall cost (Hancock 1997). Investigations to produce 
bioactive peptides under optimised conditions at a reduced cost and decreased 
time scale is ongoing (Agyei and Danquah 2011) and recombinant methodologies 
are becoming of increasing interest.  
 
Protein production by recombinant DNA technology is much less expensive and 
has been used previously to successfully produce antimicrobial peptides (AMPs) 
(Yang et al. 2016, Wanmakok et al. 2018).  E. coli is often used as the vector of 
choice due to the ease of genetic manipulation, relatively low cost and rapid 
growth rate (Tanhaiean et al. 2018b). Recombinant expression does however 
face its own challenges; these include proteolytic degradation by microbial cells, 
the protein being expressed in to inclusion bodies or cellular toxicity of the 
recombinant peptide on the producer cells (Ashcheulova et al. 2018). If these 
issues can be overcome, a recombinant protein production system can be used 
to produce large quantities of AMPs at relatively low costs. 
 
Smp24 has previously been described in chapters 3 and 4. It demonstrates broad 
spectrum antimicrobial activity, making it an interesting drug development 
prospect. Whilst Smp43 demonstrates lower mammalian cytotoxicity than 
Smp24, the large size of Smp43 is a restrictive factor in terms of drug 
development. Due to this, the strategy to develop an “in-house” recombinant 
expression system has initially been limited to Smp24. 
 
One of the major limiting factors when working with the synthetically produced 
peptides has been the quantity available for assay, which ranged between 10 and 
15 mg for the purpose of this study. The development of a recombinant protein 
expression system would enable larger quantities of Smp24 to be produced, 
which would enable a more extensive investigation in to the antimicrobial activity 




6.2  Study aims  
 
The main aim of this chapter was to develop a recombinant expression system 
for the over production of Smp24 to determine whether peptides produced in this 
recombinant system would retain their native activity. 
 
The second aim of this chapter was to produce a library of mutant peptides using 
site-directed mutagenesis, initially based upon the results from chapter 3 (section 
3.4.2.2) to inform the relationship between structure and function. 
 
6.3 Experimental design 
 
6.3.1 Recombinant expression of antimicrobial peptides in E. coli 
 
Following the successful production of recombinant neurotoxins in an E. coli 
expression system (Lyukmanova et al., 2007), a similar strategy was adopted to 
express the previously described scorpion venom-derived peptide, Smp24. 
Smp24 is 24 amino acids in length with a molecular mass of 2.578 kDa and 
belongs to the short-chain family of scorpion AMPs (Abdel-Rahman et al. 2013).  
 
The expression system described by Lyukmanova et al, for the recombinant 
production of neurotoxin II (NTII) in E. coli is shown in figure 6.1. The expression 
system was developed in the expression vector pET22b. pET22b vectors are T7 
promoter vectors, which enable high-level  protein expression. The system is 
ideal for expressing soluble, non-toxic proteins in due to the low production cost 
and ease of use.  
 
In the Lyukmanova et al., (2007) study, the signal peptide from heat-stable E. coli 
enterotoxin (STII) was fused to the N-terminal of a gene encoding the peptide 
sequence for neurotoxin II (NTII). Upon protein expression, a special signal-
recognising particle (SRP) binds to the signal peptide in the bacterial cytoplasm, 
which is then transferred to the inner membrane. Situated at the inner bacterial 
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cell membrane is a membrane translocation complex. The primary protein 
constituents of the bacterial complex are Ffh (an SRP54-like protein of 
eukaryotes) and FtsY (an SRP receptor [subunit]-like protein of eukaryotes) 
which  is thought to use ATP to carry the protein to the SecYEG complex in the 
periplasmic space with the signal peptide acting as a membrane anchor (Saier 
2006). The signal peptide is then cleaved at the external side of the internal 
membrane, thereby leaving the innate N-terminal of the protein of interest. The 
protein, or in this case neurotoxin, can then accumulate in the periplasmic space 





Figure 6.1: Vector design for the expression of neurotoxins in E. coli.  The synthetic genes for neurotoxins were attached to the signal peptide of E. coli 
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Signal peptide II (STII) 
Neurotoxin II (NTII) 
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The gene insert for the signal peptide coded for expression of the neurotoxin 
shown in table 6.1. 
 
Table 6.1: The amino acid sequence for the signal peptide (STII) and neurotoxin II 
sequence (NTII) is shown in black. 
 
Construct Amino Acid sequence 
STII/NTII MKKNIAFLLASMFVFSIATNAYALECHNQQSSQPPTTKTCSGETNCYKK
WWSDHRGTIIERGCGCPKVKPGVNLNCCRTDRCNN 
The amino acid sequence for STII is shown in blue and the NTII sequence is shown in 
black. A 252 bp insert was spliced in to the pET22b(+) vector (Novagen) between the 
NdeI and HindIII restriction sites. 
 
The system used by Lyukmanova et al, (2007) expressed neurotoxins in minimal 
media (M9) to produce toxins for downstream experiments with nuclear magnetic 
resonance (NMR) and electrophysiology. This process yielded 1 - 20 mg 
quantities of neurotoxins per litre of culture media, which varied depending on the 
presence of disulphide bonds in the neurotoxins. Neurotoxins with more 
disulphide bonds typically produced smaller quantities of peptides in the 
recombinant system. This strategy was to be adopted for the expression of 
antimicrobial peptides in E. coli due to the previous success observed. 
 
6.3.2 Experimental design for the overproduction of Smp24 protein 
 
The strategy adopted for the recombinant expression of Smp24 genes and 
overproduction of the protein is shown in figure 6.2. 
 
Briefly, a vector for the expression of an Smp24 gene to produce Smp24 protein 
was designed, transformed in to an expression vector and induced for protein 
overproduction. The recombinant protein was purified and the presence of the 
protein validated via numerous techniques, including traditional gel 
electrophoresis and matrix-assisted laser-desorption ionisation mass 












Figure 6.2: Strategy for the production of recombinant Smp24 in a prokaryotic 
expression system.  
Vector design





















6.3.3 Vector design for the expression of Smp24 
 
To enable the overproduction of Smp24, the Lyukmanova et al, protein 
expression system was modified. The genetic sequence for a gene encoding 
Smp24 conjugated with the STII insert was calculated using E. coli codon usage 
tables which yielded the highest frequency of successful incorporation.  The 
sequence for the insertion of the Smp24 gene is shown in figure 6.3. Start and 
stop codons were included on each respective end of the gene fragment to allow 
the expression of the gene of interest. The genes were incorporated in to the 
vector by the Standard Genes gene synthesis program offered by Eurofins 
(Ebersberg, Germany). The pET22b vector was purchased from Novagen 





Figure 6.3: pET22b(+) vector map and the corresponding codon usage sequences for STII and Smp24 for insertion of the gene between the HindIII 
and NdeI restriction sites. The insert between the two restriction sites was 144 bp in length, coding for the expression of Smp24 and the signal peptide. 
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6.3.4 Transformation & Confirmation of transformation 
 
To produce Smp24 in E. coli BL21 λDE3, the pET22b/STII/Smp24 vector was 
transformed into the expression strain by electroporation (section 2.10.1). To 
confirm successful transformation, plasmids were extracted and the T7 cloning 
region amplified by PCR and the PCR product was visualised on a 1% agarose 
gel with 0.01% ethidium bromide. The PCR product was expected to be 409 base 




Figure 6.4: Visualisation of the PCR product from the extraction of pET22b/STII/Smp24 
from E. coli BL21 λDE3. Primers which flanked the T7 expression region were used. Well 
(1) 1 kb Hyperladder (Bioline, London, UK), (2) no DNA control and (3) STII/Smp24 
insert. 
 
6.3.5 Recombinant production of Smp24 protein 
 
E. coli BL21 λDE3 pLysS strain was chosen for the expression vector as E. coli 
BL21 strains are widely used for the expression of target proteins encoded by 
pET vectors. This strain is deficient in Ion and ompT proteases, which is 
advantageous for protein expression due to reducing the likelihood of 
degradation of the recombinant peptide. DE3 indicates that the host is a lysogen 
of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase 
gene under control of the lacUV5 promoter. This enables the production of protein 
from target genes cloned in to pET vectors via induction with IPTG. The pLysS 
strains express T7 lysozyme, which suppresses basal expression of T7 RNA 
polymerase prior to induction, which stabilises pET recombinants encoding target 
proteins that affect growth and viability. 
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To overproduce the Smp24 protein, an overnight culture of E. coli containing the 
pET22b/STII/Smp24 vector was prepared in LB broth with ampicillin and protein 
production was induced by the addition of IPTG (section 2.12). Due to the 
presence of the STII leader sequence, it was anticipated the Smp24 protein would 
be transported out of the cell and in to the culture media. 
 
6.3.6 Validation of protein overproduction 
 
Following the overproduction of Smp24, the recombinant protein was separated 
from the bacterial culture (section 2.12). The results of the protein overproduction 
were initially visualised on a 10% standard sodium dodecyl-sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel and stained with Coomassie 
















Figure 6.5: SDS-PAGE gel of the overproduction of Smp24 in E. coli. (1) Dual Xtra 
Precision Plus standard (Bio-Rad), (2) pellet before IPTG induction, (3) pellet following 
IPTG induction, (4) pellet from second centrifugation, (5 to 8) culture media supernatant. 
The arrow represents the expected size of the recombinant protein (2.5 kDa). 
 
As shown in figure 6.5, it was not possible to identify the recombinant Smp24 
protein in the culture media. The resolution of the gel in the low molecular range 
prevented the successful identification of the Smp24 protein (2.5 kDa). Due to the 
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protein being eluted in to the supernatant, it was anticipated the concentration of 
the produced protein would be low which would further inhibit the visualisation of 
the protein. Due to the low cost of purification by column chromatography, it was 
decided to continue with the purification process. 
 
6.3.7 Protein purification  
 
The next stage of the process was to purify recombinant Smp24. Due to the highly 
charged nature of Smp24 (+3), it was expected that the peptide would strongly 
bind to the column and any impurities would bind to the column more weakly and 
thus elute first. The culture media supernatant was diluted 2-fold with Milli-Q 
deionised water and applied by peristaltic pump to a Sepharose Fast Flow Resin 
column (GE Healthcare, Buckinghamshire, UK) for cation exchange. The protein 
was eluted against a sodium chloride (NaCl) gradient from 0 - 1 M NaCl at 4°C 
using the AKTA Design system (GE Healthcare, Buckinghamshire, UK). Protein 










Figure 6.6: Purification of Smp24 - A280 trace for the purification of overproduced protein. Each peak represents the elution of peptide bound to the 
column. The fraction containing the asterisk denotes the fraction expected to contain Smp24, due to the highly charged nature of the peptide. 
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The peaks on the A280 AKTA trace indicate the presence of protein, specifically 
proteins with a cationic charge due to the cation exchange column used for 
purification. The more positively charged peptides bind more strongly to the 
column and thus require a greater salt concentration for elution. The sample 
suspected to contain Smp24 was strongly bound to the cation exchange column 
and required a 1 M NaCl concentration to elute from the column after 400 
minutes.  
 
All samples from the purification process were collected for further analysis, to 
confirm the identity of the protein from all of the fractions. 
 
Whilst the above trace was cause for optimism due to the presence of large 
protein peaks, the results were not reproducible. The protein expression process 
was repeated from transformation of the plasmid in to the expression vector and 
the induction of protein production under the same conditions. Despite conditions 
remaining identical, difficulties were experienced producing replicable results for 
the recombinant expression and purification of Smp24 in E. coli. The trace 
depicting the elution of samples from the column was not reproducible and a peak 
at the retention time of 400 minutes was not observed in subsequent purification 
attempts.  
 




Validating the presence of the peptide in the AKTA fraction proved to be 
challenging. The peptide was impossible to visualise on an SDS-PAGE gel, due 
to the small size (2.5 kDa). The concentration of acrylamide within the SDS gel 
was optimised by increasing the acrylamide concentration up to 20% in the 
separation gel yet the resolution of the gel in the small molecular weight range 





6.3.8.2 TRIS-tricine PAGE 
 
Following unsuccessful identification of the peptide by SDS-PAGE, the next 
approach to visualising the peptide was TRIS-tricine gels. Tricine gels offer much 
higher resolution for peptides with a molecular weight below 10 kDa. The 
increased resolution is achieved by slowing the migration rate of peptide-SDS 
complexes which helps separate smaller peptides from faster moving SDS-
micelles which interfere with the resolution at the smaller molecular weight range. 
A series of TRIS-tricine gels were produced to identify the peptide of interest.  
 
Gels within the range of 10-20% were analysed but the resolution remained poor 
at the low molecular weight range. It was theorised the highly charged nature of 
the peptide could also contribute to the challenges of visualisation on the gel. The 
positive charge of the peptides could prevent the peptides from entering the gel, 
as they could move towards the negative electrode prior to electrophoresis. 
Peptides with increased hydrophilicity can also demonstrate a decreased 
propensity to enter the gel. The anticipated low concentration of the peptide could 
have also inhibited the ability to detect the peptide. Alternatively, it was also 
possible the peptide was not always present in the culture and therefore not 
possible to detect. To improve the limit of detection, a mass spectrometry 
approach was taken to identify the peptides.   
 
6.3.8.3 Matrix assisted laser desorption/ionisation time of flight mass 
spectrometry (MALDI-TOF MS) 
 
MALDI-TOF MS was used to identify the eluted peptides, as shown in figure 6.7. 
The protein samples from AKTA purification were co-crystallised with α-cyano-4-
hydroxycinnamic-acid (CHCA) matrix on a target plate. The plate was analysed 








Figure 6.7: MALDI-MS spectral identification of Smp24. (A) MALDI-MS spectra from the 
analysis of the labelled peak from the AKTA trace from figure 6.6. (B) MALDI-MS spectra 







The mass of the protein fraction determined by MALDI-TOF MS (2579 Da) was 
consistent with that expected of Smp24 (2578 Da). Up to 2 Dalton differences 
have previously been observed between the natural and synthetic peptides within 
the literature (Kim, Kang, et al. 2018). Mass differences were observed within this 
study as the synthetically synthesised Smp24 demonstrating a mass of 2580 
Daltons. The mass difference between synthetic and recombinant protein could 
be attributed to post-translational modifications, such as amidation, 
phosphorylation, hydroxylation or methylation (Grangeasse et al. 2015) which 
would result in a minor increase in the molecular mass of the peptide. 
Identification of a peptide of the expected size was sufficient confirmation to 
proceed with additional purification steps in this instance.  
 
6.3.8.4 Detection of Smp24 in the presence of salt 
 
As previously discussed, issues with the reproducibility of the AKTA traces were 
faced and peptides with a mass similar to that of Smp24 were not identified in 
subsequent purification attempts. Whilst initially the presence of salt had not 
inhibited the detection of protein, the presence of salt can influence the ionic 
nature of charged peptides. Two additional experiments were carried out. 
Synthetic Smp24, synthesised by solid phase synthesis was used as a mass 
control for the instrumentation. The peptide flew down the MALDI and presented 
at the mass range expected. The sample was then dissolved in 500mM NaCl to 






Figure 6.8: MALDI MS analysis of Smp24. Synthetic Smp24 (A) shows a peak at the 
mass range expected (2.5 kDa) but in the presence of 50 mM NaCl (B) the peptide can 
no longer be detected. 
 
As shown in figure 6.8, the presence of salt inhibited the detection of synthetic 
Smp24 via MALDI MS, with no peak present in the mass range expected. As a 
result, the purified samples were de-salted via Zip-Tips and analysed via MALDI-
MS. It was still not possible to detect peptides in the mass range expected for 





faced was related to detection or if there was an issue with the protein over-
production and the peptide was not present at all. 
 
6.3.9 Additional protein purification 
 
The sample from figure 6.8 (from the AKTA purification peak containing a protein 
of the expected mass range) was de-salted by membrane dialysis, lyophilised 
and re-suspended for further purification to remove any additional impurities. The 
sample was purified using a second cation exchange column, a MonoS HR5/5 
column (GE Healthcare, Massachusetts, USA) equilibrated with 10 mM 





Figure 6.9: AKTA A280 trace for additional purification of Smp24. The column was 
equilibrated with sodium acetate buffer and the sample applied under the same 
conditions. 
 
As shown in figure 6.9, the attempt to additionally purify Smp24 was 
unsuccessful. Despite the column being washed with 5 column volumes of buffer 
and equilibrated to the conditions required for protein binding, the sample did not 
bind to the column. The sample was also diluted in the same sodium acetate 
182 
 
buffer to further encourage binding to the column. Unfortunately, the sample not 
binding to the column resulted in the sample flowing straight through the column 
and in to the waste, preventing further analysis from being performed on this 
sample.  
 
As difficulties were being faced with the detection of produced protein from the 
purification fractions, an immunological approach was taken.  
 
6.3.10 Immunological detection of Smp24 
 
Polyclonal antibodies against Smp24 were raised in rabbits following a SuperFast 
28 day immunisation schedule by David's Biotechnologie (Regensburg, 
Germany). The 28-day protocol yields antibodies with titres comparable to 
standard 63 or 90 day procedures.  
 
The sensitivity of the antibody was determined by performing dot blots with a 
titration of 0-10 mg/ml concentration of synthetically synthesised peptide 
standards (David’s Biotechnologie). It was determined the antibodies detected 
the presence of Smp24 to a concentration of 31 μg/ml dissolved in water. When 
the peptide was dissolved in broth, that the detection limit was reduced to 125 








Figure 6.10: Optimisation of antibody detection using dot blot for the detection of Smp24. 
Synthetic peptide dissolved in H2O is shown in A and synthetic peptide dissolved in M9 
broth is shown in B. (1) BSA control. (2) Smp24 (10 mg/ml).  Rows 3 - 10 - dilutions of 
peptides. (3) 1 mg/ml, (4) 500 μg/ml, (5) 250 μg/ml, (6) 125 μg/ml, (7) 62.5 μg/ml, (8) 
31.75 μg/ml, (9) 16.125 μg/ml, (10) 8.09 μg/ml (11) Negative binding control (water or 
M9 broth). The limit of detection is highlighted by the box. 
 
Following the induction of protein expression and the separation of the cell pellet 
and supernatant by centrifugation, the pellet and supernatant was analysed by 
dot blot (figure 6.11). Despite the binding affinity of the antibodies being validated 
from former assays, it was not possible to detect Smp24 from the overproduction 
samples. The protein over production system remained blind and it was not 
known if the peptide was being expressed or if the limit of detection for the 
expressed peptides was not low enough to detect the expressed proteins within 






Figure 6.11: Immunological detection of expressed proteins in E. coli. A - BSA, B - 10 
mg/ml synthetic Smp24, (1) and (2) pellets from the overproduction of Smp24 and (3) 
supernatant from the overproduction of Smp24.  
 
6.3.11 Alternative approach for protein detection 
 
Whilst the G. mellonella model is a marker of pathogenicity, for the purpose of 
this investigation it was used as method validation to determine if recombinant 
protein was being produced. It was hypothesised that G. mellonella (wax worms) 
injected with induction culture would demonstrate increased survival due to 
antimicrobial activity of the recombinant peptide against E. coli. Previous 
experimental data has shown induction with IPTG resulted in reduced growth rate 
(please refer to appendix 1). Samples for this assay were as follows: E. coli BL21 
λDE3 transformed with the vector pET22b/STII/Smp24, E. coli BL21 λDE3 
transformed with the vector and induced for protein expression with 0.05 mM 
IPTG an un-transformed E. coli BL21 λDE3 was used as a negative control. 
 
The pathogenicity model was adapted from Peleg et al and Henly et al (Peleg et 
al. 2009, Henly et al. 2019).  The number of surviving individuals was recorded 
daily. An untreated (non-injected (NI)) group and a group injected with PBS were 
used as negative controls.  
 





Figure 6.12: Galleria mellonella pathogenicity results. BL21 depicts G. mellonella 
injected with laboratory strain E. coli BL21 λDE3 with no vector. E. coli BL21 λDE3 
transformed with the vector pET22b/STII/Smp24 is shown by the purple line. E. coli BL21 
λDE3 transformed with pET22b/STII/Smp24 and induced for protein expression is shown 
by the green line. * p-value <0.05 as determined by log-rank reduction test. ** BL21 vs 
Smp24, * 24 vs 24+ 
 
A log-rank reduction test was performed on the data to determine the statistical 
significance (section 2.17 for methodology). Statistical difference is shown 
between the untransformed strain vs the strain transformed with the vector, with 
a p-value of 0.008. This demonstrates the presence of the expression vector in 
the expression strain reduced the pathogenicity overall, which could imply leaky 
expression of the Smp24 protein is taking place. Whilst the results could be 
deemed indicative of protein overproduction, the presence of the plasmid could 
affect the growth rate or copy number of the bacteria which in turn could have 
affected the pathogenicity. 
 
Statistical significance can also be observed between the transformed strain and 
the induced strain, with a p-value of 0.015. The observed decrease in 
pathogenicity for the strain induced for protein production vs the transformed 
strain alone could imply that there is expression of the antimicrobial peptide. As 
Smp24 is an antimicrobial peptide, the production of the protein could lead to the 
AMP interacting with the bacteria to decrease membrane integrity. This could 
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result in a lower viable count within the bacteria and thus the observable 
differences in survival of the larvae between the induced and transformed strains. 
The overall pathogenicity of the induced strain was equal to that of the non-
injected control, which suggests the combination of antimicrobial peptide with 
bacterial isolate results in lower pathogenesis than injection with bacteria alone.  
E. coli BL21 is a laboratory strain of E. coli commonly used for recombinant 
protein production (Jeong et al. 2015). E. coli BL21 demonstrates a low level of 
pathogenicity and is not capable of producing long-chain lipopolysaccharide 
(LPS) which makes the bacteria vulnerable to degradation (Chart et al. 2000) or 
potential lysis by antimicrobial peptides. Previous investigations in to the 
induction of cultures with IPTG resulted in reduced survival of bacteria with 
increased gene induction (experimental data not shown).  
 
6.4 Limitations of the signal peptide expression system 
 
The protein overproduction system was challenging for a number of reasons. The 
small size of the peptide combined with the highly charged nature of the peptide 
and a low overall concentration made the identification of the protein difficult and 
thus the process blind. The presence of peaks in the AKTA spectra confirmed the 
presence of protein despite some of the difficulties faced with detection. It would 
have been preferable to use the NTII system as a proof of concept prior to the 
production of antimicrobial peptides within bacteria in order to predict any issues 
that have since been faced, but due to genetic modification restrictions placed on 
this project, this was not possible. 
 
The concentration of IPTG for induction of protein production by the bacteria was 
determined via growth curve analysis. For M9 media, the optimum concentration 
appeared to be 0.05 mM as this enabled the cells to progress through log phase 
steadily prior to stationary and death phase where minimal protein production is 
observed. 
 
The small molecular mass of Smp24 combined with the positive charge of the 
peptide has caused detection issues. Despite numerous attempts at optimising 
gels for detection, it was not possible to detect the protein via gel electrophoresis. 
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The presence of salt inhibited the detection of the protein by MALDI-MS and the 
anti-Smp24 antibodies raised in rabbits did not exhibit a detection range sensitive 
enough for the detection of recombinant Smp24 in this expression system. The 
results from the G. mellonella investigation provided some evidence the protein 
was being produced; however, many challenges have been faced with this 
expression system. Whilst it is possible the issue faced is with detection, it is also 
possible that the protein is not being produced or the transportation system of the 
signal peptide is not functioning as anticipated.  
 
Numerous observations within the investigation implied the protein was being 
expressed by the gene and overproduced in the bacteria. The E. coli growth was 
observed to be slower when IPTG was added to the culture media, implying more 
energy was spent overproducing the gene and thus less energy was available for 
growth and division. After induction, a decrease in pathogenicity was observed in 
the G. mellonella model, suggesting protein production was occurring and the 
viability of the injected bacteria was reduced. Peaks were present at 280 nm on 
the UV spectra from AKTA analysis, indicating the presence of protein. 
Additionally, a protein of the correct mass was initially identified by MALDI-MS 
from the first attempt of expression and purification. This suggested the protein 
was being produced but at a concentration below the limit of detection of the 
methodologies used. 
 
As there was confidence in the production of the protein, a new detection method 
was adopted. A new strategy was designed to enable a recombinant production 
system for the expression of Smp24 in E. coli BL21 λDE3. This included the 
tagging of the peptide with a FLAG-tag to enable identification via anti-FLAG 
antibodies which offer a low limit of detection whilst retaining the ability to purify 
the protein using on-column techniques. It was anticipated the FLAG system 
would offer a sensitivity below 100 μg/ml as observed for the anti-Smp24 
antibodies. The FLAG system was used as this incorporates a small fusion tag to 
the gene, which can be added at the N or C - terminal of the gene. The FLAG tag 
can then be cleaved by incorporating a cleavage site in to the expressed gene. 
The vector was to be transformed in to E. coli BL21 λDE3 and induced for protein 
production via the addition of IPTG.  The recombinant protein would be detected 







Figure 6.13: New strategy for the optimisation of production of recombinant antimicrobial 
peptide in E. coli BL21 λDE3. 
FLAG vector 
design














6.5 Plasmid construct design with affinity tag  
 
Producing antimicrobial peptides as fusion proteins can reduce the effects of host 
toxicity (Wanmakok et al. 2018). In addition to protecting AMPs from potential 
proteolytic degradation, the incorporation of a fusion tag to the peptide would 
assist with the detection. The FLAG system was chosen for the affinity tag due to 
its relatively small size (DYKDDDDK) and the ability to cleave the tag via the 
inclusion of a cleavage site thus reducing the likelihood of the tag interfering with 
protein function. The hydrophilicity of the tag was also appealing to facilitate 
detection of expressed proteins using antibodies. Protein fusion partners can also 
promote the purification process, whilst increasing the expression efficiency and 
solubility of the peptides (Wanmakok et al. 2018) 
 
A vector was utilised for the expression of the Smp peptide in E. coli BL21 λDE3 
with pET22b vectors as discussed previously (section 6.3.2). Expression systems 
were designed both with and without the signal peptide tag to determine which 
methodology would produce the greatest protein yield. A vector containing the 
signal peptide was affinity-tagged at the N-terminus and a vector without the 
signal peptide was tagged at the C-terminus. As the initial protein production 
system had faced challenges with either the production or detection of protein, 
the gene was tagged at the C-terminal in absence of the signal peptide leader 
sequence. The effect of the signal peptide on Smp24 was not known, the N-
terminal tag may have had mechanistic implications for peptide functionality, or 
the signal peptide sequence may not have been cleaved upon transportation to 
the periplasm, thus affecting the detection. If the protein overproduction was 
successful, the concentration of peptide produced and being expressed in a large 
volume of liquid still remained a challenge. The tagging of the peptide at the C-
terminal, if successful, would enable purification from the cell pellet from a smaller 
volume. This would potentially eliminate the low concentration aspect of the 
protein production and purification process. 
 
A gene was designed for the expression of the Smp24 protein with the signal 
peptide to promote transportation of the protein out of the cell. The gene was 
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designed for optimum codon usage in E. coli and synthesised by Eurofins 





Figure 6.14: The design of pET22b/STII/FLAG/Smp24. The FLAG tag was added at the N-terminal of the sequence after the signal peptide, which is 
cleaved upon exit of the expressed protein from the periplasm. The gene with the affinity tag was spliced between the NdeI and HindIII restriction sites 





Figure 6.14 depicts the design of the insertion region for the expression of 
STII/FLAG/Smp24 in a recombinant system. The FLAG tag was added upstream 
of the STII sequence as the signal peptide would be cleaved upon exit of the 
periplasm, theoretically resulting in FLAG-tagged Smp24 in to the culture 
supernatant. The incorporation of the cleavage site enabled the FLAG tag to be 
cleaved from the protein via the addition of thrombin following protein purification. 
 
As previous experiments (section 3.4.2.1) suggested the N-terminal of Smp24 
was important for the antimicrobial function, the effect of adding the fusion tag to 
the N-terminal of the sequence was uncertain.  
 
A second approach was taken to observe the effect of expression of the Smp24 
gene without the signal peptide at the N-terminal. A gene was designed for the 
expression of Smp24 with the fusion tag at the C-terminal of the peptide. A 
cleavage site was added prior to the FLAG tag to enable to affinity tag to be 
cleaved from the produced protein. The vector construction for the C-terminally 
tagged fusion protein is shown in figure 6.15. The codon usage was optimised for 
E. coli, the gene inserts were synthesised, and the correct sequences determined 





Figure 6.15: Creation of the vector pET22b/Smp24/FLAG. The FLAG tag was added to the C-terminal of the Smp24 sequence. A cleavage site was 





Vectors were transformed in to E. coli BL21 λDE3 as per methods (section 2.10.1) 
confirmation of plasmid incorporation was determined via extracting the plasmids, 
amplifying the T7 region via PCR and running the PCR product on a 1% agarose 





Figure 6.16: Agarose gel electrophoresis for the transformation of FLAG-tagged vectors 
in to E. coli BL21 λDE3. (1) 1kb Hyperladder (Bioline, London, UK), (2) pET22b, (3) 
pET22b/Smp24/FLAG, (4) pET22b/STII/FLAG/Smp24. 
 
6.5.2 Affinity tagged protein over production 
 
The production of affinity tagged protein was optimised to promote the maximum 
yield. Growth conditions were monitored in M9, auto-induction (AIM) and LB 
broth. It was determined that the optimal growth and expression occurred in LB 
broth with room temperature incubation (22°C) with 1 mM IPTG added for 
induction of protein production. 
 
Cells were harvested by centrifugation according to the methodology in section 
2.19.1. The pellet was frozen at -20°C and the cells were lysed by the addition of 
CellLytic B to extract protein. The supernatant (soluble) fraction was separated 
from the pellet (insoluble) fraction. Both fractions were analysed by dot blot 
(section 2.19.2) to determine the location of the fusion protein. The fusion protein 
was present in both the soluble and insoluble fractions, with the C-terminally 
tagged protein demonstrating a stronger signal via dot blot, as shown in figure 
6.17. 
 





Figure 6.17: Dot blot for the analysis of Smp24 expression. (1) BSA control, (2) E. coli 
BL21, (3) Smp24-FLAG, (4) SP-FLAG-Smp24. Row A denotes the soluble fraction; row 
B denotes the insoluble fraction of cell free extract.  
 
6.5.3 Affinity tagged protein purification 
 
The soluble fraction containing the recombinant protein was added to M2 affinity 
gel on a rocking platform with protease inhibitors at 4°C overnight to enable the 
fusion proteins to bind to the agarose beads. The gel was washed and the 
protein eluted as per the methodology (section 2.20). The eluted protein was 
stored at -20°C and analysed via dot blot. 
 
Following purification via the anti-FLAG affinity gel, samples were assayed by dot 











Figure 6.18: Dot blot analysis of Smp24-FLAG purification. Row A: (1) BSA, (2) 
unbound, (3) wash through, (4) cell lysate (pre-purification). Row B: (1 – 4) samples 
eluted from the affinity gel. 
 
As shown in figure 6.18, the protein could not be detected in the post-purification 
samples. As shown by the spot in position A2, the sample did not bind to the 
column and spot A3 shows any residual FLAG-tagged Smp24 was washed from 
the gel. The reason for this was not known as the conditions (temperature, pH) 
had been adjusted as per manufacturer’s instruction to enable the binding of the 
fusion protein to the gel and elution from the gel.  
 
6.5.4 Additional optimisation 
 
As it was not possible to detect Smp24 in the fraction eluted from the M2 affinity 
gel. The protocol was optimised, and the soluble fraction was diluted 2-fold in 
lysis buffer prior to binding to the M2 affinity gel at 4°C overnight. The gel was 
washed, and the protein eluted as per the method in section 2.20.1. All fractions, 
including the unbound and was through, from the purification process were kept 






Figure 6.19: Dot blot analysis of Smp24-FLAG purification. Row A: (1)   BSA, (2)  cell 
lysate (pre-purification), (3) and (4)  samples eluted from the affinity gel. Row B: (2) 
unbound sample and (3) wash through. 
 
As shown in figure 6.19, challenges were still being faced with protein purification 
as no recombinant protein could be detected in the samples eluted from the 
affinity gel. The produced protein was not binding to the affinity gel beads under 
the conditions used and consequently, the protein could not be purified by the 
affinity process. As time on the project was restricted, this was the end point of 
the purification strategy.  
 
6.5.5 Mutagenesis of Smp peptides 
 
In addition to the optimisation of a methodology to produce recombinant 
antimicrobial peptides, a strategy was taken to modify Smp24 to express modified 
peptides which have demonstrated increased antimicrobial activity, as discussed 
in chapter 3 (section 3.7).  
 
As solid phase synthesis is an expensive method to produce modified peptides, 
the optimisation of an in-house system to produce mutant peptides on a bigger 
scale at lower cost is appealing.  
 
A system to produce mutant peptides within the laboratory would be low cost as 
the reagents required for site-directed mutagenesis (SDM) and overproduction of 
protein are cheap compared with the cost of solid-phase synthesis. The lead-time 
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on production of the peptides is reduced, as the mutants could be produced in 
the laboratory as and when required. This would enable a library of mutant 
peptides to be created for antimicrobial and cytotoxicity screening. As stated 
previously, the major limiting factor of solid-phase synthesis is the quantity of 
peptide received, as the production of protein within a recombinant system can 
be up-scaled, this would also remove one of the major limiting factors of this 
project.  
 
As the modifications to increase the charge of Smp24 yielded peptides with 
enhanced antimicrobial activity, a strategy was taken to introduce single amino 
acid substitutions to recreate the modified peptides via SDM. The S3K, S15K and 
S24K modifications were selected for initial candidates for the creation of 
expression genes. Primers were designed which contained the codon with the 











Table 6.2: Primer design for the site-directed mutagenesis of pET22b/STII/Smp24. Primers were redesigned for the creation of the S3K mutant as 
previous attempts to modify the gene were unsuccessful. The codon which to introduce the mutation in to the DNA coding sequence for the protein is 
shown in bold. 
 
Mutation Direction Primer sequence Primer length Melting temp 
°C 
S3K Reverse 5'-GTCGCCGCTTTAATCAAAAACTTCCAAATCGCATACGCGTTG-3' 42 79.2 
S3K Forward 5'-CAACGCGTATGCGATTTGGAAGTTTTTGATTAAAGCGGCGAC-3' 42 79.2 
S3K redesign Reverse 5'-GGTTGCAGCTTTGATCAGGAACTTCCAAATGGCATAAGCATTCG-3' 44 79.32 
S3K redesign Forward 5'-CGAATGCTTATGCCATTTGGAAGTTCCTGATCAAAGCTGCAACC-3' 44 79.32 
S15K Reverse 5'-TTTCTTCCCACCACCAAACAACTTAGGTAACAGTTTGGTTGCAGC-3' 45 78.06 
S15K Forward 5'-GCTGCAACCAAACTGTTACCTAAGTTGTTTGGTGGTGGGAAGAAA-3 45 78.06 
S24K Reverse 5'-GCGGCCGCAAGCTTTTACTTGTCTTTCTTCCCACCA-3 36 78.83 




Mutations were introduced in to the vector (section 2.11). The plasmids were 
extracted from the transformed E. coli and the T7 region amplified via PCR prior 
to sending the samples to Eurofins, Ebersberg for sequencing. The PCR products 





Figure 6.20: Agarose gel electrophoresis depicting the mutagenesis of Smp24.  (1)  1kb 
Hyperladder (Bioline, London, UK), (2) negative DNA control, (3) pET22b/STII/Smp24, 
(4) pET22b/STII/Smp24/S15K, (5)  pET22b/STII/Smp24/S24K. (6) pET22b. 
 
The confirmed sequences of the mutated peptides are shown in table 6.3.  The 
sequencing results confirmed successful creation of vectors capable of 
expressing mutant peptides with the sequences S15K Smp24 and S24K Smp24.  
Despite attempts to create mutant peptide with an enhanced charge at the N-
terminus of the chain (S3K Smp24), this remained unsuccessful.  
 
The SDM methodology was adapted for S3K Smp24 to enhance the elongation 
times of the PCR process, which remained unsuccessful. The SDM primers were 
redesigned and the optimisation process repeated to create the S3K mutant. 
None of the mutagenesis attempts revealed incorporation of the S3K mutation in 
the Smp24 gene. The difficulties faced with the creation of the S3K mutant could 
be attributed to the potent antimicrobial activity observed from the synthetically 
synthesised peptide discussed in chapter 3, section 3.7.1. The observable MIC 
for this modification against the E. coli strain tested (JM109) was 1 µg/ml, 
demonstrating the toxicity of this peptide to the expression strain. Due to this, any 
leaky expression within the vector would have resulted in cell death. The mutation 
could have been too toxic for the for the cells resulting in death and no observable 
incorporation of the substitution in to the gene of interest. 





Table 6.3: Confirmed sequences of mutated Smp24 peptides, as produced by site-directed mutagenesis. 
Mutated amino acids are highlighted in bold. 
 
Peptide Charge GRAVY Molar Mass (Da) PI Sequence 
Smp24 +3 0.312 2578.09 10.00 IWSFLIKAATKLLPSLFGGGKKDS 
Smp24 S15K +4 0.183 2619.19 10.18 IWSFLIKAATKLLPKLFGGGKKDS 
Smp24 S24K +4 0.183 2619.19 10.18 IWSFLIKAATKLLPSLFGGGKKDK 





Following the successful creation of the S15K and S24K mutant genes, SDM was 
performed to create a double charge modification resulting in the expression of 
Smp24 S15K/S24K. This was achieved by using the S15K primers to introduce 
the S15K mutation to the successfully created Smp24/S24K gene. As the 
antimicrobial activity of a double charge modification had previously been 
observed (S3K/S15K in section 3.4.2), it was of interest to observe the effect of 
increasing the charge at the C-terminal end of the peptide. 
 
The mutant plasmid vectors were transformed in to E. coli BL21 lDE3 and 
induced for protein expression (section 2.13).  The  purification and detection of 
the modified peptides faced the same challenges as discussed previously, with 
issues with reproducibility. It was not possible to detect the presence  of the 
modified peptides  in the purified fractions. The plasmids mutated contained the 
leader sequence, which according to the FLAG-tagged methodology in section 
6.5.2 was determined to be a less efficient system for protein production.  The 
future approach of the mutagenesis strategy would be to incorporate the 




Antimicrobial peptides are of increasing therapeutic interest, with 60 peptide-
based drugs approved by the FDA and a further 140 peptide candidates in 
various phases of clinical trials (Hazam et al. 2019). Whilst the properties of 
Smp24 and derived modifications have been investigated in peptides synthesised 
via solid-phase synthesis, this is not a sustainable strategy for long-term 
production due to the small quantities produced, the lead time on production and 
the high cost.   
 
Lipopeptide antibiotics have been successfully produced by recombinant 
methodologies for pharmaceutical purposes. Daptomycin is recombinantly 
produced by Streptomyces roseosporus, Streptomyces lividans TK23 and S. 
lividans TK64 strains when the 128 kbp region of cloned S. roseosporus DNA 
containing the daptomycin gene cluster is inserted site-specifically in the 
ϕC31 attB site (Miao et al. 2005, Penn et al. 2006). This methodology enabled 20 
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- 55 mg of daptomycin to be produced per litre of bacterial culture (Penn et al. 
2006). The success of recombinant production of daptomycin is encouraging 
when looking for a system to exploit the production of antimicrobial peptides via 
similar methodologies. 
 
The challenges faced with expressing and purifying AMPs have previously been 
noted. The production of the peptides within the system needs to overcome the 
risk of proteolytic degradation of the peptide within the microbial cells. 
Conversely, the negative effects of the AMP on the microbial producer cells (in 
terms of toxicity) must be avoided (Ashcheulova et al. 2018). 
 
Whilst the production system for Smp24 has not yet been perfected, the detection 
of the protein prior to purification via the fusion tag is positive and suggests further 
improvements to the process could yield promising results. The ability to detect 
the protein prior to purification was previously a limiting factor for the project, as 
it made the purification process blind. The inclusion of a fusion tag has improved 
the detection aspect of this methodology. 
 
Difficulties were initially faced with the detection of the produced peptide. A gel 
methodology was unsuccessful for the detection of the peptide; due to the small 
mass of the protein combined with its positive charge.  Whilst SDS binds with 
proteins to create a negatively charged protein, the efficiency at which this occurs 
differs between proteins. Highly hydrophobic proteins bind SDS more efficiently, 
as Smp24 is a peptide with an abundance of hydrophilic residues, the ability to 
bind SDS could be reduced.  
 
Several factors were considered when choosing a fusion system for the detection 
and purification of Smp24. The main consideration when choosing a tag is that it 
should not interfere with the native folding of the protein. Whilst structural 
investigations revealed Smp24 is disordered in solution and adopts its alpha-
helical conformation upon membrane binding (see chapter 3, section 3.5.3), the 
effect of a tag of the N or C-terminus remains unknown. Whilst the produced 
protein was found to lack antimicrobial activity and this could be due to the FLAG-
tag, it is most likely due to the low concentration. Secondly, the tag should be 
water soluble; this is an important factor when considering the antimicrobial 
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property of the peptide and the potential future application as a therapeutic. 
Thirdly, the tag should be suitable for an inexpensive purification procedure, to 
make the procedure more cost-effective than solid-phase synthesis. Finally, the 
tag should be easy to remove in order to gain the native peptide. Taking all of 
these factors in to consideration, the FLAG tag was chosen for the purification of 
Smp24. 
 
The FLAG tag was originally designed as a hydrophilic tag which could be 
removed from the target protein by enterokinases (Sasaki et al. 2012). FLAG tags 
were added to the N and C-terminal of Smp24 to determine the effect on function 
as N-terminal tags have previously been shown to inhibit the functionality of 
proteins (Sandhu et al. 2019). 
 
The addition of the FLAG tag aided the identification of expressed Smp24 from 
bacterial overproduction. The C-terminally tagged peptide was ultimately chosen 
for protein overproduction due to a higher level of expression as determined by 
dot blot analysis when compared with the N-terminally tagged protein. The 
sensitivity of the commercially available antibodies is not always sufficient to 
detect low-level protein expression (Sandhu et al. 2019), which could explain the 
lack of detection for the N-terminally tagged protein within the culture 
supernatant. It is also possible the N-terminally tagged protein did not express, 
though the reason for this is unknown. 
 
The detection of the protein via anti-FLAG antibodies supported results 
previously observed in this study. The decrease in pathogenicity of the 
overproduction strain of E. coli vs the control strain was indicative of successful 
production of Smp24. The difficulty faced creating the S3K mutation via site-direct 
mutagenesis was also supportive of protein expression due to the microbial 
potency observed in chapter 3, section 3.4.2. With leaky expression within the 
system potentially resulting in lethality.  
 
Issues have been faced with the purification of the protein from the M2 agarose 
beads. This could potentially be due to the batch purification process adopted, as 
each time the gel beads were centrifuged, a volume of the beads was lost. As it 
is anticipated that small quantities of protein are produced with the overproduction 
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system, volume losses could be crucial to this project. The future direction with 
this work would be to purify the fusion proteins via a column method. Packing the 
gel in a column format would prevent loss of the affinity gel and the associated 
fusion protein. This would also enable an upscale on production, which would 
maximise protein recovery. The M2-conjugated agarose bead system has been 
used for the pull down of proteins on small and large scales. Gerace and Moazed, 
2015 described an immunoprecipitation method for affinity purification combined 
with elution with a 3x FLAG peptide which could be adopted. 
 
The elution method adopted could have also contributed to the lack of recovery 
from the purification process. Lowering the pH was chosen as the initial method 
for elution due to ease of use and low cost. Other methods of elution from the gel 
include antibody-mediated affinity chromatography in a calcium-dependent 
manner and elution with synthetic peptides (Einhauer and Jungbauer 2001). 
Competition with a 3x FLAG peptide has previously been describe to elute FLAG-
tagged fusion proteins from M2 affinity gel (Gerace and Moazed, 2015). This 
methodology operates via competition of the 3x FLAG protein with the FLAG- 
tagged fusion protein for binding to the M2 agarose beads, which releases the 
protein in to the eluate. In future experiments, these elution methods would be 
considered. 
 
Following the optimisation of the purification process for Smp24, the activity of 
the peptide would initially be assayed whilst leaving the FLAG tag on the peptide. 
The antigenicity of the FLAG tag is essential for the detection of the Smp24 
peptide, due to previous issues encountered. It has been previously reported that 
for small scale laboratory production the FLAG tag may be left on if the tag is 
shown not to interfere with the activity of the protein or peptide (Einhauer and 
Jungbauer 2001).  
 
Whilst protein production via inclusion body formation was avoided during this 
project, this strategy has been shown to be successful in the literature. 
Ashcheolova et al (2018) utilised both the fusion tag and inclusion body formation 
to produce large quantities of an antimicrobial peptide. A ketosteroid isomerase 
(KSI) fusion tag was combined with protein production through insoluble inclusion 
bodies for recombinant production of ubiquicidin (UBI). This strategy was 
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optimised to benefit the fusion protein and the microbial host. The produced 
protein which was protected from proteolytic degradation by being forced in to 
inclusion bodies which in turn protected the host cell from the activity of the 
peptide. The procedure was optimised to yield up to 72 mg of an ubiquicidin 
variant (KSI-2xUBI18-35) at 95% purity (Ashcheulova et al. 2018). The production 
of Smp24 via inclusion body formation could be an interesting avenue to 
investigate; it was avoided in this project due to the uncertainty as to whether the 
recombinant protein would retain its solubility. The extraction and purification 
method from inclusion bodies can be complicated and often requires 
optimisation. It is necessary to isolate and purify inclusion body aggregates into 
homogeneity before solubilisation and refolding (Singh et al. 2015).   
 
Other considerations for future work would involve alternative affinity tags and 
purification methodologies. The His-tags (consisting of at least 6-histidine 
residues tagged at the N or C-terminus of the peptide) have been utilised for the 
successful recombinant production of AMPs in E. coli. The coding sequence for 
cLF chimera was cloned in to a pET expression vector and overproduced in E. 
coli via IPTG induction in LB broth, resulting in a yield of 0.42g of protein per litre 
of culture media (Tanhaiean et al. 2018b).  
 
When looking to upscale the project, recombinant expression in mammalian cells 
could be considered. 60-70% of recombinant protein pharmaceuticals are 
produced in immortalised mammalian cell lines, such as HEK-293 or Chinese 
Hamster Ovary (CHO) (Wurm, 2004).  
 
CHO cells have been used successfully for recombinant protein expression due 
to being a hardy and reliable cell line. The annual global revenue from products 
derived from CHO cells totals $100 billion, which increases every year 
(Bandaranayake and Almo 2014). During recombinant production in CHO cells, 
the recombinant gene with the necessary transcriptional regulatory elements is 
transferred in to the cells. A second gene is then transferred in to the cells which 
confers a selective advantage. This second gene is transferred a few days after 
the first and only the cells containing the selector gene survive. Following the 
selection process, survivors are transferred as single cells in to a new vessel and 
expanded for recombinant expression (Wurm 2004).  Optimisation of expression 
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within CHO cells can result in a protein yield of 2 - 6 grams per litre 




In summary, a vector capable of expressing Smp24 has been created. The 
plasmid has been successfully overexpressed in E. coli to overproduce Smp24 
protein and a purification strategy has been devised. C-terminal FLAG-tagging 
resulted in the greatest yield of peptide, as opposed to the original method of 
overproduction with a signal peptide.  
 
Whilst issues been faced with the purification and elution of the expressed 
peptide, initial problems with the expression system (such as detection of the 
peptide) have been overcome which suggests the process could be further 
optimised to gain an in-house method of protein production. Additionally, SDM 
methodology has been established which would enable high-throughput 










7.1 Improving the understanding of structure and function 
 
The purpose of this study was to gain an insight in to the relationship between 
structure, function and cytotoxicity of antimicrobial peptides (AMPs) derived from 
venom. Throughout this study, two antimicrobial peptides, Smp24 and Smp43, 
from the venom of Scorpio maurus palmatus have been modified. Some of the 
modifications have produced peptides with enhanced antimicrobial activity, whilst 
other modifications resulted in reduced eukaryotic cytotoxicity.  
 
For both Smp24 and Smp43, peptides with enhanced therapeutic indices (TIs) 
have been produced. The S3K, F4A, D23F and S24K modifications of Smp24 
and the W3A, W5A and W14A modifications of Smp43 all had enhanced TIs 
when compared with the native peptides. The combined results of  antimicrobial 







Table 7.1: Comparison of prokaryotic and eukaryotic activity of Smp24, Smp43 and derived modifications that yielded peptides with enhanced TIs. 
 
Peptide Charge GRAVY MIC (μg/ml) LD50 (μg/ml) HC50 (μg/ml) Therapeutic index 
E.  coli S. aureus HepG2 HEK-293 HaCaT RBCs HepG2 HEK-293 HaCaT RBCs 
Smp24 +3 0.31 32 8 37 39 34 76 1* 1 1 2 
Smp24 S3K +4 0.18 1 0.5 34 38 18* 11* 35* 39* 19* 11* 
Smp24 F4A +3 0.27 32 16 63* 56* 57* 423* 2* 2* 2* 13* 
Smp24 D23F +4 0.58 32 32 >512* 38 137* 33* 16* 1* 4* 1 
Smp24 S24K +4 0.18 8 4 36 23* 142 15* 5* 3* 18* 2 
 
Smp43 +4 -0.316 32 >512 161.95 35.86 179 >512 4 1 6 16 
Smp43 W3A +4 -0.25 16 >512 172 76* 194 >512 11* 5* 11* 32* 
Smp43 W5A +4 -0.25 8 >512 46* 39 327 >512 6* 5* 4* 64* 
Smp43 W14A +4 -0.13 4 >512 77* 29 53* >512 19* 7* 12* 128* 
Daptomycin -6 -1.93 >512 4 >512 >512 >512 >512 128 128 nc 128 
Polymyxin B +5 nc 2 32 >512 351 >512 >512 256 256 nc 178 
 




The modified Smp24 peptides which demonstrated improved antimicrobial 
activity also demonstrated increased haemolytic activity. The greatest increase 
in antimicrobial activity was observed for the S3K modification which was also the 
most potent peptide against red blood cells out of all of the peptides in this study. 
Similar results have previously been observed for antimicrobial peptides 
extracted from Australian tree frogs, with improvements in antimicrobial activity 
accompanied by 4-fold increases in haemolytic activity (Fernandez et al. 2008). 
Lysine substitutions in VmCT1 which resulted in 4-fold improvements in 
antimicrobial activity yielded peptides with a similar fold increase in haemolytic 
activity (Pedron et al. 2019). Conversely, the structural manipulation of AMPs has 
also demonstrated reductions in the haemolytic propensity in the literature. 
Sequence modifications to pep 5, which replaced three leucine residues for 
alanine residues, resulted in a 4-fold decrease in potency against Staphylococcus 
spp and a 2-fold reduction in haemolysis (Hollmann et al. 2016).  
 
Pedron et al., 2017 performed lysine substitutions across the N-, mid and C-
terminal of VmCT1, with a serine-lysine substitution at position 11. All the lysine 
modifications to VmCT1 produced peptides with enhanced antimicrobial and 
haemolytic activity. A modification to incorporate a tryptophan residue in to the 
peptide (W9) resulted in the largest polar angle and produced a peptide with 
reduced haemolytic activity and reduced antimicrobial activity (Pedron et al. 
2017). The results of this study followed a similar pattern, with the greatest 
decrease in antimicrobial and haemolytic activity observed by the K7F 
modification of Smp24. Additionally, upon CD spectroscopy, the W9 modification 
of VmCT1 demonstrated a similar profile to Smp24 K7F, with a less pronounced 
alpha-helix in membrane mimetic conditions, suggesting that the ability of AMPs 
to adopt their alpha-helical structure is important for the function of the peptides. 
 
7.2 AMPs and membrane interactions 
 
The lipid composition of bacterial cytoplasmic membranes is an important factor 
for the mechanism of action of AMPs. Whilst membrane composition differs 
between species, anionic phosphatidylglycerol (PG) and cardiolipin and 
zwitterionic phosphatidylethanolamine (PE) are essential for the organisation of 
212 
 
bacterial membranes (Epand and Epand 2009). Differences in the antimicrobial 
activity of the AMPs against different species was observed, which could be 
linked to the membrane composition of the target and the mechanism of action 
of the peptide. Gram positive membranes present with a lower proportion of 
zwitterionic PE (Pedron et al. 2017). Smp24 demonstrated increased potency 
against S. aureus compared with the two Gram negative strains while Smp43 
demonstrated no detectible antimicrobial activity against S. aureus.   
 
As the lipid composition of bacterial membranes plays a role in AMP mechanism 
of action, the membrane composition of mammalian cells used for cytotoxicity 
assays needs to be considered. Previously, haemolysis assays have been used 
as a marker of cytotoxicity, but the results of this study highlight the differences 
between HC50 and LD50 concentrations and how measuring the HC50 alone can 
be an inaccurate representation of cytotoxicity. Differences in activity were noted 
between the activities of the peptides against the various secondary cell lines 
used, which was attributed partially to the difference in membrane composition, 
with cancer cell membranes often having similar physicochemical properties to 
bacterial membranes. As such, the usage of cancer-derived cell lines could 
produce misleading cytotoxicity results, due to potentially greater electrostatic 
attraction between the AMP and cancer cell membranes. Many AMPs have 
demonstrated anti-cancer properties (Zhu et al. 2017a), further supporting the 
conclusion that the usage of secondary cell lines may not be an accurate marker 
of cytotoxicity. When this hypothesis was tested within the confines of this study, 
a significant reduction in cytotoxicity was observed for the primary HUEPC cell 
line for both peptides (LD50 >512 µg/ml). This highlights the importance of 
assessing the activity of the peptides against numerous cell types, with a 
preference for primary cell lines which are more representative of healthy 
eukaryotic cells (Wilkening et al. 2003). The usage of immortalised cell lines could 
result in potential drug targets being overlooked on the basis of inaccurate 
cytotoxicity results. 
 
Future work would involve further screening of the AMPs against primary cell 
lines with varied membrane compositions and membrane potentials to determine 
the role of membrane composition on the determined cytotoxicity. Additionally, 
numerous bacterial cell lines would be screened to assess the spectrum of 
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activity of the peptides and the relationship between bacterial membrane 
composition and AMP activity. 
 
7.3 Elucidating the mechanism of action 
 
It has been established that cationic peptides play an important role in microbial 
defence of many species (Pedron et al. 2017). The peptides are generally 
positively charged and fold in to a helical structure enabling the clustering of 
hydrophilic residues which promotes interaction between the peptide and the 
anionic bacterial cell membrane (Jiang et al. 2008). The hydrophobic faces of the 
helix are thought to be responsible for insertion in to membranes (Kang et al. 
2012). As differences between antimicrobial activity and cytotoxicity were 
observed by adjusting the charge and hydrophobicity parameters of the peptides, 
investigating the effect of the pore-forming mechanism of the modified peptides 
would be an interesting avenue to pursue. 
 
To investigate the effect of the amino acid modifications on pore-formation, future 
work would involve observing the effect of the peptides on phospholipid vesicles. 
Giant unilaminar vesicles composed of PG:PE would be produced and a free-
standing membrane prepared on a borosilicate glass chip by applying a negative 
pressure using the Nanion Port-a-Patch system (Song et al. 2013). Manzo et al 
used the Port-a-Patch system to elucidate the effect that minor sequence 
modifications of temporin B had on membrane activity. A similar strategy would 
be adopted for Smp24, S3K and K7F to determine if the structural modifications 
resulted in mechanistic changes in terms of pore formation. The Nanion system 
would enable the activity of the peptides to be distinguished on the basis of 
peptide concentration,  latency  (i.e. the time taken for conductance (pore 
formation) to begin after the addition of the peptides), the duration of the 
conductance activity, the amplitude and number of each conductance event, and 
whether the peptide caused the membrane to break (Manzo et al. 2018). 
Ultimately, this would enable the concentration at which pore formation occurs to 
be ascertained, the number and size of pores to be quantified and the breakage 
of the membrane to be identified. The pore-forming abilities of the membranes on 
eukaryotic membranes could also be determined by the usage of patch-clamp 
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techniques at a whole cell level. A greater understanding of the mechanisms of 
pore formation may lead to further modifications to the AMPs, such as truncation, 
to further enhance the therapeutic index. 
 
7.4 Development of novel antimicrobials 
 
The rational design of new antimicrobial compounds follows several rules; the 
drugs must be well-absorbed, non-toxic and active against a specific target. 
Lipinski's rules are the most recognised rules governing the industry (Durand et 
al. 2019). The "rule of 5" predicts that poor absorption or drug permeability is 
more likely if a drug has more than 5 H-bond donors, 10 H-bond acceptors, a 
molecular weight exceeding 500 Da and a calculated log P greater than 5 
(Lipinski et al. 1997). The rule of 5 was intended to enable high-throughput 
screening of new drugs and identify poorly behaving drugs early in the discovery 
process to reduce drug development costs. Despite the original intentions, the 
rule of 5 has become a mainstay of decision making; drugs which fail two or more 
of the rules are often rejected. Only seven orally active antibiotics fit the Lipinski 
criteria at the time of publications (Mckerrow and Lipinski 2017). Similar to 
antibiotics, antimicrobial peptides also fail to follow the "rule of 5." 
 
Previous attempts to introduce novel antimicrobials have faced many difficulties. 
In addition to the drug requirements listed above, antimicrobials face several 
other hurdles. Telithromycin (Ketek) was authorised in the European Union in 
2001 and initially marketed in France in 2002 with great success. The adverse 
effect profile of the drug was noted and despite the claim Ketek held a novel 
mechanism of action, it was found to be no more effective than existing macrolide 
antibiotics. This led to the withdrawal of two of the three telithromycin analogues 
(licensing was retained for the treatment of community acquired pneumonia) from 
the clinical setting in 2006. The decision to withdraw Ketek was the result of a 
change in non-inferiority trials for the approval of antibacterial drugs by the Food 
and Drug Administration (FDA). In 2018, the drug was officially removed from the 
market by Sanofi Aventis, citing economic reasons. Echols, (2011) has argued 
that the withdrawal of Ketek for the treatment of acute bacterial sinusitis and acute 
bacterial exacerbation of chronic bronchiectasis has caused collateral damage to 
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the antibacterial pipeline, particularly for molecules with novel mechanisms of 
action. The usage of non-inferiority trials to approve new antibacterial products 
has resulted in a dramatic decline in the approval of new drugs (DiNubile 2016). 
This does present a challenge when assessing molecules for potential 
therapeutic application, such as within the confines of this study. Whilst 
comparisons have been made between the modified Smp peptides and 
commercially available compounds, the venom peptides are inferior. Some of the 
peptides, such as the W14A modification of Smp43 did produce a TI of 128 
against erythrocytes, which was equal to that of daptomycin (128) but lower than 
the calculated TI of polymyxin B (256).  For Smp24, however, the highest 
calculated TI was the S3K modification against HEK-293 cells (38.7) whilst this 
is far superior than the TI of native Smp24 (1.2) it does demonstrate inferiority 
against the commercially available AMP-like antibiotics used in this study. 
 
Despite the difficulties faced with the development of novel antimicrobials, new 
drugs are entering clinical trials which provides some optimism. Omiganan is a 
topical 12-amino acid peptide (Sader et al. 2004) which has recently completed 
phase III clinical trials for the treatment of rosacea. Novexatin is a potent AMP 
undergoing clinical trials for the brush on treatment for onychmycosis (fungal nail 
infection). This AMP, developed by NovaBiotics, has demonstrated safety, 
tolerance and efficacy in phase I and IIa clinical trials.  This highlights the 
antimicrobial drug approval landscape is changing and why the efforts of smaller 
pharmaceutical companies, biotech and studies in academic groups like this one 
are important for the introduction of new antimicrobials in to clinical trials. 
 
Clinical trials may be a longer term goal for the peptides in this study, but further 
modifications of the peptides and investigations in to the mechanism of action of 
some of the identified peptides with enhanced TIs is warranted. 
 
7.5 Recombinant peptide production 
 
As discussed in chapter 6 (section 6.1), one of the limitations of this study is the 
cost of peptide synthesis. Progress was made with the expression system as 
detectable quantities of Smp24 were being produced but difficulties were faced 
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with the purification. Challenges have been faced in the expression of 
antimicrobial peptides, with protein yield varying substantially between AMPs and 
the chosen bacterial expression system. Song et al., (2014) report yields of 0.6 
mg/L of the AMP Dermaseptin S4 whilst Chen et al., (2015) report yields of 35 
mg/L of plectasin highlighting a degree of variability between the recombinant 
production of AMPs (Song et al. 2014, Chen et al. 2015).  
 
The future of this work would be to optimise the purification strategy by performing 
column chromatography as opposed to the batch purification discussed in 
chapter 6 (section 6.6). Purification in column format would minimise the loss of 
product and of agarose beads, which in turn would reduce the financial cost of 
the work. The antimicrobial, haemolytic and cytotoxic activity of the purified 
product would be assessed both with and without the FLAG-tag to determine the 
effect of the fusion tag on the mechanism of action. The activity of FLAG-tagged 
products can be retained without cleavage of the tag (Fu et al. 2019). Wu et al., 
(2013) investigated the in vitro antimicrobial activity of the AMP thanatin(S) both 
with and without a FLAG tag. Both AMPs demonstrated antimicrobial activity and 
it was determined the FLAG-tag had little effect on the antimicrobial activity of 
thanatin(S). If the activity of Smp24 could be retained without cleavage of the tag, 
this would create a more streamlined process in the laboratory and result in a 
reduced risk of losing peptide yield during additional processes. Additionally, the 
recombinant system would enable the creation of a library of genes for expression 
of mutated Smp24 peptides to further investigate the relationship between 
structure and function. 
 
7.6 Improving the stability of AMPs 
 
One of the major disadvantages of natural AMPs is susceptibility to proteolytic 
degradation which dominates the pharmacokinetic profile (Travkova et al. 
2017). In general, AMPs possessing low molecular weights and high positive 
charges are inherently bactericidal and prone to proteolytic degradation in vivo 
(Wibowo and Zhao 2019). Increasing the stability of AMPs by reducing 
susceptibility to proteolysis is a major goal for  AMP improvement, as it would be 
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beneficial for practical application and their production through biotechnology 
(Zhu et al. 2017a).  
 
The incorporation of D-amino acids (D-AAs) in to the AMP structure is a strategy 
which can enhance the therapeutic application of AMPs. The incorporation of D-
AAs can increase stability, provide resistance to enzymatic degradation and 
reduce haemolytic activity whilst preserving the bioactive properties of peptides. 
However, including D-AAs in to peptide chain can be difficult to synthesise and 
may result in the loss of the secondary structure. Additionally the incorporation of 
D-AAs is also likely incompatible with recombinant production techniques 
(Cardoso et al. 2018). Hong et al., (1999) produced 6 analogues of the AMP 
KLSK which incorporated D-AAs in to the structure. The study concluded the 
incorporation of D-lysine at the N- and C- terminal regions of the peptide had little 
effect on the helical content and thus the peptide retained its antimicrobial activity 
whilst demonstrating enhanced stability and increased resistance from proteolytic 
degradation by serine proteases. The incorporation of D-lysine in the central 
region of the peptide resulted in complete loss of both the helical content and 
antimicrobial activity (Hong et al. 1999). Single substitutions of asparginine4, 
glycine8, alanine10 and leucine18 for D-lysine residues of ascaphin-8, an AMP 
derived from the skin of the American tailed frog Ascaphus truei, produced 
peptides which retained the antimicrobial activity of native (L-) ascaphin-8 but 
demonstrated reduced haemolytic activity (Michael Conlon et al. 2008). Other 
studies have replaced L-amino acids with their respective D- enantiomers. 
Modification of temporin L (TL) to include D-enantiomers produced peptides which 
retained antimicrobial activity and generally demonstrated reduced haemolytic 
activity (Grieco et al. 2012).  
 
The incorporation of D-amino acids in to the chain of Smp24 (particularly the S3K 
modification) using a similar methodology to that used by Grieco et al., (2012) for 
the modification of TL would be an interesting strategy to adopt. The inclusion of 
D-lysine at position 3 (Smp24 S3D-K) could be investigated to determine if the D-
enantiomer retains the antimicrobial activity of Smp24 S3K and demonstrates 
reduced haemolytic activities as shown by the inclusion of D-AAs in other studies. 
(Hong et al. 1999, Grieco et al. 2012). This strategy would be adopted for all of 
the peptides in this study which demonstrated enhanced therapeutic indices 
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(TIs), which are S3K, F4A, D23F and S24K modifications of Smp24 (to produce 
F4D-A, D23D-F and S24D-K) and W3A, W5A and W14A modifications of Smp43 
(to produce W3D-A, W5D-A and W14D-A). The peptides would be characterised in 
terms of antimicrobial, cytotoxicity and haemolytic activity under the same 
conditions used in this study to enable direct comparisons between the D- and L-
enantiomers. The structure of the peptides would be assessed by performing 
circular dichroism (CD) spectroscopy to  determine if the inclusion of D-
enantiomers affected the helical content of the peptides when compared with the 
native L-peptides. The stability of the peptides would also be assessed, this could 
be achieved via the addition of trypsin and quenching the reaction at different 
time points and characterising the peptides by reversed phase high performance 
liquid chromatography (RP-HPLC)  (Najjar et al. 2017). 
 
7.7 Higher resolution structural biology approaches 
 
Protein structure determination by nuclear magnetic resonance (NMR) is a 
continually evolving technology which enables the dynamics of proteins to be 
quantitatively characterised and the relevance for function to be elucidated. NMR 
is unique among the structure-determination approaches in its ability to provide 
kinetic insights in to protein dynamics without requiring modification of the protein 
(Arthanari et al. 2019).  
 
The α-helical structure of Smp24, Smp24 S3K, Smp24 K7F and Smp43 have 
been determined by CD spectroscopy. NMR would enable differences in the 
helical content of the peptides to be determined, by enabling the visualisation of 
the helical content between amino acid residues. As ab-initio modelling of the 
peptides has been used to support the link between structure and function, NMR 
could be utilised to provide experimental data on the structural changes which 
have arisen due to single amino acid substitutions (Imamura et al. 2008).  
 
Solid-state NMR can provide information on the 3D conformation of the peptide 
as well as the mode of interaction with model lipid membranes. The utilisation of 
NMR could enable the identification of the biophysical properties of critical 
residues which mediate interactions between the AMPs and the membrane (Li et 
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al. 2017). Elucidating the mechanism of interaction between AMPs and lipid 
bilayers can require extensive computational resources and provide an 
experimental challenge, as such, the interactions of AMPs with micelles is often 
used as an alternative methodology. This technique enables longer simulations 
and permits the monitoring of biological phenomena of longer time scales 
(Khandelia and Kaznessis 2005). This methodology would be particularly 
interesting to adopt to investigate the structural and membrane interaction 
changes between native Smp24 and the single amino acid modifications which 
resulted in potently increased and drastically reduced antimicrobial activity. The 
utilisation of NMR to understand the relationship between structure and function 




The development of novel antimicrobials with less susceptibility to bacterial 
resistance is of high importance. In this thesis, modified scorpion venom-derived 
antimicrobial peptides have been produced which show enhanced therapeutic 
profiles when compared with native AMPs. These modified peptides are 
interesting candidates for further investigations to aid the drug discovery 
approach. A system for recombinant production of AMPs in E. coli has been 
developed and with further optimisation this could be a useful tool for large-scale 
AMP production in the laboratory. When combined with the optimised site-
directed mutagenesis methodology, this will enable a library of mutant peptides 
to be produced and further screening (such as cytotoxicity assessment against 
primary cell lines and proteolytic stability) to be assessed. The utilisation of an 
SDM approach would enable virtually limitless modified peptides to be produced 
at an extremely low cost. The power of directed or even random substitutions 
could be huge and result in a greater understanding of the structure-function 
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Growth curve analysis of E. coli BL21 λDE3 containing the Smp24 vector. Once 
bacterial growth reached mid-log phase (approximately 0.6 OD600) isopropyl-1-
thio-β-D-galactopyranoside (IPTG) was added to varying concentrations 
(0.025mM to 2mM) and the growth was observed by recording the OD600 every 
20 minutes over 18 hours. Data presents the average of three replicates. As 
shown in the appendix 1, upon addition of IPTG, the growth rate of E. coli was 
reduced, thus suggesting energy was spent on protein production with less 
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